{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-11-21 14:35:05 [INFO] agent.utils - ğŸ’¬len(messages)=1,research_topic=WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "æ—¶é—´November 21, 2025\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-11-21 14:35:12 [INFO] agent.graph - ğŸ”§continue_to_web_research|ğŸ“„ä»»åŠ¡ 0: search_query='WEE1 inhibitor clinical trials pipeline 2024 2025'\n",
      "2025-11-21 14:35:12 [INFO] agent.graph - ğŸ”§continue_to_web_research|ğŸ“„ä»»åŠ¡ 1: search_query='WEE1 targeted therapy development status oncology'\n",
      "2025-11-21 14:35:12 [INFO] agent.graph - ğŸ”§continue_to_web_research|ğŸ“„ä»»åŠ¡ 2: search_query='WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ'\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›:æˆ‘å°†ä¸ºæ‚¨æœç´¢WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±•å’Œä¸´åºŠè¯•éªŒçš„ç›¸å…³ä¿¡æ¯ã€‚è®©æˆ‘å…ˆè¿›è¡Œä¸€äº›é’ˆå¯¹æ€§çš„æœç´¢ã€‚\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '1'}}, 'id': 'call_00_kJTErgJUWga9PY5DJNhnBDkc', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '1'}}\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›:I'll conduct targeted Google searches to gather comprehensive information about WEE1 targeted therapy development status in oncology, and use the clinical trials tool when appropriate. Let me start with some diverse searches.\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor targeted therapy oncology clinical development status 2024 2025', 'state': {'search_query': 'WEE1 inhibitor targeted therapy oncology clinical development status 2024 2025', 'id': 'search_1'}}, 'id': 'call_00_jdn4Bqj7tSqqz2XtAg9eSZmr', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor targeted therapy oncology clinical development status 2024 2025', 'state': {'search_query': 'WEE1 inhibitor targeted therapy oncology clinical development status 2024 2025', 'id': 'search_1'}}\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›:I'll conduct comprehensive research on WEE1 inhibitor clinical trials pipeline for 2024-2025. Let me start with targeted Google searches and then use the clinical trials database for specific trial information.\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor clinical trials 2024 2025 pipeline development status', 'state': {'search_query': 'WEE1 inhibitor clinical trials 2024 2025 pipeline development status', 'id': '1'}}, 'id': 'call_00_QDZauAWS5nwDIoDJePuH3gmy', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:33 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor clinical trials 2024 2025 pipeline development status', 'state': {'search_query': 'WEE1 inhibitor clinical trials 2024 2025 pipeline development status', 'id': '1'}}\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1æŠ‘åˆ¶å‰‚ Azenosertib ZN-c3 æœ€æ–°ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ Azenosertib ZN-c3 æœ€æ–°ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '2'}}, 'id': 'call_00_q5Jx4dpcc4pM4hHmnsRt8lcb', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1æŠ‘åˆ¶å‰‚ Azenosertib ZN-c3 æœ€æ–°ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ Azenosertib ZN-c3 æœ€æ–°ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '2'}}\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 ovarian cancer pancreatic cancer', 'state': {'search_query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 ovarian cancer pancreatic cancer', 'id': 'search_2'}}, 'id': 'call_00_xkkoSSzULNHLDHbFkpMYplQw', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:45 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 ovarian cancer pancreatic cancer', 'state': {'search_query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 ovarian cancer pancreatic cancer', 'id': 'search_2'}}\n",
      "2025-11-21 14:35:46 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:35:46 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 latest results', 'state': {'search_query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 latest results', 'id': '2'}}, 'id': 'call_00_xYl17ni6AH8BWfswleWK6Goa', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:46 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:46 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 latest results', 'state': {'search_query': 'WEE1 inhibitor azenosertib ZN-c3 clinical trials 2024 2025 latest results', 'id': '2'}}\n",
      "2025-11-21 14:35:59 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:35:59 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor adavosertib AZD1775 clinical trials 2024 2025 ovarian cancer solid tumors', 'state': {'search_query': 'WEE1 inhibitor adavosertib AZD1775 clinical trials 2024 2025 ovarian cancer solid tumors', 'id': 'search_3'}}, 'id': 'call_00_b5YTYPvEUQAEz3S9nVVNSyzf', 'type': 'tool_call'}]\n",
      "2025-11-21 14:35:59 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:35:59 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor adavosertib AZD1775 clinical trials 2024 2025 ovarian cancer solid tumors', 'state': {'search_query': 'WEE1 inhibitor adavosertib AZD1775 clinical trials 2024 2025 ovarian cancer solid tumors', 'id': 'search_3'}}\n",
      "2025-11-21 14:36:04 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:04 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1æŠ‘åˆ¶å‰‚ Debio0123 ACR-2316 ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ Debio0123 ACR-2316 ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '3'}}, 'id': 'call_00_9ihM7ZNUrknmMlQtfc7Z9QEr', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:04 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:04 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1æŠ‘åˆ¶å‰‚ Debio0123 ACR-2316 ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ Debio0123 ACR-2316 ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '3'}}\n",
      "2025-11-21 14:36:05 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:05 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials 2024 2025 glioblastoma', 'state': {'search_query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials 2024 2025 glioblastoma', 'id': '3'}}, 'id': 'call_00_PbmIqX1YIqwtOWvRYxaMdRah', 'type': 'tool_call'}, {'name': 'web_search', 'args': {'query': 'WEE1 inhibitor APR-1051 Aprea Therapeutics clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitor APR-1051 Aprea Therapeutics clinical trials 2024 2025', 'id': '4'}}, 'id': 'call_01_QKp481lni7YNYm6Ku8WSxf2c', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:05 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:05 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials 2024 2025 glioblastoma', 'state': {'search_query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials 2024 2025 glioblastoma', 'id': '3'}}\n",
      "2025-11-21 14:36:10 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor APR-1051 Aprea Therapeutics clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitor APR-1051 Aprea Therapeutics clinical trials 2024 2025', 'id': '4'}}\n",
      "2025-11-21 14:36:11 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:11 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'get_clinical_results', 'args': {'keywords': 'WEE1 inhibitor clinical trials oncology'}, 'id': 'call_00_xPWNyKddaJZD5EasCPpNAN3n', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:11 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:11 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'WEE1 inhibitor clinical trials oncology'}\n",
      "2025-11-21 14:36:15 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:15 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'get_clinical_results', 'args': {'keywords': 'WEE1 inhibitor clinical trials'}, 'id': 'call_00_89RRhPXpnZknbfTfWNxBcVzW', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:15 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:15 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'WEE1 inhibitor clinical trials'}\n",
      "2025-11-21 14:36:16 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:16 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials glioblastoma 2024 2025', 'state': {'search_query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials glioblastoma 2024 2025', 'id': 'search_4'}}, 'id': 'call_00_9NJevjcw0VgKU7JjeIc0uZux', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:16 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:16 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials glioblastoma 2024 2025', 'state': {'search_query': 'WEE1 inhibitor Debio-0123 Debiopharm clinical trials glioblastoma 2024 2025', 'id': 'search_4'}}\n",
      "2025-11-21 14:36:20 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:20 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1æŠ‘åˆ¶å‰‚ AZD1775 Adavosertib ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ AZD1775 Adavosertib ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '4'}}, 'id': 'call_00_nrdj3nnfMdqIg2pbhtC9uGWe', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:20 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:20 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1æŠ‘åˆ¶å‰‚ AZD1775 Adavosertib ä¸´åºŠè¯•éªŒ 2024 2025', 'state': {'search_query': 'WEE1æŠ‘åˆ¶å‰‚ AZD1775 Adavosertib ä¸´åºŠè¯•éªŒ 2024 2025', 'id': '4'}}\n",
      "2025-11-21 14:36:24 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:36:24 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'get_clinical_results', 'args': {'keywords': 'WEE1 inhibitor clinical trials'}, 'id': 'call_00_sDrMchnDxFEMc7fGuJFdB0Nj', 'type': 'tool_call'}]\n",
      "2025-11-21 14:36:24 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:36:24 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'WEE1 inhibitor clinical trials'}\n",
      "2025-11-21 14:37:12 [INFO] agent.graph - get_tools|llmè¿”å›:# WEE1 Targeted Therapy Development Status in Oncology - Research Report\n",
      "\n",
      "## Executive Summary\n",
      "\n",
      "WEE1 inhibitors represent an emerging class of targeted therapies in oncology that disrupt cancer cells' ability to manage stress and control cell division timing. The clinical development landscape is rapidly evolving with multiple compounds in various stages of clinical trials, primarily focusing on aggressive and hard-to-treat tumors.\n",
      "\n",
      "## Key WEE1 Inhibitors in Clinical Development\n",
      "\n",
      "### 1. Azenosertib (ZN-c3) - Zentalis Pharmaceuticals\n",
      "\n",
      "**Current Status:** Phase 2 clinical trials with promising efficacy data\n",
      "\n",
      "**Key Clinical Developments:**\n",
      "- **Ovarian Cancer:** In the Phase 2 DENALI trial (NCT05128825), azenosertib monotherapy demonstrated an overall response rate (ORR) of 34.9% among 43 response-evaluable patients with cyclin E1-positive platinum-resistant ovarian cancer [targetedonc, onclive]\n",
      "- **Pancreatic Cancer:** Phase 2 trial (NCT06015659) ongoing evaluating azenosertib in combination with gemcitabine for advanced pancreatic cancer after FOLFIRINOX progression [larvol, ascopubs]\n",
      "- **Regulatory Status:** FDA granted Fast Track designation for Cyclin E1-positive platinum-resistant epithelial ovarian cancer [onclive]\n",
      "\n",
      "**Safety Concerns:** In June 2024, FDA placed a partial clinical hold on three azenosertib trials after two patient deaths due to presumed sepsis [onclive, clinicaltrialsarena]\n",
      "\n",
      "### 2. Adavosertib (AZD1775/MK-1775)\n",
      "\n",
      "**Current Status:** Phase 2 clinical trials\n",
      "\n",
      "**Key Clinical Developments:**\n",
      "- **Ovarian Cancer:** Phase 2 trial (NCT01357161) showed improved progression-free survival when combined with carboplatin and paclitaxel in TP53-mutated platinum-sensitive ovarian cancer [nih, aacrjournals]\n",
      "- **Combination Therapy:** Demonstrated 38% ORR when combined with carboplatin in TP53-mutated platinum-resistant ovarian cancer [asco]\n",
      "- **Monotherapy:** Showed 36% ORR in CCNE1-amplified epithelial ovarian cancer [ascopubs, nih]\n",
      "- **Regulatory Status:** Received Orphan Drug designation in the European Union for ovarian cancer [researchandmarkets]\n",
      "\n",
      "### 3. Debio-0123 (Zedoresertib) - Debiopharm\n",
      "\n",
      "**Current Status:** Phase 1/2 clinical trials\n",
      "\n",
      "**Key Clinical Developments:**\n",
      "- **Glioblastoma:** Open-label Phase 1/2 study (NCT05765812) investigating Debio-0123 in combination with temozolomide for recurrent/progressive glioblastoma and newly diagnosed patients [pharmatimes, oup]\n",
      "- **Unique Feature:** Brain-penetrant WEE1 inhibitor, important for treating brain tumors [drugdiscoverytrends]\n",
      "- **Study Design:** Includes dose escalation phase to identify recommended Phase 2 dose [oup]\n",
      "\n",
      "### 4. Other WEE1 Inhibitors in Development\n",
      "\n",
      "- **APR-1051, SC0191, and ACR-2316** - Various early-stage development [patsnap]\n",
      "- **SY-4835** - Phase 1 for advanced malignant solid tumors (status unknown) [PharmaOne]\n",
      "\n",
      "## Clinical Trial Landscape and Design\n",
      "\n",
      "The clinical trial landscape for WEE1 inhibitors employs various designs:\n",
      "- Phase I dose-escalation studies\n",
      "- Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies [patsnap]\n",
      "- Smarter trial models integrating molecular context as defining features [clinicalleader]\n",
      "\n",
      "## Combination Strategies\n",
      "\n",
      "Current research focuses on combination approaches:\n",
      "- **With Chemotherapy:** Gemcitabine, carboplatin, paclitaxel, temozolomide\n",
      "- **With Targeted Therapies:** PKMYT1 inhibitors\n",
      "- **With Immunotherapy:** Immune checkpoint inhibitors to render tumor microenvironment more immunogenic [patsnap]\n",
      "- **With Antibody-Drug Conjugates (ADCs)**\n",
      "\n",
      "## Challenges and Future Directions\n",
      "\n",
      "**Key Challenges:**\n",
      "- Determining which patients are most likely to benefit\n",
      "- Managing toxicities, including hematological toxicities\n",
      "- Overcoming clinical holds due to safety concerns [clinicalleader]\n",
      "\n",
      "**Future Progress:**\n",
      "- More sophisticated approaches integrating real-time data metrics\n",
      "- AI emerging as a key enabler for trial optimization\n",
      "- Refining patient selection biomarkers (Cyclin E1, TP53 mutations, CCNE1 amplification) [clinicalleader]\n",
      "\n",
      "## Regulatory Status and Approvals\n",
      "\n",
      "- **Fast Track Designation:** Azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer\n",
      "- **Orphan Drug Designation:** Adavosertib in EU for ovarian cancer\n",
      "- No WEE1 inhibitors have received full regulatory approval as of November 2025\n",
      "\n",
      "## Conclusion\n",
      "\n",
      "WEE1 targeted therapy development continues to advance with promising clinical activity observed in multiple tumor types, particularly ovarian cancer and glioblastoma. The field is characterized by active clinical development, combination strategy exploration, and ongoing optimization of patient selection criteria. While safety concerns have emerged with some compounds, the therapeutic potential of WEE1 inhibition in oncology remains significant, with continued research focused on maximizing efficacy while managing toxicity profiles.\n",
      "\n",
      "*Report compiled based on search results current through November 21, 2025*\n",
      "2025-11-21 14:37:12 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:37:12 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:37:26 [INFO] agent.graph - get_tools|llmè¿”å›:# WEE1 Inhibitor Clinical Trials Pipeline 2024-2025: Comprehensive Analysis\n",
      "\n",
      "## Executive Summary\n",
      "\n",
      "The WEE1 inhibitor clinical development landscape in 2024-2025 shows significant activity across multiple compounds, with several programs advancing through clinical trials. The most advanced programs include azenosertib (ZN-c3), Debio-0123 (zedoresertib), and APR-1051, with development focused on various solid tumors including ovarian cancer, glioblastoma, and other malignancies.\n",
      "\n",
      "## Key WEE1 Inhibitor Programs\n",
      "\n",
      "### 1. Azenosertib (ZN-c3) - Zentalis Pharmaceuticals\n",
      "\n",
      "**Development Status**: Phase 2/3 clinical trials\n",
      "\n",
      "**Key Clinical Trials**:\n",
      "- **DENALI Trial** (NCT05128825): Phase 2 in platinum-resistant ovarian cancer (PROC) with Cyclin E1+ tumors\n",
      "- **TETON Trial**: Recurrent or persistent uterine serous carcinoma\n",
      "- **MAMMOTH Study** (ZN-c3-006): PARP-inhibitor resistant ovarian cancer\n",
      "- **ZN-c3-016**: Combination with encorafenib and cetuximab for metastatic BRAF V600E mutant colorectal cancer\n",
      "\n",
      "**2024-2025 Key Developments**:\n",
      "- **FDA Regulatory**: Partial clinical hold placed in June 2024 due to two deaths in DENALI trial; lifted in September 2024 after safety review [onclive]\n",
      "- **Efficacy Data** (as of December 2024):\n",
      "  - Cyclin E1+ PROC patients: ORR 34.8%, mDOR 5.2 months (ZN-c3-001 study) [natlawreview, zentalis]\n",
      "  - DENALI Part 1b: ORR 34.9% in response-evaluable Cyclin E1+ PROC patients [zentalis, targetedonc]\n",
      "  - MAMMOTH study: ORR 31.3% in Cyclin E1+ patients [natlawreview]\n",
      "\n",
      "**Future Plans**: Registration-intent DENALI Part 2 topline data anticipated by end of 2026 [natlawreview]\n",
      "\n",
      "### 2. Debio-0123 (Zedoresertib) - Debiopharm\n",
      "\n",
      "**Development Status**: Phase 1/2 clinical trials\n",
      "\n",
      "**Key Clinical Trial**: NCT05765812 - Combination with temozolomide for recurrent/progressive glioblastoma and with TMZ+radiotherapy for newly diagnosed GBM\n",
      "\n",
      "**2024-2025 Status**:\n",
      "- Arm B (with concomitant TMZ and RT) permanently halted based on safety findings [clinicaltrials]\n",
      "- Phase 2 portion ongoing to assess efficacy in combination with TMZ vs standard of care\n",
      "- Oral, brain-penetrant selective WEE1 inhibitor [debiopharm]\n",
      "\n",
      "### 3. APR-1051 - Aprea Therapeutics\n",
      "\n",
      "**Development Status**: Phase 1 clinical trials\n",
      "\n",
      "**Key Clinical Trial**: ACESOT-1051 Phase 1 trial (NCT06260514)\n",
      "\n",
      "**2024-2025 Timeline**:\n",
      "- **March 2024**: FDA IND clearance [globenewswire]\n",
      "- **June 2024**: Trial initiation with initial cohorts (10 mg, 20 mg, 30 mg) [patsnap]\n",
      "- **March 2025**: Enrolling Cohort 5 (70 mg dose) [biospace]\n",
      "- **November 2025**: Advanced to 150 mg once-daily cohort [aprea]\n",
      "\n",
      "**Preliminary Results**:\n",
      "- Dose Level 6 (100 mg once daily): 3/4 heavily pretreated patients achieved stable disease [aprea]\n",
      "- Disease stabilization in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations [aprea]\n",
      "- Manageable safety profile with mostly Grade 1/2 adverse events [aprea]\n",
      "\n",
      "### 4. Adavosertib (AZD1775) - AstraZeneca\n",
      "\n",
      "**Development Status**: Discontinued\n",
      "- AstraZeneca discontinued adavosertib due to tolerability issues in 2022 [oncologypipeline]\n",
      "- Previous Phase II trial showed limited clinical activity as monotherapy in SETD2-altered advanced solid tumors [nih]\n",
      "\n",
      "## Clinical Trial Landscape Analysis\n",
      "\n",
      "### Active Clinical Trials (from Local Database)\n",
      "\n",
      "The local clinical trials database shows 30 active WEE1 inhibitor trials, with key patterns:\n",
      "\n",
      "**Most Active Compounds**:\n",
      "- Azenosertib: 12 trials across multiple indications\n",
      "- Zedoresertib: 5 trials\n",
      "- APR-1051: 1 trial (NCT06260514)\n",
      "\n",
      "**Key Indications**:\n",
      "- Ovarian cancer (6 trials)\n",
      "- Colorectal cancer (4 trials)\n",
      "- Glioblastoma (2 trials)\n",
      "- Breast cancer (3 trials)\n",
      "- Pancreatic cancer (2 trials)\n",
      "\n",
      "**Trial Status Distribution**:\n",
      "- Recruiting: 16 trials\n",
      "- Not yet recruiting: 3 trials\n",
      "- Terminated: 4 trials\n",
      "- Withdrawn: 3 trials\n",
      "- Active, not recruiting: 1 trial\n",
      "\n",
      "## Development Challenges and Trends\n",
      "\n",
      "### Safety Concerns\n",
      "- **Hematological toxicity**: Common challenge with WEE1 inhibitors due to WEE1 activity in normal proliferating cells [patsnap]\n",
      "- **Regulatory holds**: Azenosertib experienced partial clinical hold in 2024\n",
      "- **Combination toxicity**: Debio-0123 arm with TMZ+RT halted due to safety findings\n",
      "\n",
      "### Biomarker-Driven Development\n",
      "- **Cyclin E1 overexpression**: Emerging as key biomarker for patient selection across multiple programs\n",
      "- **Genetic alterations**: Focus on FBXW7, CCNE1, KRASG12V + TP53 alterations\n",
      "\n",
      "### Combination Strategies\n",
      "- With DNA-damaging agents (chemotherapy, radiation)\n",
      "- With targeted therapies (encorafenib, cetuximab)\n",
      "- With immunotherapies (pembrolizumab)\n",
      "\n",
      "## Market and Competitive Landscape\n",
      "\n",
      "**Leading Developers**:\n",
      "- Zentalis Pharmaceuticals (azenosertib)\n",
      "- Debiopharm (Debio-0123)\n",
      "- Aprea Therapeutics (APR-1051)\n",
      "\n",
      "**Discontinued Programs**:\n",
      "- AstraZeneca's adavosertib (tolerability issues)\n",
      "- Several terminated trials across the pipeline\n",
      "\n",
      "## Future Outlook\n",
      "\n",
      "The WEE1 inhibitor pipeline remains active with multiple compounds advancing through clinical development. Key near-term milestones include:\n",
      "\n",
      "1. **2025-2026**: Additional data readouts from ongoing azenosertib trials\n",
      "2. **2026**: Topline data from registration-intent DENALI Part 2 study\n",
      "3. **Ongoing**: Dose escalation and optimization for APR-1051 and Debio-0123\n",
      "\n",
      "The field continues to evolve with improved understanding of patient selection biomarkers and combination strategies to maximize efficacy while managing toxicity profiles.\n",
      "\n",
      "*Sources: Multiple clinical trial registries, company announcements, and peer-reviewed publications as cited throughout the report.*\n",
      "2025-11-21 14:37:26 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:37:26 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:37:41 [INFO] agent.graph - get_tools|llmè¿”å›:# WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±•åŠä¸´åºŠè¯•éªŒæŠ¥å‘Š\n",
      "\n",
      "åŸºäº2024-2025å¹´çš„æœ€æ–°ç ”ç©¶æ•°æ®ï¼Œä»¥ä¸‹æ˜¯WEE1é¶ç‚¹è¯ç‰©ç ”å‘çš„å…¨é¢è¿›å±•æŠ¥å‘Šï¼š\n",
      "\n",
      "## ä¸€ã€WEE1é¶ç‚¹ç”Ÿç‰©å­¦æœºåˆ¶\n",
      "\n",
      "**WEE1æ¿€é…¶ä½œç”¨æœºåˆ¶**ï¼š\n",
      "- WEE1æ¿€é…¶æ˜¯ç»†èƒå‘¨æœŸçš„å…³é”®è°ƒèŠ‚å› å­ï¼Œé€šè¿‡æŠ‘åˆ¶CDK1/2æ¥ç¡®ä¿ç»†èƒå‘¨æœŸæ­£å¸¸è¿›è¡Œå’ŒåŸºå› ç»„å®Œæ•´æ€§\n",
      "- WEE1æŠ‘åˆ¶å¯è¿«ä½¿DNAå—æŸçš„ç»†èƒè¿›å…¥æœ‰ä¸åˆ†è£‚ï¼Œå¯¼è‡´ç»†èƒæ­»äº¡ï¼Œç‰¹åˆ«æ˜¯åœ¨p53ç¼ºé™·çš„è‚¿ç˜¤ä¸­æ•ˆæœæ˜¾è‘—\n",
      "- WEE1æŠ‘åˆ¶å‰‚è¿˜èƒ½ä½¿ç™Œç»†èƒå¯¹DNAæŸä¼¤å‰‚ï¼ˆå¦‚åŒ–ç–—æˆ–æ”¾ç–—ï¼‰æ•æ„Ÿï¼Œå¢å¼ºæŠ—è‚¿ç˜¤ååº”\n",
      "\n",
      "*æ¥æºï¼š[patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*\n",
      "\n",
      "## äºŒã€ä¸»è¦WEE1æŠ‘åˆ¶å‰‚ä¸´åºŠè¿›å±•\n",
      "\n",
      "### 1. Azenosertib (ZN-c3)\n",
      "\n",
      "**ç›‘ç®¡çŠ¶æ€æ›´æ–°**ï¼š\n",
      "- 2024å¹´9æœˆï¼ŒFDAè§£é™¤äº†å¯¹Azenosertibè¯•éªŒçš„éƒ¨åˆ†ä¸´åºŠæç½®ï¼Œå…è®¸æ‰€æœ‰ç ”ç©¶æ¢å¤æ‚£è€…æ‹›å‹Ÿ\n",
      "- è¯¥å†³å®šæºäºDENALIè¯•éªŒä¸­æŠ¥å‘Šçš„ä¸¤ä¾‹å› æ¨å®šè´¥è¡€ç—‡å¯¼è‡´çš„æ­»äº¡äº‹ä»¶\n",
      "\n",
      "*æ¥æºï¼š[clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-0), [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-2)*\n",
      "\n",
      "**å…³é”®ä¸´åºŠè¯•éªŒ**ï¼š\n",
      "- **ZN-c3-001**ï¼š1æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œæ²»ç–—æ™šæœŸå®ä½“ç˜¤ï¼Œå·²å®Œæˆæ‹›å‹Ÿï¼ˆn=274ï¼‰\n",
      "- **DENALI**ï¼š2æœŸç ”ç©¶ï¼Œé’ˆå¯¹é“‚è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œï¼Œé¢„è®¡2025å¹´ä¸ŠåŠå¹´å¼€å§‹æ‹›å‹Ÿ\n",
      "- **TETON**ï¼š2æœŸç ”ç©¶ï¼Œé’ˆå¯¹å¤å‘æ€§æˆ–æŒç»­æ€§å­å®«æµ†æ¶²æ€§ç™Œ\n",
      "- **ZN-c3-016**ï¼šä¸è¾‰ç‘åˆä½œçš„1/2æœŸç ”ç©¶ï¼Œè”åˆEncorafenibå’Œè¥¿å¦¥æ˜”å•æŠ—æ²»ç–—è½¬ç§»æ€§BRAF V600Eçªå˜å‹ç»“ç›´è‚ ç™Œ\n",
      "\n",
      "*æ¥æºï¼š[onclive](https://vertexaisearch.cloud.google.com/id/2-1), [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2)*\n",
      "\n",
      "**ä¸´åºŠç–—æ•ˆæ•°æ®**ï¼ˆæˆªè‡³2024å¹´12æœˆ2æ—¥ï¼‰ï¼š\n",
      "- åœ¨Cyclin E1+é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€…ä¸­ï¼Œå®¢è§‚ç¼“è§£ç‡ï¼ˆORRï¼‰è¾¾34.8%ï¼ˆ8/23ï¼‰\n",
      "- ä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ï¼ˆmDORï¼‰ä¸º5.2ä¸ªæœˆ\n",
      "- DENALIè¯•éªŒ1béƒ¨åˆ†ä¸­ï¼Œå•è¯Azenosertibåœ¨43åå¯è¯„ä¼°æ‚£è€…ä¸­äº§ç”Ÿ34.9%çš„ORR\n",
      "\n",
      "*æ¥æºï¼š[onclive](https://vertexaisearch.cloud.google.com/id/2-1), [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)*\n",
      "\n",
      "**å®‰å…¨æ€§ç‰¹å¾**ï¼š\n",
      "- åœ¨æ€»æ—¥å‰‚é‡â‰¥300mgæ—¶è€å—æ€§è‰¯å¥½\n",
      "- æœªè§‚å¯Ÿåˆ°3çº§ä»¥ä¸Šèƒƒè‚ é“æ²»ç–—ç›¸å…³ä¸è‰¯äº‹ä»¶\n",
      "- 3çº§ä»¥ä¸Šè¡€æ¶²å­¦æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½\n",
      "\n",
      "*æ¥æºï¼š[onclive](https://vertexaisearch.cloud.google.com/id/2-1)*\n",
      "\n",
      "### 2. Debio0123\n",
      "\n",
      "**è¯ç‰©ç‰¹æ€§**ï¼š\n",
      "- é€‰æ‹©æ€§WEE1æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼Œèƒ½å¤Ÿç©¿é€è¡€è„‘å±éšœ\n",
      "- ä½œä¸ºå•è¯æ²»ç–—å’Œè”åˆæ²»ç–—åœ¨å„ç§å®ä½“ç˜¤ä¸­ç ”ç©¶\n",
      "\n",
      "*æ¥æºï¼š[debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)*\n",
      "\n",
      "**ä¸´åºŠè¯•éªŒè¿›å±•**ï¼š\n",
      "- å¤šé¡¹ä¸´åºŠç ”ç©¶æ­£åœ¨è¿›è¡Œï¼Œæ—¨åœ¨å¢å¼ºDNAæŸä¼¤å‰‚çš„æ•ˆæœ\n",
      "- ä¸æ ‡å‡†åŒ–ç–—è”åˆæ²»ç–—å°ç»†èƒè‚ºç™Œå’Œèƒ¶è´¨æ¯ç»†èƒç˜¤\n",
      "- ä¸Lunresertibï¼ˆPKMYT1æŠ‘åˆ¶å‰‚ï¼‰è”åˆæ²»ç–—æ™šæœŸå®ä½“ç˜¤\n",
      "- åœ¨ç¾å›½ã€è¥¿ç­ç‰™å’Œç‘å£«è¿›è¡Œçš„1æœŸå•è¯æ²»ç–—ç ”ç©¶\n",
      "\n",
      "*æ¥æºï¼š[drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1), [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)*\n",
      "\n",
      "### 3. ACR-2316\n",
      "\n",
      "**è¯ç‰©ç‰¹æ€§**ï¼š\n",
      "- æ–°å‹é€‰æ‹©æ€§åŒé‡WEE1/PKMYT1æŠ‘åˆ¶å‰‚\n",
      "- è®¾è®¡ç”¨äºä¼˜è¶Šçš„å•è¯æ´»æ€§\n",
      "\n",
      "*æ¥æºï¼š[acrivon](https://vertexaisearch.cloud.google.com/id/3-2)*\n",
      "\n",
      "**å¼€å‘è¿›å±•**ï¼š\n",
      "- Acrivon Therapeuticsè®¡åˆ’åœ¨2024å¹´ç¬¬å››å­£åº¦æäº¤INDç”³è¯·\n",
      "- 1æœŸå•è¯æ²»ç–—ç ”ç©¶æ­£åœ¨è¿›è¡Œï¼Œæ‚£è€…ç»™è¯å·²å¼€å§‹\n",
      "- åœ¨å­å®«å†…è†œç™Œä¸­è§‚å¯Ÿåˆ°ç¡®è®¤çš„éƒ¨åˆ†ç¼“è§£\n",
      "- é¢„è®¡2025å¹´ä¸‹åŠå¹´å…¬å¸ƒ1æœŸç ”ç©¶çš„é¦–æ‰¹ä¸´åºŠæ•°æ®\n",
      "\n",
      "*æ¥æºï¼š[acrivon](https://vertexaisearch.cloud.google.com/id/3-3), [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5)*\n",
      "\n",
      "### 4. AZD1775 (Adavosertib)\n",
      "\n",
      "**ä¸´åºŠç ”ç©¶ç»“æœ**ï¼š\n",
      "- é’ˆå¯¹SETD2çªå˜æ™šæœŸå®ä½“ç˜¤çš„IIæœŸç ”ç©¶æ˜¾ç¤ºå•è¯æ²»ç–—ä¸´åºŠæ´»æ€§æœ‰é™\n",
      "- æœªè§‚å¯Ÿåˆ°å®¢è§‚ååº”ï¼Œä½†éƒ¨åˆ†æ‚£è€…å‡ºç°è½»å¾®è‚¿ç˜¤æ¶ˆé€€å’Œå»¶é•¿ç–¾ç—…ç¨³å®š\n",
      "- è”åˆæ²»ç–—åœ¨æŸäº›ç™Œç—‡ç±»å‹ä¸­æ˜¾ç¤ºæ›´å¥½æ•ˆæœ\n",
      "\n",
      "*æ¥æºï¼š[aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0), [nih](https://vertexaisearch.cloud.google.com/id/4-1)*\n",
      "\n",
      "## ä¸‰ã€ç»„åˆæ²»ç–—ç­–ç•¥\n",
      "\n",
      "**å½“å‰æ¢ç´¢çš„ç»„åˆ**ï¼š\n",
      "- WEE1æŠ‘åˆ¶å‰‚ä¸åŒ–ç–—è¯ç‰©è”åˆ\n",
      "- ä¸PKMYT1æŠ‘åˆ¶å‰‚è”åˆï¼ˆå¦‚Lunresertibï¼‰\n",
      "- ä¸æŠ—ä½“è¯ç‰©å¶è”ç‰©ï¼ˆADCsï¼‰è”åˆ\n",
      "- ä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚è”åˆ\n",
      "\n",
      "*æ¥æºï¼š[clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*\n",
      "\n",
      "## å››ã€æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®åº“ç»“æœ\n",
      "\n",
      "æ ¹æ®æœ¬åœ°ä¸´åºŠè¯•éªŒå·¥å…·æŸ¥è¯¢ï¼Œå½“å‰æ´»è·ƒçš„WEE1ç›¸å…³ä¸´åºŠè¯•éªŒåŒ…æ‹¬ï¼š\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— + Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06351332 | å¡é“‚ + å¸•åšåˆ©ç å•æŠ— + Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ + Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "\n",
      "*æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)*\n",
      "\n",
      "## äº”ã€æŒ‘æˆ˜ä¸æœªæ¥æ–¹å‘\n",
      "\n",
      "**ä¸»è¦æŒ‘æˆ˜**ï¼š\n",
      "- è·å¾—æ€§è€è¯\n",
      "- æ¯’æ€§ç®¡ç†\n",
      "- æ‚£è€…é€‰æ‹©ä¼˜åŒ–\n",
      "\n",
      "*æ¥æºï¼š[nih](https://vertexaisearch.cloud.google.com/id/1-5)*\n",
      "\n",
      "**æœªæ¥é‡ç‚¹**ï¼š\n",
      "- è¯†åˆ«æœ€å¯èƒ½å—ç›Šçš„æ‚£è€…ç¾¤ä½“\n",
      "- å¼€å‘æ›´æ™ºèƒ½çš„è¯•éªŒæ¨¡å‹ä»¥è·Ÿè¸ªè‚¿ç˜¤ååº”\n",
      "- åˆ¶å®šè°¨æ…çš„ç»™è¯ç­–ç•¥ä»¥ç®¡ç†æ¯’æ€§\n",
      "\n",
      "*æ¥æºï¼š[clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*\n",
      "\n",
      "## å…­ã€æ€»ç»“\n",
      "\n",
      "WEE1æŠ‘åˆ¶å‰‚ä½œä¸ºæœ‰å‰æ™¯çš„ç™Œç—‡æ²»ç–—é¶ç‚¹ï¼Œåœ¨2024-2025å¹´å–å¾—äº†æ˜¾è‘—è¿›å±•ã€‚Azenosertibåœ¨ç›‘ç®¡éšœç¢è§£é™¤åé‡æ–°è¿›å…¥å¿«é€Ÿå‘å±•è½¨é“ï¼Œåœ¨åµå·¢ç™Œå’Œå­å®«ç™Œä¸­æ˜¾ç¤ºå‡ºæœ‰å¸Œæœ›çš„ç–—æ•ˆã€‚æ–°å‹åŒé‡æŠ‘åˆ¶å‰‚ACR-2316å’Œé€‰æ‹©æ€§æŠ‘åˆ¶å‰‚Debio0123ä¹Ÿè¿›å…¥ä¸´åºŠå¼€å‘é˜¶æ®µã€‚ç»„åˆæ²»ç–—ç­–ç•¥çš„æ¢ç´¢ä¸ºWEE1æŠ‘åˆ¶å‰‚çš„ä¸´åºŠåº”ç”¨å¼€è¾Ÿäº†æ–°çš„å¯èƒ½æ€§ã€‚éšç€æ›´å¤šä¸´åºŠæ•°æ®çš„ç§¯ç´¯ï¼ŒWEE1æŠ‘åˆ¶å‰‚æœ‰æœ›æˆä¸ºå¤šç§ç™Œç—‡ç±»å‹çš„é‡è¦æ²»ç–—é€‰æ‹©ã€‚\n",
      "\n",
      "*æŠ¥å‘Šæ—¥æœŸï¼š2025å¹´11æœˆ21æ—¥*\n",
      "2025-11-21 14:37:41 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:37:41 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:37:41 [INFO] agent.utils - ğŸ’¬len(messages)=1,research_topic=WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\n",
      "2025-11-21 14:37:41 [INFO] agent.graph - ğŸ¤”summaries=Several WEE1 inhibitor programs are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). These inhibitors are being evaluated in clinical trials across a spectrum of malignancies, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, uterine serous carcinoma, small cell lung cancer, glioblastoma, and head and neck cancers [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**Specific WEE1 Inhibitors and their Development Status:**\n",
      "\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in several clinical trials [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "    *   Azenosertib is being studied in combination with LB-100 (a PP2A inhibitor) in a Phase Ib setting for patients with metastatic colorectal cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   A Phase 2 single-arm trial is investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   Zentalis Pharmaceuticals is focusing on azenosertib's development, particularly in cyclin E1-positive, platinum-resistant ovarian cancer [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4). A potentially registrational study is expected to start in 2025, with data readout by the end of 2026 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "    *   Azenosertib is also being evaluated in combination with topoisomerase I (TOP1) inhibitor-based antibody-drug conjugates (ADCs) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Azenosertib, in combination with gemcitabine, is being investigated in an upcoming Investigator-Initiated Phase 2 trial for relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   The FDA had placed a partial clinical hold on azenosertib trials due to patient deaths but has since lifted it, allowing studies to resume [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Adavosertib (AZD1775):** This WEE1 inhibitor is also in clinical development [nih](https://vertexaisearch.cloud.google.com/id/1-6) [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7).\n",
      "\n",
      "    *   A Phase II trial of adavosertib in SETD2-altered advanced solid tumor malignancies showed limited clinical activity as a monotherapy [nih](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "    *   AstraZeneca is a major player in developing therapies for WEE1 protein inhibitors, including adavosertib [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7). However, AstraZeneca discontinued adavosertib due to tolerability issues in 2022 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "*   **Debio-0123:** Debiopharm, a biopharma company based in Switzerland, is developing this WEE1 inhibitor [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3). It is currently in a Phase I/II trial in combination with temozolomide for patients with glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3).\n",
      "*   **APR-1051:** Aprea Therapeutics is developing this oral WEE1 inhibitor [openpr](https://vertexaisearch.cloud.google.com/id/1-9). Early data from an ongoing Phase 1 study showed that 3 out of 4 heavily pretreated patients achieved stable disease [openpr](https://vertexaisearch.cloud.google.com/id/1-9). The trial is advancing to higher dose levels [openpr](https://vertexaisearch.cloud.google.com/id/1-9).\n",
      "*   **ACR-2316:** A Phase 1 study of ACR-2316 in specific advanced solid tumors is underway [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**General Trends and Challenges:**\n",
      "\n",
      "*   Most clinical trials involving WEE1 inhibitors are in early-phase development (Phase I or Phase Ib/II) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   WEE1 inhibitors are being explored for their potential to sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Challenges in WEE1 inhibitor development include potential toxicity and side effects, as WEE1 is also active in normal proliferating cells [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Patient selection and overcoming resistance remain obstacles to clinical implementation [nih](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Here's an update on the clinical trials of azenosertib (ZN-c3), a WEE1 inhibitor, with a focus on the latest results from 2024 and 2025: \n",
      "\n",
      " **1. Clinical Trials & Target Patient Populations** \n",
      "\n",
      " *   **Advanced Solid Tumors:** Azenosertib is being investigated as a monotherapy for advanced solid tumors in a Phase 1 trial (ZN-c3-001) [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Platinum-Resistant Ovarian Cancer (PROC):** It's also being evaluated in patients with platinum-resistant ovarian cancer in the Phase 2 DENALI trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). The DENALI trial focuses on high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). Part 2 of the DENALI study will be conducted in subjects whose tumors are Cyclin E1 positive [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). \n",
      " *   **Uterine Serous Carcinoma:** Azenosertib is under investigation for women with recurrent or persistent uterine serous carcinoma in the TETON trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [cancer](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      " *   **Metastatic BRAF V600E Mutant Colorectal Cancer:** Azenosertib is being evaluated in combination with encorafenib and cetuximab for patients with this type of colorectal cancer in the ZN-c3-016 study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **PARP-inhibitor resistant ovarian cancer:** Azenosertib is also being evaluated in patients with PARP-inhibitor resistant ovarian cancer in the MAMMOTH (ZN-c3-006) study [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Relapsed or Refractory Osteosarcoma:** Azenosertib is being studied in combination with gemcitabine for adult and pediatric patients with relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " **2. Key Developments in 2024** \n",
      "\n",
      " *   **FDA Partial Clinical Hold Lifted:** In June 2024, the FDA placed a partial clinical hold on trials evaluating azenosertib due to two deaths reported in the DENALI trial from presumed sepsis [onclive](https://vertexaisearch.cloud.google.com/id/2-0). This hold was lifted in September 2024 after the FDA reviewed a comprehensive safety assessment from Zentalis Pharmaceuticals [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Data Readouts:** Additional data for azenosertib was anticipated in the fourth quarter of 2024 [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      "\n",
      " **3. Efficacy Results (as of December 2, 2024 data cutoff)** \n",
      "\n",
      " *   **ZN-c3-001 Study:** Patients with Cyclin E1+ PROC, who were dosed at an intermittent schedule, experienced an objective response rate (ORR) of 34.8% and a median duration of response (mDOR) of 5.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Part 1b:** In patients with Cyclin E1+ PROC tumors who were response-evaluable, an ORR of 34.9% was observed [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). In the intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3% and the mDOR was approximately 5.5 months [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **MAMMOTH (ZN-c3-006) study:** Cyclin E1+ patients treated at the primary dose-of interest 400mg QD 5:2 had an ORR of 31.3% and an mDOR of 4.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Azenosertib in combination with chemotherapy:** Patients with Cyclin E1 overexpressing tumors demonstrated significant improvements in ORR and PFS vs patients with tumors having low expression [asco](https://vertexaisearch.cloud.google.com/id/2-7). \n",
      "\n",
      " **4. Safety and Tolerability** \n",
      "\n",
      " *   **Generally Tolerable:** Azenosertib has generally been well-tolerated in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      " *   **Low rates of Grade 3+ hematological toxicity:** The majority of hematological toxicity events were Grade 3 [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **Low rate of TRAEs leading to discontinuation:** A low rate of treatment-related adverse events led to discontinuation [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Trial Grade 5 Events:** There were two previously reported treatment-related Grade 5 events in the DENALI study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      "\n",
      " **5. Ongoing and Future Plans** \n",
      "\n",
      " *   **DENALI Part 2:** Topline data from the registration-intent DENALI Part 2 is anticipated by the end of 2026 [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Further Investigation:** Data supports further investigation of azenosertib with gemcitabine in patients with relapsed or refractory osteosarcoma in an upcoming Phase 2 trial [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " Keep in mind that clinical trial information can change, so it's always a good idea to consult the official sources for the most up-to-date details [cancer](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an oral, brain-penetrant, and selective WEE1 kinase inhibitor [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). Debiopharm is currently developing Debio-0123 to address the unmet needs of patients with difficult-to-treat cancers [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). WEE1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, that allows cells to repair their DNA before resuming their cell cycle [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0). Inhibition of WEE1, particularly in combination with DNA damaging agents, induces an overload of arrests in the DNA damage response process [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "Debiopharm is conducting an open-label phase 1/2 study of Debio-0123 in combination with temozolomide (TMZ) in adult participants with recurrent or progressive glioblastoma (GBM) and with TMZ and radiotherapy (RT) in newly diagnosed GBM [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is identified by ClinicalTrials.gov ID NCT05765812 [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is designed to identify the recommended phase 2 dose of Debio-0123 in combination with TMZ (Arm A) and with TMZ and RT (Arm B) and to characterize the safety and tolerability of these combinations in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3). Arm B of the study, which assessed Debio-0123 with concomitant TMZ and RT, has been permanently halted based on safety findings [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4). The primary purpose of Phase 2 of this study is to assess the efficacy of Debio 0123 at the recommended dose in combination with TMZ, compared to standard of care in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Aprea Therapeutics is currently evaluating APR-1051, a selective WEE1 inhibitor, in the ACESOT-1051 Phase 1 clinical trial for patients with advanced or metastatic solid tumors [aprea](https://vertexaisearch.cloud.google.com/id/4-0).\n",
      "\n",
      "**Key points regarding the APR-1051 clinical trials in 2024 and 2025:**\n",
      "\n",
      "*   **FDA Clearance and Trial Initiation:** The U.S. FDA cleared the Investigational New Drug (IND) application for APR-1051 in March 2024, and the Phase 1 ACESOT-1051 trial was initiated in June 2024 [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [aprea](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   **ACESOT-1051 Trial Design:** This is a biomarker-driven, first-in-human study assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7). It involves a dose escalation phase (Part 1, up to 39 patients) and a dose optimization phase (Part 2, up to 40 patients) to determine the Recommended Phase 2 Dose (RP2D) [aprea](https://vertexaisearch.cloud.google.com/id/4-8) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [biospace](https://vertexaisearch.cloud.google.com/id/4-4). Oral APR-1051 is administered daily in 28-day cycles [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "*   **Enrollment and Dosing:** Enrollment began in June 2024, with initial cohorts receiving doses of 10 mg, 20 mg, and 30 mg [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-8). By March 2025, the trial was enrolling patients in Cohort 5 (70 mg dose) [biospace](https://vertexaisearch.cloud.google.com/id/4-9). In November 2025, the trial had advanced to the 150 mg once-daily cohort [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Preliminary Data:**\n",
      "    *   **2024:** Preliminary data from the first patients in the ACESOT-1051 study indicated that APR-1051 was safe and well-tolerated, with no significant hematologic toxicity [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "    *   **2025:**\n",
      "        *   In Q2 2025, early disease control was observed in three patients during the Phase 1 ACESOT-1051 trial [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11).\n",
      "        *   Results from Dose Level 6 (100 mg once daily) showed that 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/4-10). Disease stabilization was seen in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "        *   APR-1051 was manageable, with mostly Grade 1 or 2 adverse events, mainly gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Focus on Cyclin E Overexpression:** Aprea is advancing APR-1051 as a monotherapy in cancers with Cyclin E overexpression, as these cancers represent a high unmet medical need [aprea](https://vertexaisearch.cloud.google.com/id/4-12) [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [aprea](https://vertexaisearch.cloud.google.com/id/4-13) [biospace](https://vertexaisearch.cloud.google.com/id/4-9).\n",
      "*   **Potential Advantages of APR-1051:** Aprea believes APR-1051 may address the shortcomings of other WEE1 inhibitors due to its unique molecular structure, selectivity for WEE1, improved pharmacokinetic properties, and absence of QT prolongation [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5). APR-1051 also exhibits low off-target inhibition of PLK1, PLK2, and PLK3, which may confer an improved toxicity profile [onclive](https://vertexaisearch.cloud.google.com/id/4-6).\n",
      "*   **Preclinical Studies:** Preclinical studies have demonstrated that APR-1051 suppresses the growth of CCNE1-amplified HGSOC xenografted tumors and is relatively well-tolerated in mice [aprea](https://vertexaisearch.cloud.google.com/id/4-3). It also shows potent single-agent activity across a broad panel of human and murine head and neck cancer cell lines and significant anti-tumor synergy with antiâ€“PD-1 therapies in HPV+ HNSCC models.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)*   **Financial Runway:** Aprea reported $16.5 million in cash as of June 30, 2025, which is expected to fund operations into Q2 2026.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are emerging as a promising strategy in oncology, particularly for aggressive and hard-to-treat tumors [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). These inhibitors target the pressure points that fast-growing cancers rely on to survive, especially their ability to manage stress and control the timing of cell division [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). By blocking WEE1, researchers aim to disrupt cancer's ability to stay ahead of treatment [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**WEE1 Inhibitors in Clinical Development:**\n",
      "Several WEE1 inhibitors are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Examples include:\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in various clinical trials, including a Phase 2 trial in combination with gemcitabine for second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Zentalis Pharmaceuticals is developing azenosertib (ZN-c3) as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). It is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC was presented at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-3) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2).\n",
      "*   **AZD1775 (Adavosertib or MK-1775):** Adavosertib selectively targets and inhibits WEE1, preventing the phosphorylation of CDC2 and impairing the G2 DNA damage checkpoint [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4). It is currently in Phase II clinical trials for ovarian cancer and has received Orphan Drug designation in the European Union for this indication [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4).\n",
      "*   **Debio-0123:** Debiopharm has this WEE1 inhibitor in Phase I/II trials in combination with temozolomide for glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_1-5).\n",
      "*   **APR-1051, SC0191, and ACR-2316** [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Clinical Trial Landscape and Design:**\n",
      "The clinical trial landscape for WEE1 inhibitors is rapidly evolving [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Trials employ various designs, from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Researchers are also exploring smarter trial models that track how tumors respond over time, integrating molecular context as defining features of therapeutic opportunity [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**Combination Strategies:**\n",
      "Combination approaches are driving the next wave of progress, pairing WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs) [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Combining WEE1 inhibitors with immune checkpoint inhibitors holds the promise of directly killing tumor cells and rendering the tumor microenvironment more immunogenic, permitting a more robust anti-tumor immune response [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "Success hinges on overcoming key challenges while refining trial design [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Determining which patients are most likely to benefit and managing toxicities are major priorities [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Future progress will depend on more sophisticated approaches that integrate real-time data metrics, with AI emerging as a key enabler [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Azenosertib (ZN-c3) is under investigation in clinical trials for both ovarian and pancreatic cancer in 2024 and 2025. Here's a summary of the recent findings and ongoing studies: \n",
      "\n",
      " **Ovarian Cancer:** \n",
      "\n",
      " *   **Promising Efficacy in Platinum-Resistant Ovarian Cancer:** Azenosertib monotherapy has shown promising efficacy in heavily pretreated patients with cyclin E1â€“positive platinum-resistant ovarian cancer.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   In part 1b of the phase 2 DENALI trial (NCT05128825), azenosertib achieved an overall response rate (ORR) of 34.9% (95% CI, 21.0%-50.9%) among 43 response-evaluable patients.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   As of December 2, 2024, data cutoff, the ORR in the intention-to-treat (ITT) cyclin E1â€“positive population (n = 48) was 31.3% (95% CI, 18.7%-46.3%). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The median duration of response (DOR) was approximately 5.5 months (95% CI, 2.7-not evaluable). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The FDA granted fast track designation to azenosertib for the treatment of patients with Cyclin E1â€“positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. \n",
      " *  [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)  **DENALI Trial:**  This is a multi-part Phase 2 study evaluating the efficacy and safety of azenosertib in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2) 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive. \n",
      " *  [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2)  **Ongoing Trials:** \n",
      " *   ZN-c3-002 Phase 1b dose escalation trial of azenosertib in combination with bevacizumab for platinum-sensitive ovarian cancer. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  TETON (ZN-c3-004) Phase 2 clinical trial of azenosertib as a monotherapy for uterine serous carcinoma, with data expected in the first half of 2026. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  **Clinical Hold:**  In June 2024, the FDA placed a partial clinical hold on three azenosertib trials, including the Phase II DENALI trial, after two patient deaths due to presumed sepsis. \n",
      "\n",
      " * [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)*Pancreatic Cancer:** \n",
      "\n",
      " *   **Azenosertib in Combination with Gemcitabine:** A phase II trial (NCT06015659) is ongoing, evaluating azenosertib in combination with gemcitabine for advanced pancreatic cancer after progression or intolerance with FOLFIRINOX. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-6) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  Subjects receive azenosertib once daily on days 1-5, 8-12, and 15-19, and gemcitabine on days 1 and 8 of 21-day cycles. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The trial includes a safety lead-in portion with up to 12 subjects. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The primary objective is to evaluate the efficacy of azenosertib/gemcitabine, measured by 6-month progression-free survival (PFS) among second-line advanced pancreatic cancer patients. \n",
      " *  [cancer](https://vertexaisearch.cloud.google.com/id/search_2-8)  Azenosertib combined with gemcitabine showed synergistic cytotoxicity in PDAC cell lines. \n",
      "\n",
      " I [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)t's important to note that some trials involving azenosertib have faced partial clinical holds.\n",
      " [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)\n",
      "\n",
      "---\n",
      "\n",
      "Adavosertib (AZD1775) is a selective inhibitor of WEE1 kinase, an enzyme that regulates the cell cycle [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1) [nih](https://vertexaisearch.cloud.google.com/id/search_3-2) [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3). By inhibiting WEE1, adavosertib can disrupt the G1-S and G2-M checkpoints, leading to replication stress and tumor cell death [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). It has shown promising antitumor activity as a single agent and in combination with chemotherapy in several adult and pediatric solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5).\n",
      "\n",
      "### Clinical Trials involving Adavosertib (AZD1775) in 2024 and 2025:\n",
      "\n",
      "While the provided documents do not specifically mention clinical trials scheduled for 2024 or 2025, they do refer to ongoing and recently completed trials that provide relevant information. Most of the trials were completed before 2024, the information is still relevant for the use of adavosertib in 2024 and 2025.\n",
      "\n",
      "**Ovarian Cancer:**\n",
      "\n",
      "*   **Adavosertib with Carboplatin and Paclitaxel:** A phase II trial (NCT01357161) studied adavosertib in combination with carboplatin and paclitaxel for women with TP53-mutated, platinum-sensitive ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1). The results showed improved progression-free survival (PFS) with the addition of adavosertib [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "*   **Adavosertib with Carboplatin in Platinum-Resistant Ovarian Cancer:** A phase II study evaluated the combination of adavosertib and carboplatin in patients with TP53-mutated platinum-resistant ovarian cancer [asco](https://vertexaisearch.cloud.google.com/id/search_3-7) [nih](https://vertexaisearch.cloud.google.com/id/search_3-8) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The combination was found to be safe and effective, with an objective response rate (ORR) of 38% [asco](https://vertexaisearch.cloud.google.com/id/search_3-7).\n",
      "*   **Adavosertib Monotherapy in CCNE1-Amplified Ovarian Cancer:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The results showed promising clinical activity, especially in epithelial ovarian cancer, with an ORR of 36% [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [nih](https://vertexaisearch.cloud.google.com/id/search_3-10).\n",
      "*   **Adavosertib Before Surgery:** A pilot phase I trial is studying the effects of adavosertib on tumor DNA in patients undergoing surgery for advanced, high-grade ovarian, fallopian tube, or primary peritoneal cancer [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3).\n",
      "\n",
      "**Solid Tumors:**\n",
      "\n",
      "*   **Adavosertib Monotherapy in Advanced Solid Tumors:** A phase I trial of once-daily adavosertib in patients with advanced solid tumors determined a recommended phase II dose [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). Another phase Ib study assessed the safety, tolerability, and efficacy of adavosertib monotherapy in patients with various advanced solid tumors [nih](https://vertexaisearch.cloud.google.com/id/search_3-2).\n",
      "*   **Adavosertib with Irinotecan in Pediatric Solid Tumors:** A phase I trial (ADVL1312) evaluated adavosertib in combination with irinotecan in children with relapsed solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5). The study defined the dose-limiting toxicities and recommended phase II dose of the combination [nih](https://vertexaisearch.cloud.google.com/id/search_3-5) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0). A phase II trial of the same combination was conducted for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma [umn](https://vertexaisearch.cloud.google.com/id/search_3-11).\n",
      "*   **Adavosertib in SETD2-Altered Solid Tumors:** A phase II trial (NCI 10170) assessed the efficacy of adavosertib in patients with solid tumor malignancies and clear cell renal cell carcinoma harboring a pathogenic SETD2 mutation [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12). The study found limited clinical activity of adavosertib monotherapy in this population [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12).\n",
      "*   **Adavosertib in CCNE1-Amplified Solid Tumors:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The study demonstrated a manageable toxicity profile and promising clinical activity, especially in epithelial ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9).\n",
      "\n",
      "These trials suggest that adavosertib, both as a single agent and in combination with other therapies, has potential in treating ovarian cancer and other solid tumors, particularly in specific genetic contexts such as TP53 mutations or CCNE1 amplification [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an investigational, brain-penetrant, and selective WEE1 kinase inhibitor being developed by Debiopharm [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). WEE1 is a key regulator of cell cycle checkpoints, and its inhibition, especially with DNA-damaging agents, can cause an overload of DNA breaks, potentially leading to cancer cell death [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Debiopharm is conducting clinical trials with Debio-0123 for glioblastoma [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_4-2) [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). Glioblastomas are aggressive brain tumors with limited treatment options [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Clinical trial details:\n",
      "*   **Phase 1/2 study:** Debiopharm has initiated an open-label Phase 1/2 research study of Debio-0123 [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). This study investigates Debio-0123 in combination with temozolomide (TMZ) for patients with recurrent or progressive glioblastoma (GBM) and in combination with TMZ/RT (standard of care) for newly diagnosed patients [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). The initial phase aims to determine the recommended Phase 2 doses [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "*   **NCT05765812:** A Phase 1/2 study (NCT05765812) is evaluating Debio 0123 with TMZ in patients with recurrent GBM and Debio 0123 combined with TMZ-based chemoradiotherapy in patients with newly diagnosed GBM [oup](https://vertexaisearch.cloud.google.com/id/search_4-4). The study includes a dose escalation phase to identify the recommended Phase 2 dose, followed by an assessment of safety, pharmacokinetics, and preliminary antitumor activity [oup](https://vertexaisearch.cloud.google.com/id/search_4-4).\n",
      "*   **Arms of the study:** The study has different arms focusing on different treatment combinations [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6). Arm A involves Debio 0123 combined with temozolomide (TMZ) for recurrent or progressive glioblastoma. Arm B, which was previously added to the protocol but has been permanently halted due to safety concerns, involved Debio 0123 combined with TMZ and radiotherapy (RT) for newly diagnosed glioblastoma [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5).\n",
      "*   **Phase 2:** Phase 2 will assess the efficacy of Debio 0123 in combination with TMZ compared to the standard of care for adult participants with GBM [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6).\n",
      "\n",
      "Debio-0123 has shown the ability to penetrate the brain, which is important for treating brain tumors [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3). Preclinical data suggest that Debio-0123 can cross the blood-brain barrier and inhibit tumor growth, and its combination with TMZ has demonstrated increased antitumor activity [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Here's a summary of the recent developments in WEE1-targeted drug research and clinical trials: \n",
      "\n",
      " **1. WEE1 Inhibitors & Their Role** \n",
      "\n",
      " *   WEE1 kinase is a key regulator of the cell cycle, ensuring proper progression and genomic integrity by inhibiting CDK1/2, which prevents premature mitosis [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibition forces cells with damaged DNA into mitosis, leading to cell death, especially in tumors deficient in p53 [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibitors can also sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation, enhancing the anti-tumor response [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      "\n",
      " **2. Clinical Trials &è¿›å±•** \n",
      "\n",
      " *   Several WEE1 inhibitor programs are in active clinical development. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Examples include Azenosertib (ZN-c3), Debio0123, and ACR-2316. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   These inhibitors are being evaluated in various cancers, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, and head and neck cancers. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Trials range from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **3. Specific Drug & Trial Updates** \n",
      "\n",
      " *   **Azenosertib (ZN-c3):** \n",
      " *   The FDA lifted a partial clinical hold on azenosertib trials in September 2024, allowing studies to resume. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-2)*   Azenosertib is being investigated in Phase I for solid tumors and Phase II for ovarian and uterine cancer. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1)*   A Phase 2 study is investigating azenosertib with gemcitabine in advanced pancreatic adenocarcinoma. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   **AZD1775 (Adavosertib):** \n",
      " *   A Phase II study of adavosertib in SETD2-altered advanced solid tumor malignancies did not show objective responses. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   However, minor tumor regressions and prolonged stable disease were observed in some patients. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   **Debio0123:** Preliminary findings from studies in breast cancer and small cell lung cancer have highlighted the feasibility of combination therapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **4. Combination Strategies** \n",
      "\n",
      " *   Combination approaches are being explored to pair WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs). \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Combining WEE1 inhibitors with immune checkpoint inhibitors holds promise for enhancing anti-tumor immune response. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **5. Challenges & Future Directions** \n",
      "\n",
      " *   Challenges remain, including acquired resistance, toxicity, and patient selection. \n",
      "  [nih](https://vertexaisearch.cloud.google.com/id/1-5)*   Identifying patients most likely to benefit is a key priority. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Smarter trial models are needed to track tumor responses over time. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Careful dosing strategies are necessary to manage toxicity.\n",
      " [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)\n",
      "\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ Azenosertib (ZN-c3) åœ¨ 2024 å¹´å’Œ 2025 å¹´æœ€æ–°ä¸´åºŠè¯•éªŒçš„æ›´æ–°ï¼š\n",
      "\n",
      "**ä¸´åºŠè¯•éªŒçŠ¶æ€**\n",
      "*   FDAè§£é™¤äº†å…ˆå‰å¯¹è¯„ä¼°æ™šæœŸå®ä½“ç˜¤æ‚£è€…WEE1æŠ‘åˆ¶å‰‚Azenosertibç ”ç©¶çš„éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   2024å¹´6æœˆï¼Œç›‘ç®¡æœºæ„å¯¹é’ˆå¯¹æ™šæœŸå®ä½“ç˜¤æ‚£è€…çš„1æœŸZN-c3-001è¯•éªŒ (NCT04158336)ã€é’ˆå¯¹é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€…çš„2æœŸDENALIè¯•éªŒ (NCT05128825) ä»¥åŠé’ˆå¯¹å­å®«æµ†æ¶²æ€§ç™Œæ‚£è€…çš„2æœŸT [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-0) [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ETONè¯•éªŒ (NCT04814108) å‘å¸ƒäº†éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   è¯¥å†³å®šæºäºDENALIè¯•éªŒä¸­æŠ¥å‘Šçš„ä¸¤ä¾‹å› æ¨å®šè´¥è¡€ç—‡å¯¼è‡´çš„æ­»äº¡ã€‚\n",
      "*   åœ¨å®¡æŸ¥äº†Azenosertibçš„å¼€å‘å•†Zentalis Pharmaceuticalsçš„å®Œæ•´å›å¤æ–¹æ¡ˆåï¼ŒFDAæ‰¹å‡†è¿™äº›ç ”ç©¶æ¢å¤æ‰€æœ‰æ­£åœ¨è¿›è¡Œçš„è¯¥è¯ç‰©ç ”ç©¶çš„æ‚£è€…æ‹›å‹Ÿï¼Œä¸”ä¸´åºŠå¼€å‘è®¡åˆ’æ²¡æœ‰ä»»ä½•å˜æ›´.\n",
      "\n",
      "**æ­£åœ¨è¿›è¡Œå’Œè®¡åˆ’ä¸­çš„è¯•éªŒ**\n",
      "*   **ZN-c3-001ï¼š** ä¸€é¡¹1æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€å‰‚é‡é€’å¢å’Œæ‰©å±•ç ”ç©¶ï¼Œæ—¨åœ¨ç ”ç©¶Azenosertibä½œä¸ºå•è¯ç–—æ³•æ²»ç–—æ™šæœŸå®ä½“ç˜¤æ‚£è€…ã€‚è¯¥ç ”ç©¶å·²å®Œå…¨æ‹›å‹Ÿ [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) (n=274)ã€‚\n",
      "*   **DENALIï¼š** ä¸€é¡¹2æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œçº³å…¥è‡³å°‘18å²ä¸”æ‚£æœ‰é“‚è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œã€è¾“åµç®¡ç™Œæˆ–åŸå‘æ€§è…¹è†œç™Œçš„æ‚£è€…ã€‚DENALI [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) 2æœŸè¯•éªŒé¢„è®¡å°†äº2025å¹´ä¸ŠåŠå¹´å¼€å§‹æ‹›å‹Ÿã€‚ç¬¬äºŒéƒ¨åˆ†å°†åˆ†ä¸¤ä¸ªéƒ¨åˆ†è¿›è¡Œã€‚Part 2a å°†è¯„ä¼°å¹¶ç¡®è®¤æœ€ä½³ç»™è¯ç­–ç•¥ï¼Œæ¯”è¾ƒä¸»è¦çš„ 400 æ¯«å…‹é—´æ­‡ç»™è¯æ–¹æ¡ˆï¼ˆç”¨è¯ 5 å¤©ï¼Œåœè¯ 2 å¤©ï¼‰ä¸ç›¸åŒæ–¹æ¡ˆçš„ 300 æ¯«å…‹å‰‚é‡ã€‚æ¯ä¸ªé˜Ÿåˆ—å°†æ‹›å‹Ÿçº¦ 30 åæ‚£è€…ã€‚\n",
      "*   **TETONï¼š** ä¸€é¡¹å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibåœ¨ç»„ç»‡å­¦è¯å®ä¸ºå¤å‘æ€§æˆ–æŒç»­æ€§å­å®«æµ†æ¶²æ€§ç™Œä¸”æ— æœ‰æ•ˆç–—æ³•æˆ–æ— æ³•è€å—å¯ç”¨æ ‡å‡†æ²»ç–—çš„è‡³å°‘18å²æ‚£è€…ä¸­çš„åº”ç”¨ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ã€‚\n",
      "*   **ZN-c3-016ï¼š** ä¸è¾‰ç‘åˆä½œè¿›è¡Œçš„ä¸€é¡¹1/2æœŸç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibè”åˆEncorafenibå’Œè¥¿å¦¥æ˜”å•æŠ—åœ¨è½¬ç§»æ€§BRAF V600Eçªå˜å‹ç»“ç›´è‚ ç™Œæ‚£è€…ä¸­çš„åº”ç”¨ã€‚ZN-c3-016ç ”ç©¶çš„å‰‚é‡æ¢ç´¢é˜¶æ®µå·²å®Œå…¨æ‹›å‹Ÿ (n=44)ã€‚\n",
      "\n",
      "**ä¸´åºŠæ•°æ®**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼ŒZN-c3-001çš„ç»“æœæ˜¾ç¤ºï¼Œåœ¨é—´æ­‡ç»™è¯æ–¹æ¡ˆä¸‹ï¼Œæ€»æ—¥å‰‚é‡æ°´å¹³â‰¥30 [onclive](https://vertexaisearch.cloud.google.com/id/2-1)0mgçš„Cyclin E1+ PROCæ‚£è€…ä¸­ï¼Œå®¢è§‚ç¼“è§£ç‡ (ORR)  [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)å’Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (mDOR) ä»¤äººé¼“èˆ (n=23)ã€‚åœ¨è¿™äº›æ‚£è€…ä¸­ï¼Œè§‚å¯Ÿåˆ°ORRä¸º34.8% (8/23ï¼›95% CIï¼š16.4-57.3)ï¼ŒmDORä¸º5.2ä¸ªæœˆ (95% CIï¼š2.8, 6.9)ã€‚\n",
      "*   åœ¨DENALIè¯•éªŒçš„1béƒ¨åˆ†ä¸­ï¼Œå•è¯Azenosertibåœ¨43åå¯è¯„ä¼°ååº”çš„ã€ç»è¿‡å¤§é‡é¢„å¤„ç†çš„Cyclin E1é˜³æ€§é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€… [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ä¸­äº§ç”Ÿäº†34.9%çš„å®¢è§‚ç¼“è§£ç‡ (ORR) (95% CI, 21.0%-50.9%)ã€‚\n",
      "*   æˆªè‡³2024å¹´12æœˆ2 [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5)æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨æ¥å—è‡³å°‘ä¸€å‰‚Azenosertibçš„Cyclin E1+ PROCæ„å‘æ²»ç–—æ‚£è€…ä¸­ï¼ŒORRä¸º31.3% (15/48ï¼›95% CIï¼š18.7 - 46.3)ã€‚æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œæ„å‘æ²»ç–—äººç¾¤çš„mDORä»åœ¨æˆç†Ÿï¼Œçº¦ä¸º5.5ä¸ªæœˆ (95% CIï¼š2.7 â€“ ä¸å¯ä¼°è®¡)ã€‚\n",
      "*   Zentalis PharmaceuticalsæŠ¥å‘Šäº†Azenosertibæ­£åœ¨è¿›è¡Œçš„DENALI Part 1bä¸´åºŠè¯•éªŒçš„æœ€æ–°ä¸´åºŠæ•°æ®ï¼Œåœ¨å¯è¯„ä¼°ååº”çš„æ‚£è€…ä¸­ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)ä¸º6.3ä¸ªæœˆï¼Œå®¢è§‚ç¼“è§£ç‡çº¦ä¸º35%ã€‚\n",
      "\n",
      "**å®‰å…¨æ€§ä¸è€å—æ€§**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨ZN-c3-001ç ”ç©¶ä¸­ï¼ŒAzenosertibåœ¨æ‰€æœ‰è‚¿ç˜¤ç±»å‹ä¸”ä¸è€ƒè™‘ç”Ÿç‰©æ ‡å¿—ç‰©çŠ¶æ€çš„æƒ…å†µä¸‹ï¼Œåœ¨æ€»æ—¥å‰‚é‡æ°´å¹³â‰¥300mg (n=193) æ—¶å‡æ˜¾ç¤ºå‡ºè‰¯å¥½çš„è€å—æ€§ï¼Œæœªè§‚å¯Ÿåˆ°3çº§ä»¥ä¸Šèƒƒè‚ é“æ²»ç–—ç›¸å…³ä¸è‰¯äº‹ä»¶ (TRAE)ï¼Œä¸”3çº§ä»¥ä¸Šè¡€æ¶²å­¦æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½ï¼Œå¤§å¤šæ•°è¡€æ¶²å­¦æ¯’æ€§äº‹ä»¶ä¸º3çº§ã€‚\n",
      "*   å¯¼è‡´åœè¯çš„TRAEå‘ç”Ÿç‡è¾ƒä½ (n=10, 5.2%)ã€‚ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)è¯¥ç ”ç©¶ä¸­å…ˆå‰æŠ¥å‘Šäº†ä¸€èµ·æ²»ç–—ç›¸å…³çš„5çº§äº‹ä»¶ (n=1, 0.5%)ã€‚\n",
      "*   DENALI 1béƒ¨åˆ†å…ˆå‰å·²æŠ¥å‘Šäº†ä¸¤èµ·æ²»ç–—ç›¸å…³çš„5çº§ä¸è‰¯äº‹ä»¶ (AE)ã€‚\n",
      "\n",
      "**å…¶ä»–å‘å±•**\n",
      "*   Zentalisé¢„è®¡å°†åœ¨2024å¹´ç¬¬å››å­£åº¦æä¾›Azenosertibçš„æ›´å¤šæ•°æ®ã€‚\n",
      "*   Zentalisè®¡åˆ’åœ¨2025å¹´ä¸ŠåŠå¹´å¯åŠ¨DENALIä¸´åºŠè¯•éªŒçš„ç¬¬äºŒéƒ¨åˆ†ã€‚\n",
      "*   é¢„è®¡åˆ°2026å¹´åº•å°†è·å¾—å…· [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)æœ‰æ³¨å†Œæ„å‘çš„é¡¶çº¿æ•°æ®ï¼Œè¿™ä½¿Zentalisæœ‰å¯èƒ½è·å¾—FDAçš„åŠ é€Ÿæ‰¹å‡†ã€‚\n",
      "*   ä¸´åºŠå‰æ•°æ®æ˜¾ç¤ºï¼ŒAzenosertibä¸åŸº [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)äºå¾®ç®¡æŠ‘åˆ¶å‰‚çš„æŠ—ä½“è¯ç‰©å¶è”ç‰©è”åˆä½¿ç”¨æ—¶ï¼Œæ˜¾ç¤ºå‡ºååŒæŠ—è‚¿ç˜¤ä½œç”¨ï¼Œè¿™è¡¨æ˜Azenosertibåœ¨æ²»ç–—å„ç§æ™šæœŸå®ä½“ç˜¤æ–¹é¢å…·æœ‰æ›´å¹¿æ³›çš„æ²»ç–—æ½œåŠ›ã€‚\n",
      "*   Zentalisæ­£åœ¨å‰Šå‡40%çš„å‘˜å·¥ï¼Œä»¥å°†ç°é‡‘å»¶é•¿åˆ°Azenosertibæ½œåœ¨æ³¨å†Œç ”ç©¶çš„é¢„æœŸæ•°æ®è¯»å–ä¹‹åã€‚\n",
      "*   Zentaliså·²ä¸FDAå°±éå¯¹ç…§æ³¨å†Œè¯•éªŒDenali part 2açš„ä¸€éƒ¨åˆ†â€œè¾¾æˆä¸€è‡´â€ï¼Œè¯¥å…¬å¸å¸Œæœ›è¿™å°†æ˜¯å…¶åŠ é€Ÿæ‰¹å‡†Azenosertibçš„ç¬¬ä¸€æ­¥ã€‚\n",
      " [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [nasdaq](https://vert [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6)exaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [target [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)edonc](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "\n",
      "---\n",
      "\n",
      "Im Jahr 2024 und 2025 laufen klinische Studien mit den WEE1-Inhibitoren Debio0123 und ACR-2316.\n",
      "\n",
      "**Debio0123:**\n",
      "\n",
      "*   Debio0123 ist ein selektiver WEE1-Kinase-Inhibitor, der die Blut-Hirn-Schranke Ã¼berwinden kann. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) Er wird als Monotherapie und in Kombination mit anderen Krebsbehandlungen bei verschiedenen soliden Tumoren untersucht. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)\n",
      "*   Debiopharm fÃ¼hrt mehrere klinische Studien mit Debio0123 durch, um die Wirkung von DNA-schÃ¤digenden Substanzen zu verstÃ¤rken. Eine Studie untersucht die Kombination von Debio0123 mit einer Standard-Chemotherapie bei kleinzelligem Lungenkrebs und Glioblastom.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debio0123 zeigt in vivo eine starke Synergie und Antitumorwirksamkeit in Kombination mit Chemotherapie und Strahlentherapie.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debiopharm untersucht Debio0123 auch in Kombination mit Lunresertib (einem PKMYT1-Inhibitor von Repare) bei Patienten mit fortgeschrittenen soliden Tumoren.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Eine Phase-1-Studie mit Debio0123 als Monotherapie wird in den USA, Spanien und der Schweiz durchgefÃ¼hrt, um die Sicherheit, VertrÃ¤glichkeit und vorlÃ¤ufige AntitumoraktivitÃ¤t bei Patienten mit rezidivierenden oder progressiven soliden Tumoren zu untersuchen. Zwei d [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)er drei Erweiterungsarme dieser Studie verwenden Biomarker, um Patienten mit verschiedenen soliden Tumoren vorab auszuwÃ¤hlen, wÃ¤hrend der dritte Arm Patienten mit rezidivierendem serÃ¶sem Endometriumkarzinom behandelt.\n",
      "\n",
      "**ACR-23 [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)16:**\n",
      "\n",
      "*   ACR-2316 ist ein neuartiger, selektiver dualer WEE1/PKMYT1-Inhibitor, der fÃ¼r eine Ã¼berlegene EinzelwirkstoffaktivitÃ¤t entwickelt wurde.\n",
      "*   Acrivon  [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)Therapeutics plant, bis zum vierten Quartal 2024 einen IND-Antrag (Investigational New Drug) fÃ¼r ACR-2316 einzureichen.\n",
      "*   Eine lauf [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-4)ende Phase-1-Monotherapie-Studie untersucht die Sicherheit und VertrÃ¤glichkeit von ACR-2316. Die Dosierung  [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)der Patienten in dieser Studie hat bereits begonnen.\n",
      "*   ACR-2316 z [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)eigte in prÃ¤klinischen Studien eine Ã¼berlegene AktivitÃ¤t im Vergleich zu klinischen Benchmark-Inhibitoren (Azenosertib, Debio-0123 und Lunresertib).\n",
      "*   Auf dem Gebie [acrivon](https://vertexaisearch.cloud.google.com/id/3-3) [acrivon](https://vertexaisearch.cloud.google.com/id/3-2)t des Endometriumkarzinoms wurde eine bestÃ¤tigte partielle Remission beobachtet, was auf das breite Potenzial dieses Wirkstoffs hinweist.\n",
      "*   Acrivon Therap [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5)eutics plant, in der zweiten HÃ¤lfte des Jahres 2025 erste klinische Daten aus der Phase-1-Studie mit ACR-2316 vorzulegen.\n",
      "*   Die ersten drei [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6) Dosis-Eskalationskohorten der Phase-1-Studie mit ACR-2316 sind abgeschlossen. Es wurden eine unge [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)fÃ¤hre DosisproportionalitÃ¤t, ein Target-Engagement und eine erste klinische AktivitÃ¤t mit signifikanter Tumorschrumpfung bereits bei Dosislevel drei beobachtet.\n",
      " [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ AZD1775 (Adavosertib) åœ¨ 2024 å¹´å’Œ 2025 å¹´è¿›è¡Œçš„ä¸´åºŠè¯•éªŒçš„ä¿¡æ¯ï¼š\n",
      "\n",
      "*   **å•è¯ Adavosertib ç–—æ³•:**\n",
      "    *   ä¸€é¡¹é’ˆå¯¹ SETD2 çªå˜çš„æ™šæœŸå®ä½“è‚¿ç˜¤æ‚£è€…çš„ II æœŸç ”ç©¶è¡¨æ˜ï¼Œå°½ç®¡æœ‰ä¸´åºŠå‰æ•°æ®è¡¨æ˜å…¶å…·æœ‰åˆæˆè‡´æ­»æ•ˆåº”ï¼Œä½† Adavosertib å•è¯æ²»ç–—çš„ä¸´åºŠæ´»æ€§æœ‰é™ã€‚\n",
      "    *   å°½ç®¡æ²¡æœ‰è§‚å¯Ÿåˆ°å®¢è§‚ååº”ï¼Œä½†åœ¨éƒ¨åˆ†æ‚£è€…ä¸­è§‚å¯Ÿåˆ°è½»å¾®çš„è‚¿ç˜¤æ¶ˆé€€å’Œå»¶é•¿çš„ç–¾ç—…ç¨³å®šã€‚\n",
      "\n",
      "*   **Adavosertib è”åˆç–—æ³•:**\n",
      "    *   **è‚ºé³çŠ¶ç»†èƒç™Œ:** ä¸€é¡¹é’ˆå¯¹è‚ºé³çŠ¶ç»†èƒç™Œçš„ II æœŸå•è‡‚ç ”ç©¶å°† Adavosertib ä¸å¡é“‚å’Œç´«æ‰é†‡è”åˆä½¿ç”¨ï¼Œä¸­ä½ PFS ä¸º 4.8 ä¸ªæœˆã€‚ ç–¾ç—…æ§ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)åˆ¶ç‡ (DCR) ä¸º 60.9%ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (DoR) ä¸º 4.44 ä¸ªæœˆã€‚\n",
      "    *   **å„¿ç«¥æ¶æ€§è‚¿ç˜¤:** åœ¨ AcSÃ©-ESMART è¯•éªŒçš„ C ç»„ä¸­ï¼ŒAdavosertib ä¸å¡é“‚è”åˆç”¨äºæ²»ç–—æ‚£æœ‰åˆ†å­å¯Œé›†å¤å‘/éš¾æ²»æ€§æ¶æ€§è‚¿ç˜¤ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)çš„å„¿ç«¥å’Œé’å°‘å¹´ï¼Œä½†ç”±äºè¡€æ¶²å­¦æ¯’æ€§ï¼Œæœªç¡®å®š II æœŸæ¨èå‰‚é‡ã€‚\n",
      "    *   **å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤:** ä¸€é¡¹é’ˆå¯¹å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤çš„å„¿ç§‘ II æœŸè¯•éªŒå°† Adavosertib ä¸ä¼Šç«‹æ›¿åº·è”åˆä½¿ç”¨ã€‚ ç¥ç»æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸‰ä¸ªå®¢è§‚ååº”ï¼Œæ¾æœä½“æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸€ä¸ªéƒ¨åˆ†ååº”ã€‚\n",
      "\n",
      "æ€»çš„æ¥è¯´ï¼Œç°æœ‰çš„ç ”ç©¶è¡¨æ˜ï¼ŒAdavosertib å•è¯æ²»ç–—åœ¨å®ä½“è‚¿ç˜¤ä¸­å¯èƒ½ç–—æ•ˆ [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)æœ‰é™ï¼Œä½†ä¸å…¶ä»–åŒ–ç–—è¯ç‰©è”åˆä½¿ç”¨å¯èƒ½å¯¹æŸäº›ç™Œç—‡æœ‰æ•ˆã€‚ [umn](https://vertexaisearch.cloud.google.com/id/4-5) [umn [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)](https://vertexaisearch.cloud.google.com/id/4-5) [nih](https://vertexaisearch.cloud.google.com/id/4-3) [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-4)\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ¤”is_sufficient=False,\n",
      "                 knowledge_gap=The summaries provide comprehensive information about individual WEE1 inhibitors (Azenosertib, Adavosertib, Debio-0123, APR-1051) and their clinical trials, but lack comparative analysis of efficacy, safety profiles, and competitive positioning across different WEE1 inhibitors. There is also limited information about emerging dual inhibitors (WEE1/PKMYT1) and their potential advantages over single-target inhibitors.,\n",
      "                 follow_up_queries=['What are the comparative efficacy and safety profiles of different WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051) in clinical trials for similar indications like ovarian cancer?', 'What are the key advantages and clinical progress of dual WEE1/PKMYT1 inhibitors (like ACR-2316) compared to single-target WEE1 inhibitors in terms of efficacy, safety, and mechanism of action?', 'What are the latest clinical trial results and regulatory developments for WEE1 inhibitors in combination therapies with chemotherapy, immunotherapy, and targeted agents across different cancer types?'],\n",
      "                 research_loop_count=1,\n",
      "                 number_of_ran_queries=(6, ['WEE1 inhibitor clinical trials pipeline 2024 2025', 'WEE1 targeted therapy development status oncology', 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ', 'WEE1 inhibitor clinical trials pipeline 2024 2025', 'WEE1 targeted therapy development status oncology', 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ'])\n",
      "                \n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”research_loop_count=1\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”å‘ç°3ä¸ªæ–°çš„follow-upæŸ¥è¯¢ã€‚\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”å½“å‰ç´¯è®¡å·²è¿è¡ŒæŸ¥è¯¢æ•°ï¼š6\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”Follow-up #0:'What are the comparative efficacy and safety profiles of different WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051) in clinical trials for similar indications like ovarian cancer?'(id=6)\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”Follow-up #1:'What are the key advantages and clinical progress of dual WEE1/PKMYT1 inhibitors (like ACR-2316) compared to single-target WEE1 inhibitors in terms of efficacy, safety, and mechanism of action?'(id=7)\n",
      "2025-11-21 14:37:55 [INFO] agent.graph - ğŸ”Follow-up #2:'What are the latest clinical trial results and regulatory developments for WEE1 inhibitors in combination therapies with chemotherapy, immunotherapy, and targeted agents across different cancer types?'(id=8)\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - get_tools|llmè¿”å›:I'll help you research the latest clinical trial results and regulatory developments for WEE1 inhibitors in combination therapies. Let me start by conducting targeted searches and using the clinical trials database.\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors combination therapy chemotherapy immunotherapy targeted agents clinical trial results 2024 2025', 'state': {'search_query': 'WEE1 inhibitors combination therapy chemotherapy immunotherapy targeted agents clinical trial results 2024 2025', 'id': '1'}}, 'id': 'call_00_v5m4tEeYUaLXD9J5BDhGChAh', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors combination therapy chemotherapy immunotherapy targeted agents clinical trial results 2024 2025', 'state': {'search_query': 'WEE1 inhibitors combination therapy chemotherapy immunotherapy targeted agents clinical trial results 2024 2025', 'id': '1'}}\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - get_tools|llmè¿”å›:I'll conduct comprehensive research on dual WEE1/PKMYT1 inhibitors, particularly focusing on ACR-2316, and compare them with single-target WEE1 inhibitors. Let me start with targeted searches.\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials efficacy safety mechanism of action', 'state': {'search_query': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials efficacy safety mechanism of action', 'id': '1'}}, 'id': 'call_00_5vHvFrxpUh5iXXLCQmoScsBP', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:13 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials efficacy safety mechanism of action', 'state': {'search_query': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials efficacy safety mechanism of action', 'id': '1'}}\n",
      "2025-11-21 14:38:19 [INFO] agent.graph - get_tools|llmè¿”å›:I'll help you research the comparative efficacy and safety profiles of WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051) in clinical trials for ovarian cancer. Let me start by conducting targeted searches and querying clinical trial data.\n",
      "2025-11-21 14:38:19 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'Azenosertib WEE1 inhibitor clinical trials ovarian cancer efficacy safety 2024 2025', 'state': {'search_query': 'Azenosertib WEE1 inhibitor clinical trials ovarian cancer efficacy safety 2024 2025', 'id': '1'}}, 'id': 'call_00_fNIsx2vnbhMXBzqsqmdCkEap', 'type': 'tool_call'}, {'name': 'web_search', 'args': {'query': 'Debio-0123 WEE1 inhibitor clinical trials ovarian cancer results 2024 2025', 'state': {'search_query': 'Debio-0123 WEE1 inhibitor clinical trials ovarian cancer results 2024 2025', 'id': '2'}}, 'id': 'call_01_sLylMMWzrzwdoFhH6Mzk7wAV', 'type': 'tool_call'}, {'name': 'web_search', 'args': {'query': 'APR-1051 WEE1 inhibitor clinical trials ovarian cancer latest data 2024 2025', 'state': {'search_query': 'APR-1051 WEE1 inhibitor clinical trials ovarian cancer latest data 2024 2025', 'id': '3'}}, 'id': 'call_02_L5iJjekwupm1t1dW1wpLziyQ', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:19 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:19 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'Azenosertib WEE1 inhibitor clinical trials ovarian cancer efficacy safety 2024 2025', 'state': {'search_query': 'Azenosertib WEE1 inhibitor clinical trials ovarian cancer efficacy safety 2024 2025', 'id': '1'}}\n",
      "2025-11-21 14:38:26 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:26 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors regulatory developments FDA approval status 2024 2025', 'state': {'search_query': 'WEE1 inhibitors regulatory developments FDA approval status 2024 2025', 'id': '2'}}, 'id': 'call_00_ec0QedCwOzL3ycUtcr6UfHBu', 'type': 'tool_call'}, {'name': 'get_clinical_results', 'args': {'keywords': 'WEE1 inhibitors clinical trial results combination therapy'}, 'id': 'call_01_KRW6oLzAHtUbomNvIbwjAKAt', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:26 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:26 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors regulatory developments FDA approval status 2024 2025', 'state': {'search_query': 'WEE1 inhibitors regulatory developments FDA approval status 2024 2025', 'id': '2'}}\n",
      "2025-11-21 14:38:26 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'Debio-0123 WEE1 inhibitor clinical trials ovarian cancer results 2024 2025', 'state': {'search_query': 'Debio-0123 WEE1 inhibitor clinical trials ovarian cancer results 2024 2025', 'id': '2'}}\n",
      "2025-11-21 14:38:29 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:29 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors single target clinical trials efficacy safety limitations resistance mechanisms', 'state': {'search_query': 'WEE1 inhibitors single target clinical trials efficacy safety limitations resistance mechanisms', 'id': '2'}}, 'id': 'call_00_6NJVp6jSsWvReSnsdphsxidB', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:29 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:29 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors single target clinical trials efficacy safety limitations resistance mechanisms', 'state': {'search_query': 'WEE1 inhibitors single target clinical trials efficacy safety limitations resistance mechanisms', 'id': '2'}}\n",
      "2025-11-21 14:38:35 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'APR-1051 WEE1 inhibitor clinical trials ovarian cancer latest data 2024 2025', 'state': {'search_query': 'APR-1051 WEE1 inhibitor clinical trials ovarian cancer latest data 2024 2025', 'id': '3'}}\n",
      "2025-11-21 14:38:35 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'WEE1 inhibitors clinical trial results combination therapy'}\n",
      "2025-11-21 14:38:41 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:41 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors adavosertib AZD1775 clinical trial results 2024 2025 combination therapy', 'state': {'search_query': 'WEE1 inhibitors adavosertib AZD1775 clinical trial results 2024 2025 combination therapy', 'id': '3'}}, 'id': 'call_00_JlbCt3u7ab8Y9FoNU6YPKdzI', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:41 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:41 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors adavosertib AZD1775 clinical trial results 2024 2025 combination therapy', 'state': {'search_query': 'WEE1 inhibitors adavosertib AZD1775 clinical trial results 2024 2025 combination therapy', 'id': '3'}}\n",
      "2025-11-21 14:38:42 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:42 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'get_clinical_results', 'args': {'keywords': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials'}, 'id': 'call_00_tmGWDiJjpc9bSKq2DRONHl6n', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:42 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:42 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'ACR-2316 dual WEE1 PKMYT1 inhibitor clinical trials'}\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'get_clinical_results', 'args': {'keywords': 'WEE1 inhibitors Azenosertib Debio-0123 APR-1051 ovarian cancer clinical trials'}, 'id': 'call_00_YmA2epViHJcHzK8BSAbiouT6', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·get_clinical_results,å‚æ•°{'keywords': 'WEE1 inhibitors Azenosertib Debio-0123 APR-1051 ovarian cancer clinical trials'}\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'dual WEE1 PKMYT1 inhibitors vs single WEE1 inhibitors preclinical comparison efficacy safety resistance', 'state': {'search_query': 'dual WEE1 PKMYT1 inhibitors vs single WEE1 inhibitors preclinical comparison efficacy safety resistance', 'id': '3'}}, 'id': 'call_00_8F3bPxfn8deH5e1qp1DlOQ4I', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:47 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'dual WEE1 PKMYT1 inhibitors vs single WEE1 inhibitors preclinical comparison efficacy safety resistance', 'state': {'search_query': 'dual WEE1 PKMYT1 inhibitors vs single WEE1 inhibitors preclinical comparison efficacy safety resistance', 'id': '3'}}\n",
      "2025-11-21 14:38:51 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:51 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors comparative efficacy safety ovarian cancer clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitors comparative efficacy safety ovarian cancer clinical trials 2024 2025', 'id': '4'}}, 'id': 'call_00_dFBMvHzn40K0iLbZCAAKlBBu', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:51 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:51 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors comparative efficacy safety ovarian cancer clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitors comparative efficacy safety ovarian cancer clinical trials 2024 2025', 'id': '4'}}\n",
      "2025-11-21 14:38:53 [INFO] agent.graph - get_tools|llmè¿”å›:\n",
      "2025-11-21 14:38:53 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[{'name': 'web_search', 'args': {'query': 'WEE1 inhibitors combination therapy PARP inhibitors ATR inhibitors clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitors combination therapy PARP inhibitors ATR inhibitors clinical trials 2024 2025', 'id': '4'}}, 'id': 'call_00_p6ajxiiYJQUNNSRDguWvtlS2', 'type': 'tool_call'}]\n",
      "2025-11-21 14:38:53 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:38:53 [INFO] agent.graph - web_research|è°ƒç”¨å·¥å…·web_search,å‚æ•°{'query': 'WEE1 inhibitors combination therapy PARP inhibitors ATR inhibitors clinical trials 2024 2025', 'state': {'search_query': 'WEE1 inhibitors combination therapy PARP inhibitors ATR inhibitors clinical trials 2024 2025', 'id': '4'}}\n",
      "2025-11-21 14:39:52 [INFO] agent.graph - get_tools|llmè¿”å›:Based on my comprehensive search of current information (as of November 21, 2025), here is a detailed report on the key advantages and clinical progress of dual WEE1/PKMYT1 inhibitors compared to single-target WEE1 inhibitors:\n",
      "\n",
      "## Research Report: Dual WEE1/PKMYT1 Inhibitors vs Single-Target WEE1 Inhibitors\n",
      "\n",
      "### Executive Summary\n",
      "\n",
      "Dual WEE1/PKMYT1 inhibitors represent a promising advancement in cancer therapy that addresses key limitations of single-target WEE1 inhibitors. The dual inhibition strategy demonstrates superior efficacy, improved resistance profiles, and comparable safety with potential for better tolerability through optimized dosing regimens.\n",
      "\n",
      "### Clinical Development Status\n",
      "\n",
      "**ACR-2316 (Acrivon Therapeutics)**\n",
      "- **Current Status**: Phase 1 monotherapy clinical trial in patients with advanced solid tumors (NCT06667141) [researchgate, acrivon]\n",
      "- **Expected Data**: Initial clinical data anticipated in second half of 2025 [gcs-web, researcher]\n",
      "- **Design Platform**: Developed using Acrivon's Predictive Precision Proteomics (AP3) platform for optimal target selectivity [acrivon, researchgate]\n",
      "\n",
      "**Other Dual Inhibitors in Development**\n",
      "- **SGR-3515**: Phase 1 clinical trials for advanced solid tumors [schrodinger, bioworld]\n",
      "- **Multiple other WEE1/PKMYT1 inhibitors** in various clinical stages per clinical trial database [PharmaOne]\n",
      "\n",
      "### Key Advantages of Dual WEE1/PKMYT1 Inhibitors\n",
      "\n",
      "#### 1. Enhanced Efficacy and Mechanism of Action\n",
      "\n",
      "**Superior Preclinical Activity**\n",
      "- ACR-2316 demonstrates superior single-agent anti-cancer activity compared to clinical benchmark WEE1 or PKMYT1 inhibitors alone [globenewswire, researchgate, acrivon]\n",
      "- Induces tumor regression in CDX and PDX tumor mouse models [acrivon, researchgate]\n",
      "- Shows activity in tumors progressing on azenosertib (WEE1 inhibitor) [acrivon]\n",
      "\n",
      "**Enhanced Cell Cycle Disruption**\n",
      "- Dual inhibition promotes strong activation of CDK1, CDK2, and PLK1 [researchgate, acrivon, conventus]\n",
      "- Disrupts multiple cell cycle checkpoints simultaneously, leading to S/G2-M cell cycle arrest, premature mitosis, DNA damage, and pro-apoptotic cell death [acrivon, aacrjournals]\n",
      "- Creates synergistic effects in eradicating cancer cells, including those with acquired CDK4/6 inhibitor resistance [citedrive, researchgate]\n",
      "\n",
      "**Broad Spectrum Activity**\n",
      "- Demonstrates anti-cancer activity across broad spectrum of in vitro cancer line models, including those insensitive to WEE1 or PKMYT1 inhibitors alone [acrivon]\n",
      "\n",
      "#### 2. Overcoming Resistance Mechanisms\n",
      "\n",
      "**Addressing Primary Resistance Pathway**\n",
      "- Upregulation of PKMYT1 is a key mechanism of acquired resistance to single-target WEE1 inhibitors like adavosertib [frontiersin, aacrjournals]\n",
      "- Dual inhibition prevents this escape mechanism by simultaneously targeting both kinases [acrivon, researchgate]\n",
      "- Reduces cancer selective pressure against single targets, potentially decreasing treatment resistance development [nih]\n",
      "\n",
      "**Activity in Resistant Settings**\n",
      "- Effective in eliminating CDK4/6 inhibitor-resistant organoids [citedrive]\n",
      "- Shows activity against tumors that have developed resistance to single-agent WEE1 inhibitors [acrivon]\n",
      "\n",
      "#### 3. Improved Safety and Tolerability Profile\n",
      "\n",
      "**Mechanism-Based but Reversible Effects**\n",
      "- Preclinical IND-enabling studies suggest adverse events are mechanism-based but transient and fully reversible [acrivon]\n",
      "- Well-tolerated in rodent models with only mechanism-based, transient, and reversible myelosuppression [acrivon]\n",
      "\n",
      "**Optimized Dosing Strategies**\n",
      "- Supports intermittent dosing schedules to permit recovery from myelosuppression [bioworld, acrivon]\n",
      "- Multiple low-dose approach may allow exploitation of synthetic lethality while minimizing adverse effects [nih]\n",
      "- In mouse models, combination approaches demonstrated tumor regressions at sub-therapeutic monotherapy doses with good tolerability [aacrjournals]\n",
      "\n",
      "### Comparison with Single-Target WEE1 Inhibitors\n",
      "\n",
      "#### Limitations of Single-Target WEE1 Inhibitors\n",
      "\n",
      "**Resistance Development**\n",
      "- Upregulation of PKMYT1 promotes resistance to WEE1 inhibition [nih, frontiersin]\n",
      "- Tumor cells can activate alternative cell cycle checkpoints and upregulate DNA repair pathways [patsnap]\n",
      "- Reversal of expression profiles of vulnerability genes can lead to resistance [frontiersin]\n",
      "\n",
      "**Toxicity Concerns**\n",
      "- Effective dosages of adavosertib can cause high toxicity with adverse side effects [frontiersin]\n",
      "- Common toxicities include myelosuppression, nausea, vomiting, diarrhea, and fatigue [ascopubs, frontiersin]\n",
      "- Dose-limiting toxicities include supraventricular tachyarrhythmia and myelosuppression [nih]\n",
      "\n",
      "**Clinical Development Challenges**\n",
      "- Despite promising safety and efficacy, adavosertib has yet to proceed to phase 3 trials [onclive]\n",
      "- Lower than ideal specificity, with off-target effects on PLK1 [frontiersin]\n",
      "\n",
      "### Biomarker Development\n",
      "\n",
      "**CCNE1 Amplification**\n",
      "- Identified as a biomarker for sensitivity to PKMYT1 inhibition [onclive, researchgate, aacrjournals]\n",
      "- This biomarker may help identify patients most likely to benefit from dual inhibition strategies\n",
      "\n",
      "### Conclusion\n",
      "\n",
      "Dual WEE1/PKMYT1 inhibitors like ACR-2316 represent a significant advancement over single-target WEE1 inhibitors by addressing key resistance mechanisms, demonstrating superior preclinical efficacy, and offering potentially improved safety profiles through optimized dosing strategies. The ongoing clinical trials will be crucial in validating these preclinical advantages in human patients and establishing the therapeutic potential of this dual inhibition approach in cancer treatment.\n",
      "\n",
      "*Note: This report is based on search results current as of November 21, 2025, and reflects the most recent available information on this emerging therapeutic class.*\n",
      "2025-11-21 14:39:52 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:39:52 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:39:54 [INFO] agent.graph - get_tools|llmè¿”å›:Based on my comprehensive search of current clinical trial results and regulatory developments for WEE1 inhibitors in combination therapies, here is a detailed report summarizing the latest findings as of November 21, 2025:\n",
      "\n",
      "## Executive Summary: WEE1 Inhibitors in Combination Therapies\n",
      "\n",
      "### Regulatory Developments (2024-2025)\n",
      "\n",
      "**Key Regulatory Events:**\n",
      "- **June 2024**: FDA placed partial clinical hold on Zentalis Pharmaceuticals' azenosertib after two trial participants died from presumed blood-related infections [patsnap, clinicaltrialsarena]\n",
      "- **September 2024**: FDA lifted the partial clinical hold, allowing Zentalis to resume enrollment in all ongoing clinical studies [patsnap, clinicaltrialsarena, precisionmedicineonline]\n",
      "- **January 2025**: FDA granted fast track designation to azenosertib for treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who are positive for cyclin E1 [oncologynewscentral]\n",
      "- **March 2025**: FDA cleared IND application for MRANK-106, a dual WEE1/YES1 kinase inhibitor for advanced solid tumors [targetedonc]\n",
      "\n",
      "### Clinical Trial Results by Combination Type\n",
      "\n",
      "#### 1. Chemotherapy Combinations\n",
      "\n",
      "**Azenosertib (ZN-c3) with Gemcitabine:**\n",
      "- Being investigated for pancreatic cancer [patsnap]\n",
      "- Active clinical trial (NCT06015659) for pancreatic ductal adenocarcinoma and advanced pancreatic adenocarcinoma [PharmaOne]\n",
      "\n",
      "**Adavosertib (AZD1775) with Carboplatin/Paclitaxel:**\n",
      "- Phase II trial in squamous cell lung cancer showed median PFS of 4.8 months and median OS of 7.3 months [ascopubs]\n",
      "- Disease control rate of 60.9% with manageable toxicity profile [ascopubs]\n",
      "\n",
      "**Adavosertib with Carboplatin (Pediatric):**\n",
      "- Phase I/II study in children/young adults with recurrent/refractory malignancies showed 11% overall response rate [aacrjournals, nih]\n",
      "- Significant hematologic toxicity observed [aacrjournals, nih]\n",
      "\n",
      "#### 2. Immunotherapy Combinations\n",
      "\n",
      "**Azenosertib with Pembrolizumab:**\n",
      "- \"ZAP-IT\" trial testing ZN-c3 with carboplatin and pembrolizumab in metastatic triple-negative breast cancer [patsnap]\n",
      "- Active clinical trial (NCT06351332) for triple-negative breast cancer [PharmaOne]\n",
      "\n",
      "**Adavosertib with Durvalumab:**\n",
      "- Phase I study assessing safety and tolerability in advanced solid tumors [ascopubs]\n",
      "\n",
      "#### 3. Targeted Therapy Combinations\n",
      "\n",
      "**Azenosertib with Trastuzumab Deruxtecan:**\n",
      "- Being investigated in HER2-expressing solid tumors [patsnap]\n",
      "- Active clinical trial (NCT06364410) for HER2-positive gastric/esophageal junction cancer [PharmaOne]\n",
      "\n",
      "**Debio0123 with Sacituzumab Govitecan:**\n",
      "- Being evaluated in triple-negative or HR+/HER2-negative advanced/metastatic breast cancer [patsnap]\n",
      "\n",
      "#### 4. PARP/ATR Inhibitor Combinations\n",
      "\n",
      "**Adavosertib with Olaparib:**\n",
      "- Demonstrated clinical efficacy in PARPi-resistant ovarian cancer [nih]\n",
      "- Combinations with PARP inhibitors show synergistic effects regardless of HR status [mdpi]\n",
      "\n",
      "**ATR/PARP Combinations:**\n",
      "- TRESR trial tested camonsertib (ATR inhibitor) plus talazoparib (PARP inhibitor)\n",
      "- ATTACC trial tested camonsertib plus niraparib or olaparib\n",
      "- These combinations appeared safe with manageable hematologic adverse effects [oncologynewscentral]\n",
      "\n",
      "### Active Clinical Trials Landscape\n",
      "\n",
      "The local clinical trial database shows numerous ongoing studies including:\n",
      "- **NCT06351332**: Azenosertib + carboplatin + pembrolizumab in TNBC (Phase 1/2)\n",
      "- **NCT06364410**: Azenosertib + trastuzumab deruxtecan in HER2+ cancers (Phase 1)\n",
      "- **NCT06015659**: Azenosertib + gemcitabine in pancreatic cancer (Phase 2)\n",
      "- **NCT05765812**: Zedoresertib + temozolomide in glioblastoma (Phase 1/2)\n",
      "\n",
      "### Emerging WEE1 Inhibitors\n",
      "\n",
      "**New Agents in Development:**\n",
      "- **ACR-2316** (Acrivon Therapeutics): Dual WEE1/PKMYT1 inhibitor showing initial clinical activity including tumor shrinkage and confirmed partial responses [taiwannews]\n",
      "- **APR-1051**: Phase 1 trial for advanced solid tumors [patsnap]\n",
      "- **MRANK-106**: Dual WEE1/YES1 kinase inhibitor with recent IND clearance [targetedonc]\n",
      "\n",
      "### Challenges and Future Directions\n",
      "\n",
      "**Key Challenges:**\n",
      "- Overcoming acquired resistance and managing toxicity remain significant hurdles [nih]\n",
      "- TP53 mutation has not proven to be a reliable predictive biomarker [kcl]\n",
      "- Hematologic toxicity particularly problematic in pediatric populations [aacrjournals]\n",
      "\n",
      "**Future Opportunities:**\n",
      "- Machine learning models being used to predict synergistic combinations [aacrjournals]\n",
      "- Exploration of novel combinations with ATR/CHK1 inhibitors or PARP inhibitors [patsnap, kcl]\n",
      "- Biomarker development crucial for patient stratification [nih, aacrjournals]\n",
      "\n",
      "### Regulatory Outlook\n",
      "\n",
      "**Potential Accelerated Approval:**\n",
      "- Zentalis aiming for potential accelerated approval of azenosertib in late 2026 for cyclin E1-positive platinum-resistant ovarian cancer [ainvest]\n",
      "- Success depends on FDA acceptance of DENALI Phase III trial data [ainvest]\n",
      "\n",
      "This comprehensive analysis demonstrates that WEE1 inhibitors continue to show promise across multiple cancer types, particularly in combination regimens, with significant regulatory progress and ongoing clinical development through 2025.\n",
      "2025-11-21 14:39:54 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:39:54 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:40:16 [INFO] agent.graph - get_tools|llmè¿”å›:# Comparative Analysis of WEE1 Inhibitors (Azenosertib, Debio-0123, APR-1051) in Ovarian Cancer Clinical Trials\n",
      "\n",
      "## Executive Summary\n",
      "\n",
      "Based on comprehensive searches conducted through November 21, 2025, this report analyzes the comparative efficacy and safety profiles of three WEE1 inhibitors - Azenosertib, Debio-0123, and APR-1051 - in clinical trials for ovarian cancer and similar indications.\n",
      "\n",
      "## Individual Drug Profiles\n",
      "\n",
      "### Azenosertib (ZN-c3)\n",
      "\n",
      "**Development Status**: Phase 2/3 trials for ovarian cancer [onclive](https://vertexaisearch.cloud.google.com/id/1-0), [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-1)\n",
      "\n",
      "**Efficacy Data**:\n",
      "- **DENALI Trial (Platinum-Resistant Ovarian Cancer)**: Objective response rate (ORR) of 34.9% in Cyclin E1+ patients [ainvest](https://vertexaisearch.cloud.google.com/id/1-6)\n",
      "- Intent-to-treat patients with Cyclin E1+ PROC showed ORR of 31.3% and median duration of response (mDOR) of 6.3 months [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2)\n",
      "- **Combination Therapy**: In Phase 1b trial with paclitaxel, achieved 50% ORR in platinum-resistant ovarian cancer [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/4-6)\n",
      "\n",
      "**Safety Profile**:\n",
      "- Manageable safety profile with gastrointestinal toxicities and fatigue as most common treatment-related adverse events [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2)\n",
      "- **Safety Concern**: FDA placed clinical hold on monotherapy studies in June 2024 after two deaths presumed due to sepsis [patsnap](https://vertexaisearch.cloud.google.com/id/1-4), [biocentury](https://vertexaisearch.cloud.google.com/id/1-5)\n",
      "\n",
      "### Debio-0123\n",
      "\n",
      "**Development Status**: Phase 1 trials [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1), [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0)\n",
      "\n",
      "**Efficacy Data**:\n",
      "- **Phase 1 Dose-Finding Study**: Ovarian cancer was most common primary tumor (33%) in advanced solid tumor trial [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "- Two ovarian cancer patients achieved 17% and 20% reduction in target lesions, with one showing CA-125 response [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "- 32% of patients achieved stable disease for â‰¥5 weeks [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "- **Preclinical Combination**: Synergistic with PKMYT1 inhibitor lunresertib, showing complete and sustained regression in ovarian cancer models [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5)\n",
      "\n",
      "**Safety Profile**:\n",
      "- Maximum tolerated dose determined at 260 mg [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "- Most frequent treatment-related adverse events: increased blood creatinine (37%), QTcF prolongation (37%), nausea (33%), vomiting (26%) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "- Described as next-generation WEE1 inhibitor with enhanced safety profile [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0)\n",
      "\n",
      "### APR-1051\n",
      "\n",
      "**Development Status**: Phase 1 dose-escalation trial (ACESOT-1051) [biospace](https://vertexaisearch.cloud.google.com/id/3-2), [aprea](https://vertexaisearch.cloud.google.com/id/3-0)\n",
      "\n",
      "**Efficacy Data**:\n",
      "- **Dose Level 6 (100 mg once daily)**: 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/3-4), [aprea](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "- Disease stabilization observed in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations [aprea](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "\n",
      "**Safety Profile**:\n",
      "- Generally well-tolerated with mostly Grade 1 or 2 adverse events [onclive](https://vertexaisearch.cloud.google.com/id/3-3), [biospace](https://vertexaisearch.cloud.google.com/id/3-2)\n",
      "- No hematologic toxicity observed [onclive](https://vertexaisearch.cloud.google.com/id/3-3)\n",
      "- Main adverse events: gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/3-4)\n",
      "\n",
      "## Comparative Analysis\n",
      "\n",
      "### Efficacy Comparison\n",
      "\n",
      "| Drug | Development Phase | Key Efficacy Findings | Biomarker Associations |\n",
      "|------|-------------------|----------------------|------------------------|\n",
      "| **Azenosertib** | Phase 2/3 | ORR 31.3-34.9% in Cyclin E1+ PROC; 50% ORR with paclitaxel | Cyclin E1+ [ainvest](https://vertexaisearch.cloud.google.com/id/1-6) |\n",
      "| **Debio-0123** | Phase 1 | 32% stable disease; tumor reduction in ovarian cancer patients | Broad solid tumors [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3) |\n",
      "| **APR-1051** | Phase 1 | 75% stable disease at 100mg dose | FBXW7, CCNE1, KRASG12V+TP53 [aprea](https://vertexaisearch.cloud.google.com/id/3-6) |\n",
      "\n",
      "### Safety Comparison\n",
      "\n",
      "| Drug | Key Safety Findings | Notable Safety Events |\n",
      "|------|---------------------|------------------------|\n",
      "| **Azenosertib** | GI toxicities, fatigue; clinical hold due to sepsis-related deaths | Serious safety concerns requiring FDA intervention [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) |\n",
      "| **Debio-0123** | Creatinine increase, QTc prolongation, nausea/vomiting | Manageable profile with dose-dependent effects [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3) |\n",
      "| **APR-1051** | Mild GI events, fatigue; no hematologic toxicity | Favorable early safety profile [onclive](https://vertexaisearch.cloud.google.com/id/3-3) |\n",
      "\n",
      "## Clinical Trial Landscape\n",
      "\n",
      "The local clinical trial database shows multiple ongoing studies for WEE1 inhibitors in ovarian cancer:\n",
      "- **Azenosertib**: Multiple Phase 1/2 trials in uterine serous carcinoma, combination therapies with various agents [PharmaOne](http://pharma1.pharmadl.test/)\n",
      "- **APR-1051**: Phase 1 trial in advanced solid tumors (NCT06260514) [PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "## Market and Development Context\n",
      "\n",
      "The WEE1 inhibitor therapeutics market is expected to grow at a remarkable CAGR of 21.8% from 2025 to 2033, reaching approximately USD 2.36 billion by 2033 [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8).\n",
      "\n",
      "## Conclusions\n",
      "\n",
      "1. **Azenosertib** demonstrates the most advanced clinical development with promising efficacy in biomarker-selected populations but carries significant safety concerns that have impacted its development timeline.\n",
      "\n",
      "2. **Debio-0123** shows early promise with manageable safety profile and interesting combination potential, particularly with PKMYT1 inhibitors.\n",
      "\n",
      "3. **APR-1051** presents the most favorable early safety profile among the three candidates, though efficacy data remains preliminary.\n",
      "\n",
      "4. All three agents show activity in molecularly defined subgroups, supporting the trend toward personalized medicine approaches in WEE1 inhibitor development.\n",
      "\n",
      "The comparative analysis suggests that while Azenosertib leads in clinical maturity, the next-generation inhibitors (Debio-0123 and APR-1051) may offer improved safety profiles that could be advantageous for long-term clinical development and patient use.\n",
      "\n",
      "*Note: All information presented is based on publicly available clinical trial data and search results as of November 21, 2025.*\n",
      "2025-11-21 14:40:16 [INFO] agent.graph - get_tools|llmè¿”å›å·¥å…·:[]\n",
      "2025-11-21 14:40:16 [INFO] agent.graph - ----------------------------\n",
      "2025-11-21 14:40:16 [INFO] agent.utils - ğŸ’¬len(messages)=1,research_topic=WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\n",
      "2025-11-21 14:40:16 [INFO] agent.graph - ğŸ¤”summaries=Several WEE1 inhibitor programs are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). These inhibitors are being evaluated in clinical trials across a spectrum of malignancies, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, uterine serous carcinoma, small cell lung cancer, glioblastoma, and head and neck cancers [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**Specific WEE1 Inhibitors and their Development Status:**\n",
      "\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in several clinical trials [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "    *   Azenosertib is being studied in combination with LB-100 (a PP2A inhibitor) in a Phase Ib setting for patients with metastatic colorectal cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   A Phase 2 single-arm trial is investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   Zentalis Pharmaceuticals is focusing on azenosertib's development, particularly in cyclin E1-positive, platinum-resistant ovarian cancer [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4). A potentially registrational study is expected to start in 2025, with data readout by the end of 2026 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "    *   Azenosertib is also being evaluated in combination with topoisomerase I (TOP1) inhibitor-based antibody-drug conjugates (ADCs) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Azenosertib, in combination with gemcitabine, is being investigated in an upcoming Investigator-Initiated Phase 2 trial for relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   The FDA had placed a partial clinical hold on azenosertib trials due to patient deaths but has since lifted it, allowing studies to resume [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Adavosertib (AZD1775):** This WEE1 inhibitor is also in clinical development [nih](https://vertexaisearch.cloud.google.com/id/1-6) [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7).\n",
      "\n",
      "    *   A Phase II trial of adavosertib in SETD2-altered advanced solid tumor malignancies showed limited clinical activity as a monotherapy [nih](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "    *   AstraZeneca is a major player in developing therapies for WEE1 protein inhibitors, including adavosertib [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7). However, AstraZeneca discontinued adavosertib due to tolerability issues in 2022 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "*   **Debio-0123:** Debiopharm, a biopharma company based in Switzerland, is developing this WEE1 inhibitor [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3). It is currently in a Phase I/II trial in combination with temozolomide for patients with glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3).\n",
      "*   **APR-1051:** Aprea Therapeutics is developing this oral WEE1 inhibitor [openpr](https://vertexaisearch.cloud.google.com/id/1-9). Early data from an ongoing Phase 1 study showed that 3 out of 4 heavily pretreated patients achieved stable disease [openpr](https://vertexaisearch.cloud.google.com/id/1-9). The trial is advancing to higher dose levels [openpr](https://vertexaisearch.cloud.google.com/id/1-9).\n",
      "*   **ACR-2316:** A Phase 1 study of ACR-2316 in specific advanced solid tumors is underway [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**General Trends and Challenges:**\n",
      "\n",
      "*   Most clinical trials involving WEE1 inhibitors are in early-phase development (Phase I or Phase Ib/II) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   WEE1 inhibitors are being explored for their potential to sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Challenges in WEE1 inhibitor development include potential toxicity and side effects, as WEE1 is also active in normal proliferating cells [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Patient selection and overcoming resistance remain obstacles to clinical implementation [nih](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Here's an update on the clinical trials of azenosertib (ZN-c3), a WEE1 inhibitor, with a focus on the latest results from 2024 and 2025: \n",
      "\n",
      " **1. Clinical Trials & Target Patient Populations** \n",
      "\n",
      " *   **Advanced Solid Tumors:** Azenosertib is being investigated as a monotherapy for advanced solid tumors in a Phase 1 trial (ZN-c3-001) [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Platinum-Resistant Ovarian Cancer (PROC):** It's also being evaluated in patients with platinum-resistant ovarian cancer in the Phase 2 DENALI trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). The DENALI trial focuses on high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). Part 2 of the DENALI study will be conducted in subjects whose tumors are Cyclin E1 positive [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). \n",
      " *   **Uterine Serous Carcinoma:** Azenosertib is under investigation for women with recurrent or persistent uterine serous carcinoma in the TETON trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [cancer](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      " *   **Metastatic BRAF V600E Mutant Colorectal Cancer:** Azenosertib is being evaluated in combination with encorafenib and cetuximab for patients with this type of colorectal cancer in the ZN-c3-016 study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **PARP-inhibitor resistant ovarian cancer:** Azenosertib is also being evaluated in patients with PARP-inhibitor resistant ovarian cancer in the MAMMOTH (ZN-c3-006) study [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Relapsed or Refractory Osteosarcoma:** Azenosertib is being studied in combination with gemcitabine for adult and pediatric patients with relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " **2. Key Developments in 2024** \n",
      "\n",
      " *   **FDA Partial Clinical Hold Lifted:** In June 2024, the FDA placed a partial clinical hold on trials evaluating azenosertib due to two deaths reported in the DENALI trial from presumed sepsis [onclive](https://vertexaisearch.cloud.google.com/id/2-0). This hold was lifted in September 2024 after the FDA reviewed a comprehensive safety assessment from Zentalis Pharmaceuticals [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Data Readouts:** Additional data for azenosertib was anticipated in the fourth quarter of 2024 [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      "\n",
      " **3. Efficacy Results (as of December 2, 2024 data cutoff)** \n",
      "\n",
      " *   **ZN-c3-001 Study:** Patients with Cyclin E1+ PROC, who were dosed at an intermittent schedule, experienced an objective response rate (ORR) of 34.8% and a median duration of response (mDOR) of 5.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Part 1b:** In patients with Cyclin E1+ PROC tumors who were response-evaluable, an ORR of 34.9% was observed [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). In the intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3% and the mDOR was approximately 5.5 months [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **MAMMOTH (ZN-c3-006) study:** Cyclin E1+ patients treated at the primary dose-of interest 400mg QD 5:2 had an ORR of 31.3% and an mDOR of 4.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Azenosertib in combination with chemotherapy:** Patients with Cyclin E1 overexpressing tumors demonstrated significant improvements in ORR and PFS vs patients with tumors having low expression [asco](https://vertexaisearch.cloud.google.com/id/2-7). \n",
      "\n",
      " **4. Safety and Tolerability** \n",
      "\n",
      " *   **Generally Tolerable:** Azenosertib has generally been well-tolerated in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      " *   **Low rates of Grade 3+ hematological toxicity:** The majority of hematological toxicity events were Grade 3 [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **Low rate of TRAEs leading to discontinuation:** A low rate of treatment-related adverse events led to discontinuation [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Trial Grade 5 Events:** There were two previously reported treatment-related Grade 5 events in the DENALI study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      "\n",
      " **5. Ongoing and Future Plans** \n",
      "\n",
      " *   **DENALI Part 2:** Topline data from the registration-intent DENALI Part 2 is anticipated by the end of 2026 [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Further Investigation:** Data supports further investigation of azenosertib with gemcitabine in patients with relapsed or refractory osteosarcoma in an upcoming Phase 2 trial [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " Keep in mind that clinical trial information can change, so it's always a good idea to consult the official sources for the most up-to-date details [cancer](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an oral, brain-penetrant, and selective WEE1 kinase inhibitor [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). Debiopharm is currently developing Debio-0123 to address the unmet needs of patients with difficult-to-treat cancers [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). WEE1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, that allows cells to repair their DNA before resuming their cell cycle [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0). Inhibition of WEE1, particularly in combination with DNA damaging agents, induces an overload of arrests in the DNA damage response process [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "Debiopharm is conducting an open-label phase 1/2 study of Debio-0123 in combination with temozolomide (TMZ) in adult participants with recurrent or progressive glioblastoma (GBM) and with TMZ and radiotherapy (RT) in newly diagnosed GBM [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is identified by ClinicalTrials.gov ID NCT05765812 [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is designed to identify the recommended phase 2 dose of Debio-0123 in combination with TMZ (Arm A) and with TMZ and RT (Arm B) and to characterize the safety and tolerability of these combinations in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3). Arm B of the study, which assessed Debio-0123 with concomitant TMZ and RT, has been permanently halted based on safety findings [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4). The primary purpose of Phase 2 of this study is to assess the efficacy of Debio 0123 at the recommended dose in combination with TMZ, compared to standard of care in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Aprea Therapeutics is currently evaluating APR-1051, a selective WEE1 inhibitor, in the ACESOT-1051 Phase 1 clinical trial for patients with advanced or metastatic solid tumors [aprea](https://vertexaisearch.cloud.google.com/id/4-0).\n",
      "\n",
      "**Key points regarding the APR-1051 clinical trials in 2024 and 2025:**\n",
      "\n",
      "*   **FDA Clearance and Trial Initiation:** The U.S. FDA cleared the Investigational New Drug (IND) application for APR-1051 in March 2024, and the Phase 1 ACESOT-1051 trial was initiated in June 2024 [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [aprea](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   **ACESOT-1051 Trial Design:** This is a biomarker-driven, first-in-human study assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7). It involves a dose escalation phase (Part 1, up to 39 patients) and a dose optimization phase (Part 2, up to 40 patients) to determine the Recommended Phase 2 Dose (RP2D) [aprea](https://vertexaisearch.cloud.google.com/id/4-8) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [biospace](https://vertexaisearch.cloud.google.com/id/4-4). Oral APR-1051 is administered daily in 28-day cycles [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "*   **Enrollment and Dosing:** Enrollment began in June 2024, with initial cohorts receiving doses of 10 mg, 20 mg, and 30 mg [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-8). By March 2025, the trial was enrolling patients in Cohort 5 (70 mg dose) [biospace](https://vertexaisearch.cloud.google.com/id/4-9). In November 2025, the trial had advanced to the 150 mg once-daily cohort [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Preliminary Data:**\n",
      "    *   **2024:** Preliminary data from the first patients in the ACESOT-1051 study indicated that APR-1051 was safe and well-tolerated, with no significant hematologic toxicity [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "    *   **2025:**\n",
      "        *   In Q2 2025, early disease control was observed in three patients during the Phase 1 ACESOT-1051 trial [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11).\n",
      "        *   Results from Dose Level 6 (100 mg once daily) showed that 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/4-10). Disease stabilization was seen in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "        *   APR-1051 was manageable, with mostly Grade 1 or 2 adverse events, mainly gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Focus on Cyclin E Overexpression:** Aprea is advancing APR-1051 as a monotherapy in cancers with Cyclin E overexpression, as these cancers represent a high unmet medical need [aprea](https://vertexaisearch.cloud.google.com/id/4-12) [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [aprea](https://vertexaisearch.cloud.google.com/id/4-13) [biospace](https://vertexaisearch.cloud.google.com/id/4-9).\n",
      "*   **Potential Advantages of APR-1051:** Aprea believes APR-1051 may address the shortcomings of other WEE1 inhibitors due to its unique molecular structure, selectivity for WEE1, improved pharmacokinetic properties, and absence of QT prolongation [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5). APR-1051 also exhibits low off-target inhibition of PLK1, PLK2, and PLK3, which may confer an improved toxicity profile [onclive](https://vertexaisearch.cloud.google.com/id/4-6).\n",
      "*   **Preclinical Studies:** Preclinical studies have demonstrated that APR-1051 suppresses the growth of CCNE1-amplified HGSOC xenografted tumors and is relatively well-tolerated in mice [aprea](https://vertexaisearch.cloud.google.com/id/4-3). It also shows potent single-agent activity across a broad panel of human and murine head and neck cancer cell lines and significant anti-tumor synergy with antiâ€“PD-1 therapies in HPV+ HNSCC models.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)*   **Financial Runway:** Aprea reported $16.5 million in cash as of June 30, 2025, which is expected to fund operations into Q2 2026.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are emerging as a promising strategy in oncology, particularly for aggressive and hard-to-treat tumors [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). These inhibitors target the pressure points that fast-growing cancers rely on to survive, especially their ability to manage stress and control the timing of cell division [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). By blocking WEE1, researchers aim to disrupt cancer's ability to stay ahead of treatment [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**WEE1 Inhibitors in Clinical Development:**\n",
      "Several WEE1 inhibitors are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Examples include:\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in various clinical trials, including a Phase 2 trial in combination with gemcitabine for second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Zentalis Pharmaceuticals is developing azenosertib (ZN-c3) as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). It is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC was presented at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-3) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2).\n",
      "*   **AZD1775 (Adavosertib or MK-1775):** Adavosertib selectively targets and inhibits WEE1, preventing the phosphorylation of CDC2 and impairing the G2 DNA damage checkpoint [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4). It is currently in Phase II clinical trials for ovarian cancer and has received Orphan Drug designation in the European Union for this indication [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4).\n",
      "*   **Debio-0123:** Debiopharm has this WEE1 inhibitor in Phase I/II trials in combination with temozolomide for glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_1-5).\n",
      "*   **APR-1051, SC0191, and ACR-2316** [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Clinical Trial Landscape and Design:**\n",
      "The clinical trial landscape for WEE1 inhibitors is rapidly evolving [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Trials employ various designs, from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Researchers are also exploring smarter trial models that track how tumors respond over time, integrating molecular context as defining features of therapeutic opportunity [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**Combination Strategies:**\n",
      "Combination approaches are driving the next wave of progress, pairing WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs) [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Combining WEE1 inhibitors with immune checkpoint inhibitors holds the promise of directly killing tumor cells and rendering the tumor microenvironment more immunogenic, permitting a more robust anti-tumor immune response [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "Success hinges on overcoming key challenges while refining trial design [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Determining which patients are most likely to benefit and managing toxicities are major priorities [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Future progress will depend on more sophisticated approaches that integrate real-time data metrics, with AI emerging as a key enabler [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Azenosertib (ZN-c3) is under investigation in clinical trials for both ovarian and pancreatic cancer in 2024 and 2025. Here's a summary of the recent findings and ongoing studies: \n",
      "\n",
      " **Ovarian Cancer:** \n",
      "\n",
      " *   **Promising Efficacy in Platinum-Resistant Ovarian Cancer:** Azenosertib monotherapy has shown promising efficacy in heavily pretreated patients with cyclin E1â€“positive platinum-resistant ovarian cancer.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   In part 1b of the phase 2 DENALI trial (NCT05128825), azenosertib achieved an overall response rate (ORR) of 34.9% (95% CI, 21.0%-50.9%) among 43 response-evaluable patients.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   As of December 2, 2024, data cutoff, the ORR in the intention-to-treat (ITT) cyclin E1â€“positive population (n = 48) was 31.3% (95% CI, 18.7%-46.3%). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The median duration of response (DOR) was approximately 5.5 months (95% CI, 2.7-not evaluable). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The FDA granted fast track designation to azenosertib for the treatment of patients with Cyclin E1â€“positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. \n",
      " *  [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)  **DENALI Trial:**  This is a multi-part Phase 2 study evaluating the efficacy and safety of azenosertib in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2) 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive. \n",
      " *  [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2)  **Ongoing Trials:** \n",
      " *   ZN-c3-002 Phase 1b dose escalation trial of azenosertib in combination with bevacizumab for platinum-sensitive ovarian cancer. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  TETON (ZN-c3-004) Phase 2 clinical trial of azenosertib as a monotherapy for uterine serous carcinoma, with data expected in the first half of 2026. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  **Clinical Hold:**  In June 2024, the FDA placed a partial clinical hold on three azenosertib trials, including the Phase II DENALI trial, after two patient deaths due to presumed sepsis. \n",
      "\n",
      " * [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)*Pancreatic Cancer:** \n",
      "\n",
      " *   **Azenosertib in Combination with Gemcitabine:** A phase II trial (NCT06015659) is ongoing, evaluating azenosertib in combination with gemcitabine for advanced pancreatic cancer after progression or intolerance with FOLFIRINOX. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-6) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  Subjects receive azenosertib once daily on days 1-5, 8-12, and 15-19, and gemcitabine on days 1 and 8 of 21-day cycles. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The trial includes a safety lead-in portion with up to 12 subjects. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The primary objective is to evaluate the efficacy of azenosertib/gemcitabine, measured by 6-month progression-free survival (PFS) among second-line advanced pancreatic cancer patients. \n",
      " *  [cancer](https://vertexaisearch.cloud.google.com/id/search_2-8)  Azenosertib combined with gemcitabine showed synergistic cytotoxicity in PDAC cell lines. \n",
      "\n",
      " I [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)t's important to note that some trials involving azenosertib have faced partial clinical holds.\n",
      " [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)\n",
      "\n",
      "---\n",
      "\n",
      "Adavosertib (AZD1775) is a selective inhibitor of WEE1 kinase, an enzyme that regulates the cell cycle [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1) [nih](https://vertexaisearch.cloud.google.com/id/search_3-2) [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3). By inhibiting WEE1, adavosertib can disrupt the G1-S and G2-M checkpoints, leading to replication stress and tumor cell death [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). It has shown promising antitumor activity as a single agent and in combination with chemotherapy in several adult and pediatric solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5).\n",
      "\n",
      "### Clinical Trials involving Adavosertib (AZD1775) in 2024 and 2025:\n",
      "\n",
      "While the provided documents do not specifically mention clinical trials scheduled for 2024 or 2025, they do refer to ongoing and recently completed trials that provide relevant information. Most of the trials were completed before 2024, the information is still relevant for the use of adavosertib in 2024 and 2025.\n",
      "\n",
      "**Ovarian Cancer:**\n",
      "\n",
      "*   **Adavosertib with Carboplatin and Paclitaxel:** A phase II trial (NCT01357161) studied adavosertib in combination with carboplatin and paclitaxel for women with TP53-mutated, platinum-sensitive ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1). The results showed improved progression-free survival (PFS) with the addition of adavosertib [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "*   **Adavosertib with Carboplatin in Platinum-Resistant Ovarian Cancer:** A phase II study evaluated the combination of adavosertib and carboplatin in patients with TP53-mutated platinum-resistant ovarian cancer [asco](https://vertexaisearch.cloud.google.com/id/search_3-7) [nih](https://vertexaisearch.cloud.google.com/id/search_3-8) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The combination was found to be safe and effective, with an objective response rate (ORR) of 38% [asco](https://vertexaisearch.cloud.google.com/id/search_3-7).\n",
      "*   **Adavosertib Monotherapy in CCNE1-Amplified Ovarian Cancer:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The results showed promising clinical activity, especially in epithelial ovarian cancer, with an ORR of 36% [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [nih](https://vertexaisearch.cloud.google.com/id/search_3-10).\n",
      "*   **Adavosertib Before Surgery:** A pilot phase I trial is studying the effects of adavosertib on tumor DNA in patients undergoing surgery for advanced, high-grade ovarian, fallopian tube, or primary peritoneal cancer [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3).\n",
      "\n",
      "**Solid Tumors:**\n",
      "\n",
      "*   **Adavosertib Monotherapy in Advanced Solid Tumors:** A phase I trial of once-daily adavosertib in patients with advanced solid tumors determined a recommended phase II dose [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). Another phase Ib study assessed the safety, tolerability, and efficacy of adavosertib monotherapy in patients with various advanced solid tumors [nih](https://vertexaisearch.cloud.google.com/id/search_3-2).\n",
      "*   **Adavosertib with Irinotecan in Pediatric Solid Tumors:** A phase I trial (ADVL1312) evaluated adavosertib in combination with irinotecan in children with relapsed solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5). The study defined the dose-limiting toxicities and recommended phase II dose of the combination [nih](https://vertexaisearch.cloud.google.com/id/search_3-5) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0). A phase II trial of the same combination was conducted for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma [umn](https://vertexaisearch.cloud.google.com/id/search_3-11).\n",
      "*   **Adavosertib in SETD2-Altered Solid Tumors:** A phase II trial (NCI 10170) assessed the efficacy of adavosertib in patients with solid tumor malignancies and clear cell renal cell carcinoma harboring a pathogenic SETD2 mutation [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12). The study found limited clinical activity of adavosertib monotherapy in this population [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12).\n",
      "*   **Adavosertib in CCNE1-Amplified Solid Tumors:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The study demonstrated a manageable toxicity profile and promising clinical activity, especially in epithelial ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9).\n",
      "\n",
      "These trials suggest that adavosertib, both as a single agent and in combination with other therapies, has potential in treating ovarian cancer and other solid tumors, particularly in specific genetic contexts such as TP53 mutations or CCNE1 amplification [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an investigational, brain-penetrant, and selective WEE1 kinase inhibitor being developed by Debiopharm [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). WEE1 is a key regulator of cell cycle checkpoints, and its inhibition, especially with DNA-damaging agents, can cause an overload of DNA breaks, potentially leading to cancer cell death [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Debiopharm is conducting clinical trials with Debio-0123 for glioblastoma [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_4-2) [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). Glioblastomas are aggressive brain tumors with limited treatment options [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Clinical trial details:\n",
      "*   **Phase 1/2 study:** Debiopharm has initiated an open-label Phase 1/2 research study of Debio-0123 [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). This study investigates Debio-0123 in combination with temozolomide (TMZ) for patients with recurrent or progressive glioblastoma (GBM) and in combination with TMZ/RT (standard of care) for newly diagnosed patients [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). The initial phase aims to determine the recommended Phase 2 doses [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "*   **NCT05765812:** A Phase 1/2 study (NCT05765812) is evaluating Debio 0123 with TMZ in patients with recurrent GBM and Debio 0123 combined with TMZ-based chemoradiotherapy in patients with newly diagnosed GBM [oup](https://vertexaisearch.cloud.google.com/id/search_4-4). The study includes a dose escalation phase to identify the recommended Phase 2 dose, followed by an assessment of safety, pharmacokinetics, and preliminary antitumor activity [oup](https://vertexaisearch.cloud.google.com/id/search_4-4).\n",
      "*   **Arms of the study:** The study has different arms focusing on different treatment combinations [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6). Arm A involves Debio 0123 combined with temozolomide (TMZ) for recurrent or progressive glioblastoma. Arm B, which was previously added to the protocol but has been permanently halted due to safety concerns, involved Debio 0123 combined with TMZ and radiotherapy (RT) for newly diagnosed glioblastoma [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5).\n",
      "*   **Phase 2:** Phase 2 will assess the efficacy of Debio 0123 in combination with TMZ compared to the standard of care for adult participants with GBM [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6).\n",
      "\n",
      "Debio-0123 has shown the ability to penetrate the brain, which is important for treating brain tumors [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3). Preclinical data suggest that Debio-0123 can cross the blood-brain barrier and inhibit tumor growth, and its combination with TMZ has demonstrated increased antitumor activity [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Here's a summary of the recent developments in WEE1-targeted drug research and clinical trials: \n",
      "\n",
      " **1. WEE1 Inhibitors & Their Role** \n",
      "\n",
      " *   WEE1 kinase is a key regulator of the cell cycle, ensuring proper progression and genomic integrity by inhibiting CDK1/2, which prevents premature mitosis [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibition forces cells with damaged DNA into mitosis, leading to cell death, especially in tumors deficient in p53 [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibitors can also sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation, enhancing the anti-tumor response [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      "\n",
      " **2. Clinical Trials &è¿›å±•** \n",
      "\n",
      " *   Several WEE1 inhibitor programs are in active clinical development. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Examples include Azenosertib (ZN-c3), Debio0123, and ACR-2316. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   These inhibitors are being evaluated in various cancers, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, and head and neck cancers. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Trials range from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **3. Specific Drug & Trial Updates** \n",
      "\n",
      " *   **Azenosertib (ZN-c3):** \n",
      " *   The FDA lifted a partial clinical hold on azenosertib trials in September 2024, allowing studies to resume. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-2)*   Azenosertib is being investigated in Phase I for solid tumors and Phase II for ovarian and uterine cancer. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1)*   A Phase 2 study is investigating azenosertib with gemcitabine in advanced pancreatic adenocarcinoma. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   **AZD1775 (Adavosertib):** \n",
      " *   A Phase II study of adavosertib in SETD2-altered advanced solid tumor malignancies did not show objective responses. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   However, minor tumor regressions and prolonged stable disease were observed in some patients. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   **Debio0123:** Preliminary findings from studies in breast cancer and small cell lung cancer have highlighted the feasibility of combination therapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **4. Combination Strategies** \n",
      "\n",
      " *   Combination approaches are being explored to pair WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs). \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Combining WEE1 inhibitors with immune checkpoint inhibitors holds promise for enhancing anti-tumor immune response. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **5. Challenges & Future Directions** \n",
      "\n",
      " *   Challenges remain, including acquired resistance, toxicity, and patient selection. \n",
      "  [nih](https://vertexaisearch.cloud.google.com/id/1-5)*   Identifying patients most likely to benefit is a key priority. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Smarter trial models are needed to track tumor responses over time. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Careful dosing strategies are necessary to manage toxicity.\n",
      " [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)\n",
      "\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ Azenosertib (ZN-c3) åœ¨ 2024 å¹´å’Œ 2025 å¹´æœ€æ–°ä¸´åºŠè¯•éªŒçš„æ›´æ–°ï¼š\n",
      "\n",
      "**ä¸´åºŠè¯•éªŒçŠ¶æ€**\n",
      "*   FDAè§£é™¤äº†å…ˆå‰å¯¹è¯„ä¼°æ™šæœŸå®ä½“ç˜¤æ‚£è€…WEE1æŠ‘åˆ¶å‰‚Azenosertibç ”ç©¶çš„éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   2024å¹´6æœˆï¼Œç›‘ç®¡æœºæ„å¯¹é’ˆå¯¹æ™šæœŸå®ä½“ç˜¤æ‚£è€…çš„1æœŸZN-c3-001è¯•éªŒ (NCT04158336)ã€é’ˆå¯¹é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€…çš„2æœŸDENALIè¯•éªŒ (NCT05128825) ä»¥åŠé’ˆå¯¹å­å®«æµ†æ¶²æ€§ç™Œæ‚£è€…çš„2æœŸT [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-0) [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ETONè¯•éªŒ (NCT04814108) å‘å¸ƒäº†éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   è¯¥å†³å®šæºäºDENALIè¯•éªŒä¸­æŠ¥å‘Šçš„ä¸¤ä¾‹å› æ¨å®šè´¥è¡€ç—‡å¯¼è‡´çš„æ­»äº¡ã€‚\n",
      "*   åœ¨å®¡æŸ¥äº†Azenosertibçš„å¼€å‘å•†Zentalis Pharmaceuticalsçš„å®Œæ•´å›å¤æ–¹æ¡ˆåï¼ŒFDAæ‰¹å‡†è¿™äº›ç ”ç©¶æ¢å¤æ‰€æœ‰æ­£åœ¨è¿›è¡Œçš„è¯¥è¯ç‰©ç ”ç©¶çš„æ‚£è€…æ‹›å‹Ÿï¼Œä¸”ä¸´åºŠå¼€å‘è®¡åˆ’æ²¡æœ‰ä»»ä½•å˜æ›´.\n",
      "\n",
      "**æ­£åœ¨è¿›è¡Œå’Œè®¡åˆ’ä¸­çš„è¯•éªŒ**\n",
      "*   **ZN-c3-001ï¼š** ä¸€é¡¹1æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€å‰‚é‡é€’å¢å’Œæ‰©å±•ç ”ç©¶ï¼Œæ—¨åœ¨ç ”ç©¶Azenosertibä½œä¸ºå•è¯ç–—æ³•æ²»ç–—æ™šæœŸå®ä½“ç˜¤æ‚£è€…ã€‚è¯¥ç ”ç©¶å·²å®Œå…¨æ‹›å‹Ÿ [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) (n=274)ã€‚\n",
      "*   **DENALIï¼š** ä¸€é¡¹2æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œçº³å…¥è‡³å°‘18å²ä¸”æ‚£æœ‰é“‚è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œã€è¾“åµç®¡ç™Œæˆ–åŸå‘æ€§è…¹è†œç™Œçš„æ‚£è€…ã€‚DENALI [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) 2æœŸè¯•éªŒé¢„è®¡å°†äº2025å¹´ä¸ŠåŠå¹´å¼€å§‹æ‹›å‹Ÿã€‚ç¬¬äºŒéƒ¨åˆ†å°†åˆ†ä¸¤ä¸ªéƒ¨åˆ†è¿›è¡Œã€‚Part 2a å°†è¯„ä¼°å¹¶ç¡®è®¤æœ€ä½³ç»™è¯ç­–ç•¥ï¼Œæ¯”è¾ƒä¸»è¦çš„ 400 æ¯«å…‹é—´æ­‡ç»™è¯æ–¹æ¡ˆï¼ˆç”¨è¯ 5 å¤©ï¼Œåœè¯ 2 å¤©ï¼‰ä¸ç›¸åŒæ–¹æ¡ˆçš„ 300 æ¯«å…‹å‰‚é‡ã€‚æ¯ä¸ªé˜Ÿåˆ—å°†æ‹›å‹Ÿçº¦ 30 åæ‚£è€…ã€‚\n",
      "*   **TETONï¼š** ä¸€é¡¹å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibåœ¨ç»„ç»‡å­¦è¯å®ä¸ºå¤å‘æ€§æˆ–æŒç»­æ€§å­å®«æµ†æ¶²æ€§ç™Œä¸”æ— æœ‰æ•ˆç–—æ³•æˆ–æ— æ³•è€å—å¯ç”¨æ ‡å‡†æ²»ç–—çš„è‡³å°‘18å²æ‚£è€…ä¸­çš„åº”ç”¨ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ã€‚\n",
      "*   **ZN-c3-016ï¼š** ä¸è¾‰ç‘åˆä½œè¿›è¡Œçš„ä¸€é¡¹1/2æœŸç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibè”åˆEncorafenibå’Œè¥¿å¦¥æ˜”å•æŠ—åœ¨è½¬ç§»æ€§BRAF V600Eçªå˜å‹ç»“ç›´è‚ ç™Œæ‚£è€…ä¸­çš„åº”ç”¨ã€‚ZN-c3-016ç ”ç©¶çš„å‰‚é‡æ¢ç´¢é˜¶æ®µå·²å®Œå…¨æ‹›å‹Ÿ (n=44)ã€‚\n",
      "\n",
      "**ä¸´åºŠæ•°æ®**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼ŒZN-c3-001çš„ç»“æœæ˜¾ç¤ºï¼Œåœ¨é—´æ­‡ç»™è¯æ–¹æ¡ˆä¸‹ï¼Œæ€»æ—¥å‰‚é‡æ°´å¹³â‰¥30 [onclive](https://vertexaisearch.cloud.google.com/id/2-1)0mgçš„Cyclin E1+ PROCæ‚£è€…ä¸­ï¼Œå®¢è§‚ç¼“è§£ç‡ (ORR)  [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)å’Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (mDOR) ä»¤äººé¼“èˆ (n=23)ã€‚åœ¨è¿™äº›æ‚£è€…ä¸­ï¼Œè§‚å¯Ÿåˆ°ORRä¸º34.8% (8/23ï¼›95% CIï¼š16.4-57.3)ï¼ŒmDORä¸º5.2ä¸ªæœˆ (95% CIï¼š2.8, 6.9)ã€‚\n",
      "*   åœ¨DENALIè¯•éªŒçš„1béƒ¨åˆ†ä¸­ï¼Œå•è¯Azenosertibåœ¨43åå¯è¯„ä¼°ååº”çš„ã€ç»è¿‡å¤§é‡é¢„å¤„ç†çš„Cyclin E1é˜³æ€§é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€… [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ä¸­äº§ç”Ÿäº†34.9%çš„å®¢è§‚ç¼“è§£ç‡ (ORR) (95% CI, 21.0%-50.9%)ã€‚\n",
      "*   æˆªè‡³2024å¹´12æœˆ2 [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5)æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨æ¥å—è‡³å°‘ä¸€å‰‚Azenosertibçš„Cyclin E1+ PROCæ„å‘æ²»ç–—æ‚£è€…ä¸­ï¼ŒORRä¸º31.3% (15/48ï¼›95% CIï¼š18.7 - 46.3)ã€‚æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œæ„å‘æ²»ç–—äººç¾¤çš„mDORä»åœ¨æˆç†Ÿï¼Œçº¦ä¸º5.5ä¸ªæœˆ (95% CIï¼š2.7 â€“ ä¸å¯ä¼°è®¡)ã€‚\n",
      "*   Zentalis PharmaceuticalsæŠ¥å‘Šäº†Azenosertibæ­£åœ¨è¿›è¡Œçš„DENALI Part 1bä¸´åºŠè¯•éªŒçš„æœ€æ–°ä¸´åºŠæ•°æ®ï¼Œåœ¨å¯è¯„ä¼°ååº”çš„æ‚£è€…ä¸­ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)ä¸º6.3ä¸ªæœˆï¼Œå®¢è§‚ç¼“è§£ç‡çº¦ä¸º35%ã€‚\n",
      "\n",
      "**å®‰å…¨æ€§ä¸è€å—æ€§**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨ZN-c3-001ç ”ç©¶ä¸­ï¼ŒAzenosertibåœ¨æ‰€æœ‰è‚¿ç˜¤ç±»å‹ä¸”ä¸è€ƒè™‘ç”Ÿç‰©æ ‡å¿—ç‰©çŠ¶æ€çš„æƒ…å†µä¸‹ï¼Œåœ¨æ€»æ—¥å‰‚é‡æ°´å¹³â‰¥300mg (n=193) æ—¶å‡æ˜¾ç¤ºå‡ºè‰¯å¥½çš„è€å—æ€§ï¼Œæœªè§‚å¯Ÿåˆ°3çº§ä»¥ä¸Šèƒƒè‚ é“æ²»ç–—ç›¸å…³ä¸è‰¯äº‹ä»¶ (TRAE)ï¼Œä¸”3çº§ä»¥ä¸Šè¡€æ¶²å­¦æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½ï¼Œå¤§å¤šæ•°è¡€æ¶²å­¦æ¯’æ€§äº‹ä»¶ä¸º3çº§ã€‚\n",
      "*   å¯¼è‡´åœè¯çš„TRAEå‘ç”Ÿç‡è¾ƒä½ (n=10, 5.2%)ã€‚ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)è¯¥ç ”ç©¶ä¸­å…ˆå‰æŠ¥å‘Šäº†ä¸€èµ·æ²»ç–—ç›¸å…³çš„5çº§äº‹ä»¶ (n=1, 0.5%)ã€‚\n",
      "*   DENALI 1béƒ¨åˆ†å…ˆå‰å·²æŠ¥å‘Šäº†ä¸¤èµ·æ²»ç–—ç›¸å…³çš„5çº§ä¸è‰¯äº‹ä»¶ (AE)ã€‚\n",
      "\n",
      "**å…¶ä»–å‘å±•**\n",
      "*   Zentalisé¢„è®¡å°†åœ¨2024å¹´ç¬¬å››å­£åº¦æä¾›Azenosertibçš„æ›´å¤šæ•°æ®ã€‚\n",
      "*   Zentalisè®¡åˆ’åœ¨2025å¹´ä¸ŠåŠå¹´å¯åŠ¨DENALIä¸´åºŠè¯•éªŒçš„ç¬¬äºŒéƒ¨åˆ†ã€‚\n",
      "*   é¢„è®¡åˆ°2026å¹´åº•å°†è·å¾—å…· [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)æœ‰æ³¨å†Œæ„å‘çš„é¡¶çº¿æ•°æ®ï¼Œè¿™ä½¿Zentalisæœ‰å¯èƒ½è·å¾—FDAçš„åŠ é€Ÿæ‰¹å‡†ã€‚\n",
      "*   ä¸´åºŠå‰æ•°æ®æ˜¾ç¤ºï¼ŒAzenosertibä¸åŸº [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)äºå¾®ç®¡æŠ‘åˆ¶å‰‚çš„æŠ—ä½“è¯ç‰©å¶è”ç‰©è”åˆä½¿ç”¨æ—¶ï¼Œæ˜¾ç¤ºå‡ºååŒæŠ—è‚¿ç˜¤ä½œç”¨ï¼Œè¿™è¡¨æ˜Azenosertibåœ¨æ²»ç–—å„ç§æ™šæœŸå®ä½“ç˜¤æ–¹é¢å…·æœ‰æ›´å¹¿æ³›çš„æ²»ç–—æ½œåŠ›ã€‚\n",
      "*   Zentalisæ­£åœ¨å‰Šå‡40%çš„å‘˜å·¥ï¼Œä»¥å°†ç°é‡‘å»¶é•¿åˆ°Azenosertibæ½œåœ¨æ³¨å†Œç ”ç©¶çš„é¢„æœŸæ•°æ®è¯»å–ä¹‹åã€‚\n",
      "*   Zentaliså·²ä¸FDAå°±éå¯¹ç…§æ³¨å†Œè¯•éªŒDenali part 2açš„ä¸€éƒ¨åˆ†â€œè¾¾æˆä¸€è‡´â€ï¼Œè¯¥å…¬å¸å¸Œæœ›è¿™å°†æ˜¯å…¶åŠ é€Ÿæ‰¹å‡†Azenosertibçš„ç¬¬ä¸€æ­¥ã€‚\n",
      " [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [nasdaq](https://vert [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6)exaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [target [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)edonc](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "\n",
      "---\n",
      "\n",
      "Im Jahr 2024 und 2025 laufen klinische Studien mit den WEE1-Inhibitoren Debio0123 und ACR-2316.\n",
      "\n",
      "**Debio0123:**\n",
      "\n",
      "*   Debio0123 ist ein selektiver WEE1-Kinase-Inhibitor, der die Blut-Hirn-Schranke Ã¼berwinden kann. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) Er wird als Monotherapie und in Kombination mit anderen Krebsbehandlungen bei verschiedenen soliden Tumoren untersucht. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)\n",
      "*   Debiopharm fÃ¼hrt mehrere klinische Studien mit Debio0123 durch, um die Wirkung von DNA-schÃ¤digenden Substanzen zu verstÃ¤rken. Eine Studie untersucht die Kombination von Debio0123 mit einer Standard-Chemotherapie bei kleinzelligem Lungenkrebs und Glioblastom.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debio0123 zeigt in vivo eine starke Synergie und Antitumorwirksamkeit in Kombination mit Chemotherapie und Strahlentherapie.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debiopharm untersucht Debio0123 auch in Kombination mit Lunresertib (einem PKMYT1-Inhibitor von Repare) bei Patienten mit fortgeschrittenen soliden Tumoren.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Eine Phase-1-Studie mit Debio0123 als Monotherapie wird in den USA, Spanien und der Schweiz durchgefÃ¼hrt, um die Sicherheit, VertrÃ¤glichkeit und vorlÃ¤ufige AntitumoraktivitÃ¤t bei Patienten mit rezidivierenden oder progressiven soliden Tumoren zu untersuchen. Zwei d [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)er drei Erweiterungsarme dieser Studie verwenden Biomarker, um Patienten mit verschiedenen soliden Tumoren vorab auszuwÃ¤hlen, wÃ¤hrend der dritte Arm Patienten mit rezidivierendem serÃ¶sem Endometriumkarzinom behandelt.\n",
      "\n",
      "**ACR-23 [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)16:**\n",
      "\n",
      "*   ACR-2316 ist ein neuartiger, selektiver dualer WEE1/PKMYT1-Inhibitor, der fÃ¼r eine Ã¼berlegene EinzelwirkstoffaktivitÃ¤t entwickelt wurde.\n",
      "*   Acrivon  [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)Therapeutics plant, bis zum vierten Quartal 2024 einen IND-Antrag (Investigational New Drug) fÃ¼r ACR-2316 einzureichen.\n",
      "*   Eine lauf [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-4)ende Phase-1-Monotherapie-Studie untersucht die Sicherheit und VertrÃ¤glichkeit von ACR-2316. Die Dosierung  [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)der Patienten in dieser Studie hat bereits begonnen.\n",
      "*   ACR-2316 z [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)eigte in prÃ¤klinischen Studien eine Ã¼berlegene AktivitÃ¤t im Vergleich zu klinischen Benchmark-Inhibitoren (Azenosertib, Debio-0123 und Lunresertib).\n",
      "*   Auf dem Gebie [acrivon](https://vertexaisearch.cloud.google.com/id/3-3) [acrivon](https://vertexaisearch.cloud.google.com/id/3-2)t des Endometriumkarzinoms wurde eine bestÃ¤tigte partielle Remission beobachtet, was auf das breite Potenzial dieses Wirkstoffs hinweist.\n",
      "*   Acrivon Therap [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5)eutics plant, in der zweiten HÃ¤lfte des Jahres 2025 erste klinische Daten aus der Phase-1-Studie mit ACR-2316 vorzulegen.\n",
      "*   Die ersten drei [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6) Dosis-Eskalationskohorten der Phase-1-Studie mit ACR-2316 sind abgeschlossen. Es wurden eine unge [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)fÃ¤hre DosisproportionalitÃ¤t, ein Target-Engagement und eine erste klinische AktivitÃ¤t mit signifikanter Tumorschrumpfung bereits bei Dosislevel drei beobachtet.\n",
      " [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ AZD1775 (Adavosertib) åœ¨ 2024 å¹´å’Œ 2025 å¹´è¿›è¡Œçš„ä¸´åºŠè¯•éªŒçš„ä¿¡æ¯ï¼š\n",
      "\n",
      "*   **å•è¯ Adavosertib ç–—æ³•:**\n",
      "    *   ä¸€é¡¹é’ˆå¯¹ SETD2 çªå˜çš„æ™šæœŸå®ä½“è‚¿ç˜¤æ‚£è€…çš„ II æœŸç ”ç©¶è¡¨æ˜ï¼Œå°½ç®¡æœ‰ä¸´åºŠå‰æ•°æ®è¡¨æ˜å…¶å…·æœ‰åˆæˆè‡´æ­»æ•ˆåº”ï¼Œä½† Adavosertib å•è¯æ²»ç–—çš„ä¸´åºŠæ´»æ€§æœ‰é™ã€‚\n",
      "    *   å°½ç®¡æ²¡æœ‰è§‚å¯Ÿåˆ°å®¢è§‚ååº”ï¼Œä½†åœ¨éƒ¨åˆ†æ‚£è€…ä¸­è§‚å¯Ÿåˆ°è½»å¾®çš„è‚¿ç˜¤æ¶ˆé€€å’Œå»¶é•¿çš„ç–¾ç—…ç¨³å®šã€‚\n",
      "\n",
      "*   **Adavosertib è”åˆç–—æ³•:**\n",
      "    *   **è‚ºé³çŠ¶ç»†èƒç™Œ:** ä¸€é¡¹é’ˆå¯¹è‚ºé³çŠ¶ç»†èƒç™Œçš„ II æœŸå•è‡‚ç ”ç©¶å°† Adavosertib ä¸å¡é“‚å’Œç´«æ‰é†‡è”åˆä½¿ç”¨ï¼Œä¸­ä½ PFS ä¸º 4.8 ä¸ªæœˆã€‚ ç–¾ç—…æ§ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)åˆ¶ç‡ (DCR) ä¸º 60.9%ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (DoR) ä¸º 4.44 ä¸ªæœˆã€‚\n",
      "    *   **å„¿ç«¥æ¶æ€§è‚¿ç˜¤:** åœ¨ AcSÃ©-ESMART è¯•éªŒçš„ C ç»„ä¸­ï¼ŒAdavosertib ä¸å¡é“‚è”åˆç”¨äºæ²»ç–—æ‚£æœ‰åˆ†å­å¯Œé›†å¤å‘/éš¾æ²»æ€§æ¶æ€§è‚¿ç˜¤ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)çš„å„¿ç«¥å’Œé’å°‘å¹´ï¼Œä½†ç”±äºè¡€æ¶²å­¦æ¯’æ€§ï¼Œæœªç¡®å®š II æœŸæ¨èå‰‚é‡ã€‚\n",
      "    *   **å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤:** ä¸€é¡¹é’ˆå¯¹å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤çš„å„¿ç§‘ II æœŸè¯•éªŒå°† Adavosertib ä¸ä¼Šç«‹æ›¿åº·è”åˆä½¿ç”¨ã€‚ ç¥ç»æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸‰ä¸ªå®¢è§‚ååº”ï¼Œæ¾æœä½“æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸€ä¸ªéƒ¨åˆ†ååº”ã€‚\n",
      "\n",
      "æ€»çš„æ¥è¯´ï¼Œç°æœ‰çš„ç ”ç©¶è¡¨æ˜ï¼ŒAdavosertib å•è¯æ²»ç–—åœ¨å®ä½“è‚¿ç˜¤ä¸­å¯èƒ½ç–—æ•ˆ [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)æœ‰é™ï¼Œä½†ä¸å…¶ä»–åŒ–ç–—è¯ç‰©è”åˆä½¿ç”¨å¯èƒ½å¯¹æŸäº›ç™Œç—‡æœ‰æ•ˆã€‚ [umn](https://vertexaisearch.cloud.google.com/id/4-5) [umn [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)](https://vertexaisearch.cloud.google.com/id/4-5) [nih](https://vertexaisearch.cloud.google.com/id/4-3) [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-4)\n",
      "\n",
      "---\n",
      "\n",
      "Azenosertib is a WEE1 inhibitor being developed by Zentalis Pharmaceuticals for various cancers, including ovarian cancer [onclive](https://vertexaisearch.cloud.google.com/id/1-0) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-1) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2) [zentalis](https://vertexaisearch.cloud.google.com/id/1-3). It is currently being evaluated in clinical trials as both a monotherapy and in combination with other treatments [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [zentalis](https://vertexaisearch.cloud.google.com/id/1-3) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **DENALI Trial (Platinum-Resistant Ovarian Cancer):**\n",
      "    *   The DENALI trial is a Phase 2 study evaluating azenosertib in patients with platinum-resistant ovarian cancer [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-1) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5) [onclive](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   Updated data from Part 1b of the DENALI trial showed an objective response rate (ORR) of 34.9% in Cyclin E1+ patients (a biomarker-defined subgroup representing approximately 50% of PROC cases) [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "    *   In the intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3%, and the median duration of response (mDOR) was 6.3 months [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   Zentalis is on track to initiate enrollment of DENALI Part 2 in the first half of 2025 and expects to disclose topline data from DENALI Part 2 by year end 2026 [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Combination Therapies:**\n",
      "    *   Early data suggests azenosertib in combination with encorafenib and cetuximab shows a manageable safety profile and potential in metastatic BRAF V600E mutant colorectal cancer [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "    *   Preclinical data suggests azenosertib combined with microtubule inhibitor-based antibody-drug conjugates (ADCs) exhibits synergistic antitumor activity in vitro and in vivo [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Manageable Safety Profile:** The trial evaluating safety and dose escalation demonstrated a manageable safety profile, with no unexpected adverse events reported as of April 4, 2025 [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "*   **Common Adverse Events:** Gastrointestinal toxicities and fatigue were found to be the most common treatment-related adverse events [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Clinical Hold:** In June 2024, the FDA placed a clinical hold on three azenosertib monotherapy studies after two deaths occurred in the Phase II DENALI trial in platinum-resistant ovarian cancer; the deaths were presumed to be due to sepsis [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "\n",
      "**Overall:**\n",
      "\n",
      "Azenosertib is a promising WEE1 inhibitor that has shown encouraging early results in clinical trials for ovarian cancer and other solid tumors [ainvest](https://vertexaisearch.cloud.google.com/id/1-6) [onclive](https://vertexaisearch.cloud.google.com/id/1-7) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2). The FDA had placed a partial clinical hold on monotherapy studies of azenosertib after two deaths occurred in one of them [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5). Zentalis is working with the FDA to resolve the partial clinical hold [patsnap](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123 is an investigational, orally bioavailable, highly selective, and brain-penetrant ATP-competitive inhibitor of the WEE1 tyrosine kinase [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1). It is currently in phase 1 clinical trials [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0). WEE1 is a key regulator of cell cycle progression that influences entry into mitosis by modulating activity of cyclin-dependent kinase 1 (CDK1) through phosphorylation [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "Here's what the search results indicate regarding clinical trials and results of Debio-0123 in ovarian cancer for 2024 and 2025:\n",
      "\n",
      "**2024 Results:**\n",
      "\n",
      "*   **Phase 1 Dose-Finding Study:** A phase 1 dose-escalation study of Debio 0123 as a monotherapy in adult patients with advanced solid tumors (including ovarian cancer) was conducted to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   As of October 24, 2023, 27 patients were treated, with ovarian cancer being the most common primary tumor (33%) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   The MTD was determined to be 260 mg [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   Two ovarian cancer patients achieved a 17% and 20% reduction in target lesions, despite needing dose reductions during the first cycle. One of these patients also had a CA-125 response [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "*   **Debio-0123-102 Trial:** This phase 1 dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Debio 0123 in patients with advanced solid tumors [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   The most frequent treatment-related adverse events (TRAEs) were increased blood creatinine (37%), QTcF prolongation (37%), nausea (33%), vomiting (26%), dysgeusia (22%), and fatigue (22%) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   Of the 25 patients with post-baseline tumor assessment, 8 (32%) had stable disease as their best response for â‰¥5 weeks.\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "**2025 Results:**\n",
      "\n",
      "*   **AACR Annual Meeting 2025:**\n",
      "    *   Debio 0123 is currently in phase 1 clinical trials.\n",
      " [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0)    *   Preclinical data demonstrates that the WEE1 inhibitor, Debio 0123, is synergistic with the PKMYT1 inhibitor, lunresertib, and consistently leads to deep and sustained regressions in vivo in models of ovarian and breast cancer.\n",
      " [researchgate](https://vertexaisearch.cloud.google.com/id/2-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5)    *   The combination of Debio 0123 and lunresertib resulted in complete and sustained regression of all tumors in in vivo models of ovarian or breast cancer.\n",
      " [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5) [researchgate](https://vertexaisearch.cloud.google.com/id/2-4)*   **ASCO Annual Meeting 2025:**\n",
      "    *   Debiopharm presented data on Debio 0123 at the ASCO Annual Meeting.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)    *   A Trial in Progress (TiP) poster outlined the framework and objectives of the ongoing dose expansion phase of the Debio 0123-102 monotherapy study.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)    *   An abstract publication and three poster presentations highlighted Debio 0123's potential across solid tumors.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)*   **Phase 1 Study in Gynecologic Cancers:** A phase 1 study is assessing Debio 0123 in gynecologic cancers, including ovarian, uterine serous carcinoma, primary peritoneal, and fallopian tube cancers.\n",
      " [mskcc](https://vertexaisearch.cloud.google.com/id/2-7)    *   The study includes an expansion phase with patients who have recurrent uterine serous carcinoma or high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with high cyclin E1.\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8) [mskcc](https://vertexaisearch.cloud.google.com/id/2-7)    *   The primary endpoints are safety, tolerability, and overall response rate (ORR).  [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8)Secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS).\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8)*   **Debio 0123 in Combination with Lunresertib:**\n",
      "    *   Preclinical models of ovarian and breast cancer show that Debio 0123 is synergistic with lunresertib.\n",
      " [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [researchgate](https://vertexaisearch.cloud.google.com/id/2-4) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0)    *   The combination of Debio 0123 and lunresertib induces strong phosphorylation of CDK1, potentially leading to premature mitotic entry, chromosome pulverization, and cancer cell death.\n",
      " [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1)\n",
      "\n",
      "---\n",
      "\n",
      "The latest data on the APR-1051 WEE1 inhibitor in clinical trials for ovarian cancer comes from 2024 and 2025.\n",
      "\n",
      "**2024:**\n",
      "\n",
      "*   The FDA cleared Aprea Therapeutics' Investigational New Drug (IND) application for APR-1051 in March 2024 [aprea](https://vertexaisearch.cloud.google.com/id/3-0) [aprea](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "*   A Phase 1 dose-escalation trial (ACESOT-1051) was initiated to evaluate the safety, tolerability, and preliminary efficacy of APR-1051 in patients with advanced solid tumors [biospace](https://vertexaisearch.cloud.google.com/id/3-2) [aprea](https://vertexaisearch.cloud.google.com/id/3-0). The trial is ongoing at sites in the U.S [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   Preliminary data from the Phase 1 trial presented in October 2024 showed that APR-1051 was safe and well-tolerated, with mostly Grade 1 or 2 adverse events [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2) [aprea](https://vertexaisearch.cloud.google.com/id/3-4). No hematologic toxicity was observed [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   The trial enrolled patients in cohorts receiving doses from 10 mg to 150 mg once daily [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "**2025:**\n",
      "\n",
      "*   Aprea Therapeutics presented updated data from the ACESOT-1051 trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025 [aprea](https://vertexaisearch.cloud.google.com/id/3-5) [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [aprea](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   Results from Dose Level 6 (100 mg once daily) showed that 3 out of 4 patients achieved stable disease (per RECIST v1.1) in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [aprea](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   Disease stabilization was observed in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations, molecular profiles known to drive replication stress and WEE1 dependency [aprea](https://vertexaisearch.cloud.google.com/id/3-6) [aprea](https://vertexaisearch.cloud.google.com/id/3-4).\n",
      "*   Dose escalation is continuing, with patients now enrolling in the 150 mg cohort [aprea](https://vertexaisearch.cloud.google.com/id/3-6) [aprea](https://vertexaisearch.cloud.google.com/id/3-5).\n",
      "*   APR-1051 was generally well-tolerated, with mostly Grade 1 or 2 adverse events, mainly gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/3-4).\n",
      "*   Maxim Group issued a Buy Rating on Aprea (Nasdaq: APRE) with a $10 price target over the next 12 months [financialcontent](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   Aprea has cash runway into the fourth quarter of 2026 [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [financialcontent](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are being explored as a cancer therapy target due to their role in cell cycle control and potential impact on cancer cell survival [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). By inhibiting WEE1, cancer cells are forced into mitosis with damaged DNA, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/4-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). This strategy is promising against difficult-to-treat cancers [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). Many cancers, especially those with TP53 mutations, upregulate WEE1 to counteract replication stress and DNA damage, making WEE1 a key therapeutic target [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "\n",
      "**WEE1 Inhibitors in Clinical Trials:**\n",
      "\n",
      "Several WEE1 inhibitors are currently in clinical trials, including:\n",
      "\n",
      "*   **Azenosertib (ZN-c3):** A potent oral WEE1 inhibitor [patsnap](https://vertexaisearch.cloud.google.com/id/4-1) [frontiersin](https://vertexaisearch.cloud.google.com/id/4-3). Zentalis Pharmaceuticals is developing azenosertib and expects to launch a phase 3 trial in the first quarter of 2024 [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4). Clinical data has shown anti-tumor activity in difficult-to-treat tumor types when combined with standard chemotherapy regimens [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   **Adavosertib (AZD1775):** Has shown strong preclinical and clinical activity in ovarian, breast, gastrointestinal, and head and neck cancers [nih](https://vertexaisearch.cloud.google.com/id/4-2). However, it has a narrow therapeutic window and associated toxicities [onclive](https://vertexaisearch.cloud.google.com/id/4-5).\n",
      "*   **Debio 0123:** A next-generation, brain-penetrant WEE1 inhibitor with an enhanced safety profile and improved cancer treatment outcomes is currently being researched [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/4-6).\n",
      "*   **APR-1051, SC0191, and ACR-2316** [patsnap](https://vertexaisearch.cloud.google.com/id/4-1)\n",
      "\n",
      "**Efficacy and Safety in Ovarian Cancer Clinical Trials:**\n",
      "\n",
      "*   **Azenosertib:** In a Phase 1b trial of azenosertib combined with chemotherapy in patients with platinum-resistant ovarian cancer, the highest overall response rate (ORR) was 50% with azenosertib plus paclitaxel chemotherapy [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/4-6). Azenosertib is emerging as a promising clinical candidate, with demonstrated anti-tumor activity in difficult-to-treat tumor types when used in combination with standard chemotherapy regimens [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4). The addition of azenosertib increased ORRs and mPFS over those observed historically with chemotherapy alone, or compared to adavosertib in combination with chemotherapy [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   **Adavosertib:** A phase II clinical trial (NCT01164995) confirmed the safety and effectiveness of Adavosertib and carboplatin in patients with TP53-mutant epithelial OC resistant to paclitaxel and carboplatin (TC) within three months [nih](https://vertexaisearch.cloud.google.com/id/4-7). The remission rate was 43%, with one patient achieving long-term complete remission [nih](https://vertexaisearch.cloud.google.com/id/4-7). The median progression-free survival (PFS) and OS were 5.3 and 12.6 months, respectively [nih](https://vertexaisearch.cloud.google.com/id/4-7). The most common grade â‰¥ 3 adverse events (AEs) were thrombocytopenia (48%) and neutropenia (37%).  [nih](https://vertexaisearch.cloud.google.com/id/4-7)A multicenter randomized phase II clinical study (NCT01357161) evaluated the effect of Adavosertib combined with TC vs TC alone in platinum-sensitive TP53-mutant OC patients.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-7)\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   **Toxicity:** First-generation WEE1 inhibitors showed limitations due to their lack of selectivity and resulting toxicity.  [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0)AZD1775 has high toxicity at effective dosages, manifesting as adverse side-effects.\n",
      " [frontiersin](https://vertexaisearch.cloud.google.com/id/4-3)*   **Resistance:** Acquired resistance remains an obstacle to clinical implementation.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-2)*   **Patient Selection:** Patient selection remains a challenge to clinical implementation.  [nih](https://vertexaisearch.cloud.google.com/id/4-2)Biomarkers such as TP53 mutations are increasingly used to guide treatment selection.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)*   **Combinations:** WEE1 inhibitors can be combined with other anticancer treatments, including DNA-damaging agents like chemotherapy and radiation, and immune checkpoint inhibitors.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-2) [patsnap](https://vertexaisearch.cloud.google.com/id/4-1)*   **Personalized Medicine:** The increasing focus on personalized medicine is enhancing the utility of WEE1 inhibitors.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)*   **Market Growth:** The WEE1 Inhibitor Therapeutics market is expected to grow at a remarkable CAGR of 21.8% from 2025 to 2033, with forecasts indicating the market will reach approximately USD 2.36 billion by 2033.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)\n",
      "\n",
      "---\n",
      "\n",
      "ACR-2316 is a novel, selective dual inhibitor of WEE1 and PKMYT1 designed for cancer treatment [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5). Acrivon Therapeutics is currently evaluating ACR-2316 in a Phase 1 monotherapy clinical trial in patients with advanced solid tumors [researcher](https://vertexaisearch.cloud.google.com/id/1-6). Initial clinical data from this trial is expected in the second half of 2025 [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [researcher](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "Here's a breakdown of ACR-2316's mechanism of action, efficacy, and safety:\n",
      "\n",
      "**Mechanism of Action:**\n",
      "\n",
      "*   **Dual Inhibition:** ACR-2316 inhibits both WEE1 and PKMYT1 kinases [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4). This dual inhibition is designed to overcome resistance mechanisms that can arise with single-target WEE1 inhibitors [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **CDK Activation:** By inhibiting WEE1 and PKMYT1, ACR-2316 promotes strong activation of CDK1, CDK2, and PLK1 [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11). These kinases are crucial for cell cycle progression and mitotic regulation [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Disruption of Cell Cycle Checkpoints:** ACR-2316 disrupts cell cycle checkpoints, leading to S/G2-M cell cycle arrest, premature mitosis, DNA damage, and ultimately, pro-apoptotic cell death [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11).\n",
      "*   **AP3 Platform Design:** ACR-2316 was designed using Acrivon's Predictive Precision Proteomics (AP3) platform [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8). This platform allows for the rational design of drug candidates with optimal target selectivity and potency [acrivon](https://vertexaisearch.cloud.google.com/id/1-4). AP3 helps in understanding drug-induced resistance mechanisms and optimizing the target selectivity profile [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Superior Preclinical Activity:** In preclinical studies, ACR-2316 has demonstrated superior single-agent anti-cancer activity compared to clinical benchmark WEE1 or PKMYT1 inhibitors [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Tumor Regression:** ACR-2316 induces tumor regression in CDX and PDX tumor mouse models [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8). It has also shown activity in tumors progressing on azenosertib, a WEE1 inhibitor [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Broad Spectrum Activity:** ACR-2316 demonstrates anti-cancer activity across a broad spectrum of in vitro cancer line models, including those insensitive to WEE1 or PKMYT1 inhibitors [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Dose-Dependent Efficacy:** ACR-2316 demonstrates dose-dependent efficacy and near-complete regressions in a human ovarian tumor xenograft model [acrivon](https://vertexaisearch.cloud.google.com/id/1-3). It also shows comparable efficacy across a range of intermittent dosing schedules [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Mechanism-Based and Reversible Adverse Events:** Preclinical IND-enabling GLP safety-toxicity studies suggest that adverse events are mechanism-based but transient and fully reversible [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Well Tolerated:** ACR-2316 is well-tolerated in rodent models, with only mechanism-based, transient, and reversible myelosuppression observed across a range of intermittent dosing regimens [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Phase 1 Trial Focus:** The ongoing Phase 1 clinical trial is designed to assess the safety and tolerability of ACR-2316 [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are being explored as a cancer therapy, with the lead candidate being adavosertib (AZD1775) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [nih](https://vertexaisearch.cloud.google.com/id/2-2). These inhibitors target the WEE1 kinase, a key regulator of the cell cycle, particularly the G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-2). By inhibiting WEE1, cancer cells with damaged DNA are forced into mitosis, leading to mitotic catastrophe and cell death [nih](https://vertexaisearch.cloud.google.com/id/2-2) [patsnap](https://vertexaisearch.cloud.google.com/id/2-3). This approach is particularly promising in tumors with TP53 mutations, as these cells rely more heavily on the G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "Here's a breakdown of the efficacy, safety, limitations, and resistance mechanisms associated with WEE1 inhibitors in single-target clinical trials:\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Monotherapy:** Adavosertib has demonstrated promising activity as a monotherapy in some cases [onclive](https://vertexaisearch.cloud.google.com/id/2-1). For example, a phase II single-arm clinical trial of adavosertib showed a median progression-free survival (PFS) of 6.1 months in patients with recurrent or persistent Uterine Serous Carcinoma (USC) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Combination Therapy:** WEE1 inhibition can enhance the effectiveness of chemotherapies, including platinum-based agents, antimetabolites, and PARP inhibitors [nih](https://vertexaisearch.cloud.google.com/id/2-2). It also synergizes with radiotherapy and immune checkpoint inhibitors [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "*   **Specific Cancers:** Clinical trials have shown strong preclinical and clinical activity of adavosertib in ovarian, breast, gastrointestinal, and head and neck cancers [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Tolerability:** Adavosertib has been shown to be safe and tolerable as a single agent and in combination with chemotherapy [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5).\n",
      "*   **Toxicities:** The most common toxicities associated with adavosertib include myelosuppression (anemia, neutropenia, and thrombocytopenia), nausea, vomiting, diarrhea, and fatigue [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "*   **Dose-Limiting Toxicities (DLTs):** DLTs reported in clinical trials include supraventricular tachyarrhythmia and myelosuppression [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "\n",
      "**Limitations:**\n",
      "\n",
      "*   **Toxicity:** Effective dosages of adavosertib can cause high toxicity, manifesting as adverse side effects [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Specificity:** Adavosertib may have lower than ideal specificity, targeting PLK1 alongside WEE1 in therapeutic trials [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Biomarkers:** There is a need for comprehensive biomarker panels to predict response and potential toxicity [patsnap](https://vertexaisearch.cloud.google.com/id/2-3). TP53 status has been proposed as a predictive biomarker, but its utility remains inconsistent [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "*   **Clinical Development:** Despite promising safety and efficacy, adavosertib has yet to proceed to a phase 3 trial [onclive](https://vertexaisearch.cloud.google.com/id/2-1).\n",
      "\n",
      "**Resistance Mechanisms:**\n",
      "\n",
      "*   **Upregulation of PKMYT1:** A mechanism of acquired resistance to adavosertib is the upregulation of PKMYT1, a kinase functionally related to WEE1 [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-7).\n",
      "*   **Reversal of Expression Profiles:** Reversal of expression profiles of genes that are the base for WEE1 inhibitor vulnerability can lead to resistance. For example, while cyclin E overexpression sensitizes cancer cells to AZD1775, reducing cyclin E levels has the opposite effect [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0).\n",
      "*   **Activation of Alternative Cell Cycle Checkpoints:** Tumor cells can adapt to the stress induced by WEE1 inhibition by activating alternative cell cycle checkpoints [patsnap](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "*   **Upregulation of DNA Repair Pathways:** Resistance mechanisms may involve the upregulation of DNA repair pathways [patsnap](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "Dual WEE1 and PKMYT1 inhibitors are being explored as a strategy to improve cancer therapy compared to single WEE1 inhibitors, with a focus on efficacy, safety, and overcoming resistance [citedrive](https://vertexaisearch.cloud.google.com/id/3-0) [researchgate](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Synergistic effects:** Combining WEE1 and PKMYT1 inhibition has demonstrated synergistic effects in eradicating cancer cells, including ovarian cancer and breast cancer cells with acquired CDK4/6 inhibitor resistance [citedrive](https://vertexaisearch.cloud.google.com/id/3-0) [researchgate](https://vertexaisearch.cloud.google.com/id/3-1) [nih](https://vertexaisearch.cloud.google.com/id/3-2). This combination promotes CDK activation, exacerbates DNA replication stress and catastrophe, and increases genomic instability [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   **Improved anti-tumor activity:** Preclinical studies show that dual inhibitors can have stronger antitumor activity than either WEE1 or PKMYT1 inhibitors alone [bioworld](https://vertexaisearch.cloud.google.com/id/3-3). For example, SGR-3515, a dual inhibitor, resulted in marked reductions of tumor volumes and superior antitumor activity compared to single inhibitors in xenograft tumor models [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "*   **Overcoming resistance:** Dual inhibition of WEE1 and PKMYT1 can be more effective than single-agent treatments in eliminating CDK4/6 inhibitor-resistant organoids [citedrive](https://vertexaisearch.cloud.google.com/id/3-0). This approach can overcome resistance to WEE1-targeted monotherapies [citedrive](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "*   **Efficacy in specific cancers:** Studies have shown high efficacy of PKMYT1 inhibitors in late-stage, post-treatment non-small cell lung cancer models [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Low-dose approach:** A multiple low-dose approach utilizing joint WEE1 and PKMYT1 inhibition may allow exploitation of synthetic lethality while minimizing adverse effects [nih](https://vertexaisearch.cloud.google.com/id/3-2) [nih](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   **Tolerability:** In a mouse model, the combination of a PKMYT1 inhibitor (RP-6306) and a WEE1 inhibitor (Debio-0123) was well-tolerated and demonstrated tumor regressions at sub-therapeutic monotherapy doses [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   **Intermittent dosing:** Dual inhibitors like SGR-3515 can support intermittent dosing schedules to permit recovery from myelosuppression [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "*   **Phase 1 clinical trials:** SGR-3515 is currently in phase 1 clinical trials to evaluate its safety and tolerability in patients with advanced solid tumors [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8).\n",
      "\n",
      "**Resistance:**\n",
      "\n",
      "*   **Reduced resistance development:** Multiple low-dose therapy reduces cancer selective pressure against a single target, which may result in less treatment resistance [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   **Myt1 co-inhibition:** Myt1 co-inhibition enhances activity and leverages synthetic lethality, with the potential to reduce tumor resistance [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8).\n",
      "*   **Upregulation of PKMYT1:** Upregulation of PKMYT1 has been shown to promote resistance of cancer cells to WEE1 inhibition [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "**Other relevant points:**\n",
      "\n",
      "*   WEE1 and PKMYT1 are key regulators of cell cycle progression and DNA damage response [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8) [researchgate](https://vertexaisearch.cloud.google.com/id/3-9) [nih](https://vertexaisearch.cloud.google.com/id/3-10).\n",
      "*   WEE1 inhibitors, like adavosertib (AZD1775), have shown preclinical and clinical activity in various cancers [nih](https://vertexaisearch.cloud.google.com/id/3-10) [frontiersin](https://vertexaisearch.cloud.google.com/id/3-11).\n",
      "*   PKMYT1 inhibitors, such as RP-6306 and EVT-0003023, are being developed and have shown promise in preclinical studies [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5) [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   Dual inhibition can lead to increased DNA damage, premature mitosis, and cell death in cancer cells [nih](https://vertexaisearch.cloud.google.com/id/3-10) [nih](https://vertexaisearch.cloud.google.com/id/3-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   CCNE1 amplification is a biomarker for sensitivity to PKMYT1 inhibition [onclive](https://vertexaisearch.cloud.google.com/id/3-12) [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-13) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   Schrodinger Inc. has presented preclinical characterization of SGR-3515, a dual inhibitor of WEE1 and PKMYT1, which is in early clinical development for advanced solid tumors [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are emerging as a promising strategy in cancer therapy, particularly in combination with other anticancer agents like chemotherapy, immunotherapy, and targeted therapies [nih](https://vertexaisearch.cloud.google.com/id/1-0) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [kcl](https://vertexaisearch.cloud.google.com/id/1-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3). These inhibitors target the WEE1 kinase, a central regulator of the cell cycle, which prevents premature mitosis and maintains genomic integrity [nih](https://vertexaisearch.cloud.google.com/id/1-0) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1). By blocking WEE1 activity, cancer cells with damaged DNA are forced into mitosis, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "\n",
      "**Clinical Trials and Results:**\n",
      "\n",
      "*   **Combination Therapies:** Clinical trials are exploring the potential of combining WEE1 inhibitors with various other therapies [kcl](https://vertexaisearch.cloud.google.com/id/1-2) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1). These include:\n",
      "    *   Chemotherapy: WEE1 inhibitors can sensitize cancer cells to DNA-damaging agents like chemotherapy, enhancing the antitumor response [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-0). For example, ZN-c3 (Azenosertib) with gemcitabine in pancreatic cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Immunotherapy: Combining WEE1 inhibitors with immune checkpoint inhibitors holds promise for directly killing tumor cells and rendering the tumor microenvironment more immunogenic [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-0). The \"ZAP-IT\" trial is testing ZN-c3 with carboplatin and pembrolizumab in metastatic triple-negative breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Targeted therapies: Clinical trials are investigating WEE1 inhibitors with targeted agents like trastuzumab deruxtecan in HER2-expressing solid tumors [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "*   **Specific WEE1 Inhibitors in Trials:** Several WEE1 inhibitors are in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/1-1):\n",
      "    *   Azenosertib (ZN-c3): Being investigated in combination with gemcitabine for pancreatic cancer and with carboplatin and pembrolizumab for triple-negative breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Debio0123: Being evaluated in combination with sacituzumab govitecan in triple-negative or HR+/HER2-negative advanced/metastatic breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   APR-1051: Is in phase 1 trial for advanced solid tumors [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   AZD1775 (Adavosertib): In combination with carboplatin has demonstrated clinical benefit in patients with TP53-mutant, platinum-resistant ovarian cancer [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "*   **Machine Learning to predict synergistic combinations:** Machine learning models are being used to predict synergistic drug combinations with WEE1 inhibitors, identifying potential new cancer types where these combinations may be effective [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   **Resistance and Toxicity:** Overcoming acquired resistance, managing toxicity, and improving patient selection remain challenges in clinical implementation [nih](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   **Biomarkers:** Identifying biomarkers to predict patient response to WEE1 inhibitors is crucial for patient stratification and optimizing treatment strategies [nih](https://vertexaisearch.cloud.google.com/id/1-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-4). TP53 mutation has not been shown to be the most reliable predictive biomarker [kcl](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Novel Combinations:** Exploring novel combinations of WEE1 inhibitors with other agents, such as ATR/CHK1 inhibitors or PARP inhibitors, is a promising direction [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [kcl](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Here's an update on the regulatory developments and FDA approval status of WEE1 inhibitors in 2024 and 2025: \n",
      "\n",
      " **What are WEE1 Inhibitors?** \n",
      "\n",
      " WEE1 inhibitors work by blocking the WEE1 kinase, a key regulator of the cell cycle. By inhibiting WEE1, cancer cells with damaged DNA are forced into mitosis prematurely, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/2-0) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-1). This approach is particularly promising in tumors with defective p53, which rely heavily on the WEE1-regulated G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-0). Combining WEE1 inhibitors with DNA-damaging drugs can also overwhelm the cancer cells' repair mechanisms, triggering apoptosis [patsnap](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      "\n",
      " **Developments in 2024:** \n",
      "\n",
      " *   **Partial Clinical Hold on Azenosertib:** In June 2024, the FDA placed a partial clinical hold on three studies investigating Zentalis Pharmaceuticals' azenosertib after two trial participants died from presumed blood-related infections [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). The trials affected were investigating azenosertib in solid tumors (Phase I) and in ovarian and uterine cancer (Phase II) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). Monotherapy trials were paused, but dosing continued for participants in combination studies [patsnap](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      " *   **Clinical Hold Lifted:**  The FDA lifted the partial clinical hold on azenosertib in September 2024, allowing Zentalis to resume enrollment in all ongoing clinical studies without changes to the development plan [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/2-4). Following this decision, Zentalis' stock value increased significantly [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **Planned Data Presentation:** Zentalis planned to present azenosertib monotherapy data and provide updates on clinical development timelines at a corporate event later in 2024 [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3) [patsnap](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      "\n",
      " **Developments in 2025:** \n",
      "\n",
      " *   **Azenosertib Fast Track Designation:** In January 2025, the FDA granted fast track designation to azenosertib for treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who are positive for cyclin E1 [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/2-5) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      " *   **MRANK-106 IND Clearance:** The FDA cleared the investigational new drug (IND) application for MRANK-106, a dual WEE1/YES1 kinase inhibitor for advanced solid tumors, on March 7, 2025 [targetedonc](https://vertexaisearch.cloud.google.com/id/2-7). \n",
      " *   **Acrivon Therapeutics' ACR-2316:** Acrivon Therapeutics is dosing patients in a Phase 1 monotherapy dose-escalation trial of ACR-2316 (a WEE1/PKMYT1 inhibitor) for certain solid tumor types with high unmet need [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). Initial clinical activity, including tumor shrinkage and a confirmed partial response, has been observed across several solid tumor types [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). Acrivon presented data at the AACR-NCI-EORTC conference demonstrating that ACR-2316 was designed to achieve superior activity through potent WEE1 inhibition with concomitant suppression of WEE1 inhibitor-induced PKMYT1 resistance mechanisms, while triggering robust activation of CDK1, CDK2, and PLK1 to induce potent tumor cell death [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). \n",
      "\n",
      " **Ongoing Clinical Trials:** \n",
      "\n",
      " *   Azenosertib is currently in a Phase III trial (DENALI) for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). Topline data is expected by the end of 2026, with potential for an FDA accelerated approval application [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). \n",
      "\n",
      " **Potential Future Developments:** \n",
      "\n",
      " *   **Azenosertib Accelerated Approval (Potential):** Zentalis is aiming for potential accelerated approval of azenosertib in late 2026, but faces competition and regulatory hurdles [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). Success depends on the FDA's acceptance of the DENALI trial data [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). \n",
      "\n",
      " Keep in mind that clinical trials are ongoing, and the information above reflects data available up to November 21, 2025.\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "\n",
      "---\n",
      "\n",
      "Here's a summary of recent clinical trial results involving Adavosertib (AZD1775) in combination therapies, with a focus on 2024 and 2025: \n",
      "\n",
      " **Adavosertib (AZD1775) as a single agent:** \n",
      "\n",
      " *   A Phase II trial (NCT03284385) evaluated adavosertib in solid tumor malignancies with a SETD2 mutation [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).  No objective responses were observed [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). Minor tumor regressions were seen in 4/18 patients, and stable disease was the best response in 10/18 patients [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). The most common adverse events were nausea, anemia, diarrhea, and neutropenia [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). The study concluded that adavosertib monotherapy had limited clinical activity in patients with SETD2-altered solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "\n",
      " *   Another study noted limited clinical activity with single-agent adavosertib in genomically unselected patient populations, which is consistent with prior results of this agent and other single-agent WEE1 inhibitors [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "\n",
      " *   However, adavosertib monotherapy has demonstrated a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification, especially in epithelial ovarian cancer [ascopubs](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "\n",
      " **Adavosertib in Combination Therapy:** \n",
      "\n",
      " *   **Squamous Cell Lung Cancer (SqCLC):** A phase II trial combined adavosertib with carboplatin and paclitaxel in patients with advanced/metastatic SqCLC [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The median progression-free survival (PFS) was 4.8 months, and the median overall survival (OS) was 7.3 months [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The disease control rate (DCR) was 60.9% [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The most common adverse events were fatigue, diarrhea, and nausea [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The study met its primary endpoint with the combination of adavosertib with carboplatin and paclitaxel [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      " *   **Pediatric Cancers:** A Phase I/II study (AcSÃ©-ESMART Arm C) investigated adavosertib in combination with carboplatin in children and young adults with recurrent/refractory malignancies. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) The combination exhibited significant hematologic toxicity. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) The overall response rate was 11%, with partial responses in 2 patients with neuroblastoma. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4)\n",
      "\n",
      " *   **Gynecological Cancers:** A phase I study evaluated adavosertib with chemoradiation in cervical, upper vaginal, and uterine cancers. [nih](https://vertexaisearch.cloud.google.com/id/3-5) The recommended phase II dose could not be determined due to clinical toxicity. [nih](https://vertexaisearch.cloud.google.com/id/3-5) The overall response rate at 4 months was 71.4%, including four complete responses. [nih](https://vertexaisearch.cloud.google.com/id/3-5)\n",
      "\n",
      " *   **Advanced Solid Tumors:** An open-label, multicenter, phase I study is assessing the safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2)\n",
      "\n",
      " **Ongoing Research:** \n",
      "\n",
      " *   A Phase 2 study is investigating adavosertib in women with recurrent or persistent uterine serous carcinoma or uterine carcinosarcoma. [dana-farber](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Several clinical trials are exploring the combination of WEE1, ATR, and PARP inhibitors in cancer therapy [mdpi](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1). These combinations aim to overcome PARP inhibitor resistance, particularly in ovarian cancer and other solid tumors with DNA damage repair (DDR) alterations [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "\n",
      "**WEE1 Inhibitors:**\n",
      "\n",
      "*   WEE1 kinase is crucial for cell cycle checkpoint arrest in the S and G2 phases [nih](https://vertexaisearch.cloud.google.com/id/4-2) [researchgate](https://vertexaisearch.cloud.google.com/id/4-5). Inhibiting WEE1 can inactivate the G2/M checkpoint, leading to irreparable DNA damage and apoptosis, especially in tumor cells with G1/S phase checkpoint inactivation [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   Adavosertib, a WEE1 inhibitor, has shown clinical efficacy in combination with olaparib in PARPi-resistant ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/4-2). It is also used with gemcitabine for platinum-resistant or -refractory recurrent ovarian cancer [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   However, WEE1 inhibitors like adavosertib can have safety issues due to low selectivity and off-target effects [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "\n",
      "**ATR Inhibitors:**\n",
      "\n",
      "*   ATR kinase regulates cellular processes, including cell cycle arrest and replication fork initiation [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   Combining PARP inhibitors with ATR inhibitors can prevent recovery from PARP inhibitor-induced DNA damage, leading to cell death [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4). This combination has shown promise in delaying and overcoming acquired PARP inhibitor resistance in preclinical studies [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   Clinical trials are assessing the efficacy of ATR inhibitors in combination with PARP inhibitors [nih](https://vertexaisearch.cloud.google.com/id/4-1). The combination of PARPi-ATRi enhances anti-cancer effects in ATM-deficient cancer cells by promoting genome instability and cell death [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "\n",
      "**Clinical Trials and Studies:**\n",
      "\n",
      "*   Early-phase trials have tested the safety and efficacy of PARP inhibition plus ATR inhibition in patients with relapsed or refractory solid tumors with DDR alterations [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   The TRESR trial tested camonsertib (ATR inhibitor) plus talazoparib (PARP inhibitor), and the ATTACC trial tested camonsertib plus niraparib or olaparib [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4). These combinations appeared safe with manageable hematologic adverse effects and showed responses across multiple tumor types [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   The ATARI trial (ENGOT/GYN1/NCRI) is a phase 2 study assessing ceralasertib (ATR inhibitor) alone and in combination with olaparib in patients with gynecologic tumors [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "*   A Phase 2 umbrella trial (NCT04298021) is investigating the combination of AZD6738 (ATR inhibitor) with Durvalumab or Olaparib in patients with advanced biliary tract cancer [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "*   Combinations of ATR, Chk1, and Wee1 inhibitors with olaparib have shown synergistic effects in both PARP-sensitive and resistant cell lines, regardless of HR status [mdpi](https://vertexaisearch.cloud.google.com/id/4-0).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   Further studies are needed to determine the potential off-target effects and efficacy of WEE1 inhibitors in clinical practice [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   Maintaining the efficacy of inhibitors while controlling the balance between WEE1 kinase inhibitors and other drugs to deliver maximum benefits to patients remains a challenge [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   Identifying predictive biomarkers and selecting appropriate patient populations for these combination therapies is crucial [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   Further investigation is warranted in biomarker-selected populations, especially in platinum-resistant ovarian cancer [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "\n",
      "2025-11-21 14:40:30 [INFO] agent.graph - ğŸ¤”is_sufficient=False,\n",
      "                 knowledge_gap=The summaries provide comprehensive information on individual WEE1 inhibitors and their clinical development status, but lack detailed comparative analysis of efficacy, safety profiles, and competitive positioning between different WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051, ACR-2316, etc.). There is also limited information on market projections, commercial potential, and strategic positioning of these inhibitors in the oncology landscape.,\n",
      "                 follow_up_queries=['What are the comparative efficacy and safety profiles of different WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051, ACR-2316) in clinical trials for ovarian cancer and other solid tumors?', 'What are the market projections, commercial potential, and competitive landscape analysis for WEE1 inhibitors in oncology therapeutics for 2025-2030?', 'How do the different WEE1 inhibitors compare in terms of mechanism of action, selectivity, and potential for combination therapies with other cancer treatments?'],\n",
      "                 research_loop_count=2,\n",
      "                 number_of_ran_queries=(9, ['WEE1 inhibitor clinical trials pipeline 2024 2025', 'WEE1 targeted therapy development status oncology', 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ', 'WEE1 inhibitor clinical trials pipeline 2024 2025', 'WEE1 targeted therapy development status oncology', 'WEE1é¶ç‚¹è¯ç‰©ç ”å‘è¿›å±• ä¸´åºŠè¯•éªŒ', 'What are the comparative efficacy and safety profiles of different WEE1 inhibitors (Azenosertib, Debio-0123, APR-1051) in clinical trials for similar indications like ovarian cancer?', 'What are the key advantages and clinical progress of dual WEE1/PKMYT1 inhibitors (like ACR-2316) compared to single-target WEE1 inhibitors in terms of efficacy, safety, and mechanism of action?', 'What are the latest clinical trial results and regulatory developments for WEE1 inhibitors in combination therapies with chemotherapy, immunotherapy, and targeted agents across different cancer types?'])\n",
      "                \n",
      "2025-11-21 14:40:30 [INFO] agent.graph - ğŸ”research_loop_count=2\n",
      "2025-11-21 14:40:30 [INFO] agent.utils - ğŸ’¬len(messages)=1,research_topic=WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\n",
      "2025-11-21 14:40:30 [INFO] agent.graph - âš¡âš¡âš¡formatted_prompt=Generate a high-quality answer to the user's question based on the provided summaries.\n",
      "\n",
      "Instructions:\n",
      "- The current date is November 21, 2025.\n",
      "- You are the final step of a multi-step research process, don't mention that you are the final step. \n",
      "- You have access to all the information gathered from the previous steps.\n",
      "- You have access to the user's question.\n",
      "- Generate a high-quality answer to the user's question based on the provided summaries and the user's question.\n",
      "- Include the sources you used from the Summaries in the answer correctly, use markdown format (e.g. [apnews](https://vertexaisearch.cloud.google.com/id/1-0)). THIS IS A MUST.\n",
      "\n",
      "CRITICAL REQUIREMENTS:\n",
      "- Summaries include two types of data:\n",
      "  (1) Web search results\n",
      "  (2) Local structured data (e.g., tables, pipelines, or formatted clinical trial lists produced by internal tools)\n",
      "- When using LOCAL structured data, you MUST preserve the original structure and content as completely as possible.\n",
      "  * Do NOT drop rows, columns, trial IDs, drug names, phases, or statuses.\n",
      "  * Do NOT compress or shorten structured lists or tables.\n",
      "  * You may reformat the layout for readability, but the information must remain complete and faithful to the source.\n",
      "  * **When including local structured data in your answer, you MUST format it as a Markdown table**, so it can be properly rendered in the front-end.\n",
      "- Web search results may be summarized if needed, but local tool-generated data must remain detailed and intact.\n",
      "- Do NOT invent citations.\n",
      "\n",
      "\n",
      "User Context:\n",
      "- WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\n",
      "\n",
      "Summaries:\n",
      "Several WEE1 inhibitor programs are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). These inhibitors are being evaluated in clinical trials across a spectrum of malignancies, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, uterine serous carcinoma, small cell lung cancer, glioblastoma, and head and neck cancers [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**Specific WEE1 Inhibitors and their Development Status:**\n",
      "\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in several clinical trials [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "    *   Azenosertib is being studied in combination with LB-100 (a PP2A inhibitor) in a Phase Ib setting for patients with metastatic colorectal cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   A Phase 2 single-arm trial is investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   Zentalis Pharmaceuticals is focusing on azenosertib's development, particularly in cyclin E1-positive, platinum-resistant ovarian cancer [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4). A potentially registrational study is expected to start in 2025, with data readout by the end of 2026 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "    *   Azenosertib is also being evaluated in combination with topoisomerase I (TOP1) inhibitor-based antibody-drug conjugates (ADCs) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Azenosertib, in combination with gemcitabine, is being investigated in an upcoming Investigator-Initiated Phase 2 trial for relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   The FDA had placed a partial clinical hold on azenosertib trials due to patient deaths but has since lifted it, allowing studies to resume [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Adavosertib (AZD1775):** This WEE1 inhibitor is also in clinical development [nih](https://vertexaisearch.cloud.google.com/id/1-6) [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7).\n",
      "\n",
      "    *   A Phase II trial of adavosertib in SETD2-altered advanced solid tumor malignancies showed limited clinical activity as a monotherapy [nih](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "    *   AstraZeneca is a major player in developing therapies for WEE1 protein inhibitors, including adavosertib [researchandmarkets](https://vertexaisearch.cloud.google.com/id/1-7). However, AstraZeneca discontinued adavosertib due to tolerability issues in 2022 [oncologypipeline](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "*   **Debio-0123:** Debiopharm, a biopharma company based in Switzerland, is developing this WEE1 inhibitor [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3). It is currently in a Phase I/II trial in combination with temozolomide for patients with glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-3).\n",
      "*   **APR-1051:** Aprea Therapeutics is developing this oral WEE1 inhibitor [openpr](https://vertexaisearch.cloud.google.com/id/1-9). Early data from an ongoing Phase 1 study showed that 3 out of 4 heavily pretreated patients achieved stable disease [openpr](https://vertexaisearch.cloud.google.com/id/1-9). The trial is advancing to higher dose levels [openpr](https://vertexaisearch.cloud.google.com/id/1-9).\n",
      "*   **ACR-2316:** A Phase 1 study of ACR-2316 in specific advanced solid tumors is underway [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "\n",
      "**General Trends and Challenges:**\n",
      "\n",
      "*   Most clinical trials involving WEE1 inhibitors are in early-phase development (Phase I or Phase Ib/II) [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   WEE1 inhibitors are being explored for their potential to sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Challenges in WEE1 inhibitor development include potential toxicity and side effects, as WEE1 is also active in normal proliferating cells [patsnap](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   Patient selection and overcoming resistance remain obstacles to clinical implementation [nih](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "---\n",
      "\n",
      "Here's an update on the clinical trials of azenosertib (ZN-c3), a WEE1 inhibitor, with a focus on the latest results from 2024 and 2025: \n",
      "\n",
      " **1. Clinical Trials & Target Patient Populations** \n",
      "\n",
      " *   **Advanced Solid Tumors:** Azenosertib is being investigated as a monotherapy for advanced solid tumors in a Phase 1 trial (ZN-c3-001) [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Platinum-Resistant Ovarian Cancer (PROC):** It's also being evaluated in patients with platinum-resistant ovarian cancer in the Phase 2 DENALI trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). The DENALI trial focuses on high-grade serous ovarian, fallopian tube, or primary peritoneal cancer [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). Part 2 of the DENALI study will be conducted in subjects whose tumors are Cyclin E1 positive [clinicaltrials](https://vertexaisearch.cloud.google.com/id/2-1). \n",
      " *   **Uterine Serous Carcinoma:** Azenosertib is under investigation for women with recurrent or persistent uterine serous carcinoma in the TETON trial [onclive](https://vertexaisearch.cloud.google.com/id/2-0) [cancer](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      " *   **Metastatic BRAF V600E Mutant Colorectal Cancer:** Azenosertib is being evaluated in combination with encorafenib and cetuximab for patients with this type of colorectal cancer in the ZN-c3-016 study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **PARP-inhibitor resistant ovarian cancer:** Azenosertib is also being evaluated in patients with PARP-inhibitor resistant ovarian cancer in the MAMMOTH (ZN-c3-006) study [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Relapsed or Refractory Osteosarcoma:** Azenosertib is being studied in combination with gemcitabine for adult and pediatric patients with relapsed or refractory osteosarcoma [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " **2. Key Developments in 2024** \n",
      "\n",
      " *   **FDA Partial Clinical Hold Lifted:** In June 2024, the FDA placed a partial clinical hold on trials evaluating azenosertib due to two deaths reported in the DENALI trial from presumed sepsis [onclive](https://vertexaisearch.cloud.google.com/id/2-0). This hold was lifted in September 2024 after the FDA reviewed a comprehensive safety assessment from Zentalis Pharmaceuticals [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      " *   **Data Readouts:** Additional data for azenosertib was anticipated in the fourth quarter of 2024 [onclive](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      "\n",
      " **3. Efficacy Results (as of December 2, 2024 data cutoff)** \n",
      "\n",
      " *   **ZN-c3-001 Study:** Patients with Cyclin E1+ PROC, who were dosed at an intermittent schedule, experienced an objective response rate (ORR) of 34.8% and a median duration of response (mDOR) of 5.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Part 1b:** In patients with Cyclin E1+ PROC tumors who were response-evaluable, an ORR of 34.9% was observed [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). In the intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3% and the mDOR was approximately 5.5 months [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **MAMMOTH (ZN-c3-006) study:** Cyclin E1+ patients treated at the primary dose-of interest 400mg QD 5:2 had an ORR of 31.3% and an mDOR of 4.2 months [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Azenosertib in combination with chemotherapy:** Patients with Cyclin E1 overexpressing tumors demonstrated significant improvements in ORR and PFS vs patients with tumors having low expression [asco](https://vertexaisearch.cloud.google.com/id/2-7). \n",
      "\n",
      " **4. Safety and Tolerability** \n",
      "\n",
      " *   **Generally Tolerable:** Azenosertib has generally been well-tolerated in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      " *   **Low rates of Grade 3+ hematological toxicity:** The majority of hematological toxicity events were Grade 3 [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **Low rate of TRAEs leading to discontinuation:** A low rate of treatment-related adverse events led to discontinuation [zentalis](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **DENALI Trial Grade 5 Events:** There were two previously reported treatment-related Grade 5 events in the DENALI study [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [targetedonc](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      "\n",
      " **5. Ongoing and Future Plans** \n",
      "\n",
      " *   **DENALI Part 2:** Topline data from the registration-intent DENALI Part 2 is anticipated by the end of 2026 [natlawreview](https://vertexaisearch.cloud.google.com/id/2-4). \n",
      " *   **Further Investigation:** Data supports further investigation of azenosertib with gemcitabine in patients with relapsed or refractory osteosarcoma in an upcoming Phase 2 trial [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5). \n",
      "\n",
      " Keep in mind that clinical trial information can change, so it's always a good idea to consult the official sources for the most up-to-date details [cancer](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an oral, brain-penetrant, and selective WEE1 kinase inhibitor [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). Debiopharm is currently developing Debio-0123 to address the unmet needs of patients with difficult-to-treat cancers [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1). WEE1 is a key regulator of the G2/M and S phase checkpoints, activated in response to DNA damage, that allows cells to repair their DNA before resuming their cell cycle [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0). Inhibition of WEE1, particularly in combination with DNA damaging agents, induces an overload of arrests in the DNA damage response process [debiopharm](https://vertexaisearch.cloud.google.com/id/3-1) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "Debiopharm is conducting an open-label phase 1/2 study of Debio-0123 in combination with temozolomide (TMZ) in adult participants with recurrent or progressive glioblastoma (GBM) and with TMZ and radiotherapy (RT) in newly diagnosed GBM [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [pharmatimes](https://vertexaisearch.cloud.google.com/id/3-2) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is identified by ClinicalTrials.gov ID NCT05765812 [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [mskcc](https://vertexaisearch.cloud.google.com/id/3-5). The study is designed to identify the recommended phase 2 dose of Debio-0123 in combination with TMZ (Arm A) and with TMZ and RT (Arm B) and to characterize the safety and tolerability of these combinations in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3). Arm B of the study, which assessed Debio-0123 with concomitant TMZ and RT, has been permanently halted based on safety findings [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4). The primary purpose of Phase 2 of this study is to assess the efficacy of Debio 0123 at the recommended dose in combination with TMZ, compared to standard of care in adult participants with GBM [clinicaltrials](https://vertexaisearch.cloud.google.com/id/3-4) [fredhutch](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "\n",
      "\n",
      "---\n",
      "\n",
      "Aprea Therapeutics is currently evaluating APR-1051, a selective WEE1 inhibitor, in the ACESOT-1051 Phase 1 clinical trial for patients with advanced or metastatic solid tumors [aprea](https://vertexaisearch.cloud.google.com/id/4-0).\n",
      "\n",
      "**Key points regarding the APR-1051 clinical trials in 2024 and 2025:**\n",
      "\n",
      "*   **FDA Clearance and Trial Initiation:** The U.S. FDA cleared the Investigational New Drug (IND) application for APR-1051 in March 2024, and the Phase 1 ACESOT-1051 trial was initiated in June 2024 [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [aprea](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   **ACESOT-1051 Trial Design:** This is a biomarker-driven, first-in-human study assessing the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of single-agent APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7). It involves a dose escalation phase (Part 1, up to 39 patients) and a dose optimization phase (Part 2, up to 40 patients) to determine the Recommended Phase 2 Dose (RP2D) [aprea](https://vertexaisearch.cloud.google.com/id/4-8) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-5) [biospace](https://vertexaisearch.cloud.google.com/id/4-4). Oral APR-1051 is administered daily in 28-day cycles [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "*   **Enrollment and Dosing:** Enrollment began in June 2024, with initial cohorts receiving doses of 10 mg, 20 mg, and 30 mg [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [aprea](https://vertexaisearch.cloud.google.com/id/4-8). By March 2025, the trial was enrolling patients in Cohort 5 (70 mg dose) [biospace](https://vertexaisearch.cloud.google.com/id/4-9). In November 2025, the trial had advanced to the 150 mg once-daily cohort [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Preliminary Data:**\n",
      "    *   **2024:** Preliminary data from the first patients in the ACESOT-1051 study indicated that APR-1051 was safe and well-tolerated, with no significant hematologic toxicity [onclive](https://vertexaisearch.cloud.google.com/id/4-6) [patsnap](https://vertexaisearch.cloud.google.com/id/4-7).\n",
      "    *   **2025:**\n",
      "        *   In Q2 2025, early disease control was observed in three patients during the Phase 1 ACESOT-1051 trial [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11).\n",
      "        *   Results from Dose Level 6 (100 mg once daily) showed that 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/4-10). Disease stabilization was seen in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "        *   APR-1051 was manageable, with mostly Grade 1 or 2 adverse events, mainly gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/4-10).\n",
      "*   **Focus on Cyclin E Overexpression:** Aprea is advancing APR-1051 as a monotherapy in cancers with Cyclin E overexpression, as these cancers represent a high unmet medical need [aprea](https://vertexaisearch.cloud.google.com/id/4-12) [globenewswire](https://vertexaisearch.cloud.google.com/id/4-1) [aprea](https://vertexaisearch.cloud.google.com/id/4-13) [biospace](https://vertexaisearch.cloud.google.com/id/4-9).\n",
      "*   **Potential Advantages of APR-1051:** Aprea believes APR-1051 may address the shortcomings of other WEE1 inhibitors due to its unique molecular structure, selectivity for WEE1, improved pharmacokinetic properties, and absence of QT prolongation [patsnap](https://vertexaisearch.cloud.google.com/id/4-7) [lifesciencespa](https://vertexaisearch.cloud.google.com/id/4-2) [biospace](https://vertexaisearch.cloud.google.com/id/4-4) [aprea](https://vertexaisearch.cloud.google.com/id/4-5). APR-1051 also exhibits low off-target inhibition of PLK1, PLK2, and PLK3, which may confer an improved toxicity profile [onclive](https://vertexaisearch.cloud.google.com/id/4-6).\n",
      "*   **Preclinical Studies:** Preclinical studies have demonstrated that APR-1051 suppresses the growth of CCNE1-amplified HGSOC xenografted tumors and is relatively well-tolerated in mice [aprea](https://vertexaisearch.cloud.google.com/id/4-3). It also shows potent single-agent activity across a broad panel of human and murine head and neck cancer cell lines and significant anti-tumor synergy with antiâ€“PD-1 therapies in HPV+ HNSCC models.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)*   **Financial Runway:** Aprea reported $16.5 million in cash as of June 30, 2025, which is expected to fund operations into Q2 2026.\n",
      " [stocktitan](https://vertexaisearch.cloud.google.com/id/4-11)\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are emerging as a promising strategy in oncology, particularly for aggressive and hard-to-treat tumors [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). These inhibitors target the pressure points that fast-growing cancers rely on to survive, especially their ability to manage stress and control the timing of cell division [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). By blocking WEE1, researchers aim to disrupt cancer's ability to stay ahead of treatment [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**WEE1 Inhibitors in Clinical Development:**\n",
      "Several WEE1 inhibitors are currently in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Examples include:\n",
      "*   **Azenosertib (ZN-c3):** This selective WEE1 inhibitor is being investigated in various clinical trials, including a Phase 2 trial in combination with gemcitabine for second-line advanced pancreatic adenocarcinoma [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Zentalis Pharmaceuticals is developing azenosertib (ZN-c3) as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). It is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2). Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC was presented at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-3) [zentalis](https://vertexaisearch.cloud.google.com/id/search_1-2).\n",
      "*   **AZD1775 (Adavosertib or MK-1775):** Adavosertib selectively targets and inhibits WEE1, preventing the phosphorylation of CDC2 and impairing the G2 DNA damage checkpoint [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4). It is currently in Phase II clinical trials for ovarian cancer and has received Orphan Drug designation in the European Union for this indication [researchandmarkets](https://vertexaisearch.cloud.google.com/id/search_1-4).\n",
      "*   **Debio-0123:** Debiopharm has this WEE1 inhibitor in Phase I/II trials in combination with temozolomide for glioblastoma [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_1-5).\n",
      "*   **APR-1051, SC0191, and ACR-2316** [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Clinical Trial Landscape and Design:**\n",
      "The clinical trial landscape for WEE1 inhibitors is rapidly evolving [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Trials employ various designs, from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1). Researchers are also exploring smarter trial models that track how tumors respond over time, integrating molecular context as defining features of therapeutic opportunity [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "**Combination Strategies:**\n",
      "Combination approaches are driving the next wave of progress, pairing WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs) [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Combining WEE1 inhibitors with immune checkpoint inhibitors holds the promise of directly killing tumor cells and rendering the tumor microenvironment more immunogenic, permitting a more robust anti-tumor immune response [patsnap](https://vertexaisearch.cloud.google.com/id/search_1-1).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "Success hinges on overcoming key challenges while refining trial design [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Determining which patients are most likely to benefit and managing toxicities are major priorities [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0). Future progress will depend on more sophisticated approaches that integrate real-time data metrics, with AI emerging as a key enabler [clinicalleader](https://vertexaisearch.cloud.google.com/id/search_1-0).\n",
      "\n",
      "---\n",
      "\n",
      "Azenosertib (ZN-c3) is under investigation in clinical trials for both ovarian and pancreatic cancer in 2024 and 2025. Here's a summary of the recent findings and ongoing studies: \n",
      "\n",
      " **Ovarian Cancer:** \n",
      "\n",
      " *   **Promising Efficacy in Platinum-Resistant Ovarian Cancer:** Azenosertib monotherapy has shown promising efficacy in heavily pretreated patients with cyclin E1â€“positive platinum-resistant ovarian cancer.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   In part 1b of the phase 2 DENALI trial (NCT05128825), azenosertib achieved an overall response rate (ORR) of 34.9% (95% CI, 21.0%-50.9%) among 43 response-evaluable patients.  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)\n",
      " *   As of December 2, 2024, data cutoff, the ORR in the intention-to-treat (ITT) cyclin E1â€“positive population (n = 48) was 31.3% (95% CI, 18.7%-46.3%). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The median duration of response (DOR) was approximately 5.5 months (95% CI, 2.7-not evaluable). \n",
      "  [targetedonc](https://vertexaisearch.cloud.google.com/id/search_2-0) [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)*   The FDA granted fast track designation to azenosertib for the treatment of patients with Cyclin E1â€“positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. \n",
      " *  [onclive](https://vertexaisearch.cloud.google.com/id/search_2-1)  **DENALI Trial:**  This is a multi-part Phase 2 study evaluating the efficacy and safety of azenosertib in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2) 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive. \n",
      " *  [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_2-2)  **Ongoing Trials:** \n",
      " *   ZN-c3-002 Phase 1b dose escalation trial of azenosertib in combination with bevacizumab for platinum-sensitive ovarian cancer. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  TETON (ZN-c3-004) Phase 2 clinical trial of azenosertib as a monotherapy for uterine serous carcinoma, with data expected in the first half of 2026. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-3)  **Clinical Hold:**  In June 2024, the FDA placed a partial clinical hold on three azenosertib trials, including the Phase II DENALI trial, after two patient deaths due to presumed sepsis. \n",
      "\n",
      " * [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)*Pancreatic Cancer:** \n",
      "\n",
      " *   **Azenosertib in Combination with Gemcitabine:** A phase II trial (NCT06015659) is ongoing, evaluating azenosertib in combination with gemcitabine for advanced pancreatic cancer after progression or intolerance with FOLFIRINOX. \n",
      " *  [larvol](https://vertexaisearch.cloud.google.com/id/search_2-6) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  Subjects receive azenosertib once daily on days 1-5, 8-12, and 15-19, and gemcitabine on days 1 and 8 of 21-day cycles. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The trial includes a safety lead-in portion with up to 12 subjects. \n",
      " *  [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)  The primary objective is to evaluate the efficacy of azenosertib/gemcitabine, measured by 6-month progression-free survival (PFS) among second-line advanced pancreatic cancer patients. \n",
      " *  [cancer](https://vertexaisearch.cloud.google.com/id/search_2-8)  Azenosertib combined with gemcitabine showed synergistic cytotoxicity in PDAC cell lines. \n",
      "\n",
      " I [ascopubs](https://vertexaisearch.cloud.google.com/id/search_2-7)t's important to note that some trials involving azenosertib have faced partial clinical holds.\n",
      " [onclive](https://vertexaisearch.cloud.google.com/id/search_2-4) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/search_2-5)\n",
      "---\n",
      "\n",
      "Adavosertib (AZD1775) is a selective inhibitor of WEE1 kinase, an enzyme that regulates the cell cycle [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1) [nih](https://vertexaisearch.cloud.google.com/id/search_3-2) [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3). By inhibiting WEE1, adavosertib can disrupt the G1-S and G2-M checkpoints, leading to replication stress and tumor cell death [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). It has shown promising antitumor activity as a single agent and in combination with chemotherapy in several adult and pediatric solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5).\n",
      "\n",
      "### Clinical Trials involving Adavosertib (AZD1775) in 2024 and 2025:\n",
      "\n",
      "While the provided documents do not specifically mention clinical trials scheduled for 2024 or 2025, they do refer to ongoing and recently completed trials that provide relevant information. Most of the trials were completed before 2024, the information is still relevant for the use of adavosertib in 2024 and 2025.\n",
      "\n",
      "**Ovarian Cancer:**\n",
      "\n",
      "*   **Adavosertib with Carboplatin and Paclitaxel:** A phase II trial (NCT01357161) studied adavosertib in combination with carboplatin and paclitaxel for women with TP53-mutated, platinum-sensitive ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1). The results showed improved progression-free survival (PFS) with the addition of adavosertib [nih](https://vertexaisearch.cloud.google.com/id/search_3-6) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "*   **Adavosertib with Carboplatin in Platinum-Resistant Ovarian Cancer:** A phase II study evaluated the combination of adavosertib and carboplatin in patients with TP53-mutated platinum-resistant ovarian cancer [asco](https://vertexaisearch.cloud.google.com/id/search_3-7) [nih](https://vertexaisearch.cloud.google.com/id/search_3-8) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The combination was found to be safe and effective, with an objective response rate (ORR) of 38% [asco](https://vertexaisearch.cloud.google.com/id/search_3-7).\n",
      "*   **Adavosertib Monotherapy in CCNE1-Amplified Ovarian Cancer:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The results showed promising clinical activity, especially in epithelial ovarian cancer, with an ORR of 36% [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [nih](https://vertexaisearch.cloud.google.com/id/search_3-10).\n",
      "*   **Adavosertib Before Surgery:** A pilot phase I trial is studying the effects of adavosertib on tumor DNA in patients undergoing surgery for advanced, high-grade ovarian, fallopian tube, or primary peritoneal cancer [withpower](https://vertexaisearch.cloud.google.com/id/search_3-3).\n",
      "\n",
      "**Solid Tumors:**\n",
      "\n",
      "*   **Adavosertib Monotherapy in Advanced Solid Tumors:** A phase I trial of once-daily adavosertib in patients with advanced solid tumors determined a recommended phase II dose [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-4). Another phase Ib study assessed the safety, tolerability, and efficacy of adavosertib monotherapy in patients with various advanced solid tumors [nih](https://vertexaisearch.cloud.google.com/id/search_3-2).\n",
      "*   **Adavosertib with Irinotecan in Pediatric Solid Tumors:** A phase I trial (ADVL1312) evaluated adavosertib in combination with irinotecan in children with relapsed solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [nih](https://vertexaisearch.cloud.google.com/id/search_3-5). The study defined the dose-limiting toxicities and recommended phase II dose of the combination [nih](https://vertexaisearch.cloud.google.com/id/search_3-5) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0). A phase II trial of the same combination was conducted for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma [umn](https://vertexaisearch.cloud.google.com/id/search_3-11).\n",
      "*   **Adavosertib in SETD2-Altered Solid Tumors:** A phase II trial (NCI 10170) assessed the efficacy of adavosertib in patients with solid tumor malignancies and clear cell renal cell carcinoma harboring a pathogenic SETD2 mutation [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12). The study found limited clinical activity of adavosertib monotherapy in this population [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-12).\n",
      "*   **Adavosertib in CCNE1-Amplified Solid Tumors:** A phase II trial investigated adavosertib monotherapy in refractory solid tumors harboring CCNE1 amplification [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9). The study demonstrated a manageable toxicity profile and promising clinical activity, especially in epithelial ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/search_3-10) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9).\n",
      "\n",
      "These trials suggest that adavosertib, both as a single agent and in combination with other therapies, has potential in treating ovarian cancer and other solid tumors, particularly in specific genetic contexts such as TP53 mutations or CCNE1 amplification [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-0) [ascopubs](https://vertexaisearch.cloud.google.com/id/search_3-9) [aacrjournals](https://vertexaisearch.cloud.google.com/id/search_3-1).\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "Debio-0123, also known as zedoresertib, is an investigational, brain-penetrant, and selective WEE1 kinase inhibitor being developed by Debiopharm [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). WEE1 is a key regulator of cell cycle checkpoints, and its inhibition, especially with DNA-damaging agents, can cause an overload of DNA breaks, potentially leading to cancer cell death [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Debiopharm is conducting clinical trials with Debio-0123 for glioblastoma [clinicaltrials](https://vertexaisearch.cloud.google.com/id/search_4-2) [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3) [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). Glioblastomas are aggressive brain tumors with limited treatment options [debiopharm](https://vertexaisearch.cloud.google.com/id/search_4-0).\n",
      "\n",
      "Clinical trial details:\n",
      "*   **Phase 1/2 study:** Debiopharm has initiated an open-label Phase 1/2 research study of Debio-0123 [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). This study investigates Debio-0123 in combination with temozolomide (TMZ) for patients with recurrent or progressive glioblastoma (GBM) and in combination with TMZ/RT (standard of care) for newly diagnosed patients [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1). The initial phase aims to determine the recommended Phase 2 doses [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "*   **NCT05765812:** A Phase 1/2 study (NCT05765812) is evaluating Debio 0123 with TMZ in patients with recurrent GBM and Debio 0123 combined with TMZ-based chemoradiotherapy in patients with newly diagnosed GBM [oup](https://vertexaisearch.cloud.google.com/id/search_4-4). The study includes a dose escalation phase to identify the recommended Phase 2 dose, followed by an assessment of safety, pharmacokinetics, and preliminary antitumor activity [oup](https://vertexaisearch.cloud.google.com/id/search_4-4).\n",
      "*   **Arms of the study:** The study has different arms focusing on different treatment combinations [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6). Arm A involves Debio 0123 combined with temozolomide (TMZ) for recurrent or progressive glioblastoma. Arm B, which was previously added to the protocol but has been permanently halted due to safety concerns, involved Debio 0123 combined with TMZ and radiotherapy (RT) for newly diagnosed glioblastoma [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5).\n",
      "*   **Phase 2:** Phase 2 will assess the efficacy of Debio 0123 in combination with TMZ compared to the standard of care for adult participants with GBM [cancer](https://vertexaisearch.cloud.google.com/id/search_4-5) [fredhutch](https://vertexaisearch.cloud.google.com/id/search_4-6).\n",
      "\n",
      "Debio-0123 has shown the ability to penetrate the brain, which is important for treating brain tumors [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/search_4-3). Preclinical data suggest that Debio-0123 can cross the blood-brain barrier and inhibit tumor growth, and its combination with TMZ has demonstrated increased antitumor activity [pharmatimes](https://vertexaisearch.cloud.google.com/id/search_4-1).\n",
      "\n",
      "---\n",
      "\n",
      "Here's a summary of the recent developments in WEE1-targeted drug research and clinical trials: \n",
      "\n",
      " **1. WEE1 Inhibitors & Their Role** \n",
      "\n",
      " *   WEE1 kinase is a key regulator of the cell cycle, ensuring proper progression and genomic integrity by inhibiting CDK1/2, which prevents premature mitosis [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibition forces cells with damaged DNA into mitosis, leading to cell death, especially in tumors deficient in p53 [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      " *   WEE1 inhibitors can also sensitize cancer cells to DNA-damaging agents like chemotherapy or radiation, enhancing the anti-tumor response [patsnap](https://vertexaisearch.cloud.google.com/id/1-0). \n",
      "\n",
      " **2. Clinical Trials &è¿›å±•** \n",
      "\n",
      " *   Several WEE1 inhibitor programs are in active clinical development. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Examples include Azenosertib (ZN-c3), Debio0123, and ACR-2316. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   These inhibitors are being evaluated in various cancers, including metastatic colorectal cancer, pancreatic adenocarcinoma, breast cancer, and head and neck cancers. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   Trials range from Phase I dose-escalation studies to Phase Ib/II studies combining WEE1 inhibitors with chemotherapy, targeted therapies, and immunotherapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **3. Specific Drug & Trial Updates** \n",
      "\n",
      " *   **Azenosertib (ZN-c3):** \n",
      " *   The FDA lifted a partial clinical hold on azenosertib trials in September 2024, allowing studies to resume. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/1-2)*   Azenosertib is being investigated in Phase I for solid tumors and Phase II for ovarian and uterine cancer. \n",
      "  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-1)*   A Phase 2 study is investigating azenosertib with gemcitabine in advanced pancreatic adenocarcinoma. \n",
      "  [patsnap](https://vertexaisearch.cloud.google.com/id/1-0)*   **AZD1775 (Adavosertib):** \n",
      " *   A Phase II study of adavosertib in SETD2-altered advanced solid tumor malignancies did not show objective responses. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   However, minor tumor regressions and prolonged stable disease were observed in some patients. \n",
      "  [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3)*   **Debio0123:** Preliminary findings from studies in breast cancer and small cell lung cancer have highlighted the feasibility of combination therapies. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **4. Combination Strategies** \n",
      "\n",
      " *   Combination approaches are being explored to pair WEE1 inhibitors with chemotherapy, PKMYT1 inhibitors, and antibody-drug conjugates (ADCs). \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Combining WEE1 inhibitors with immune checkpoint inhibitors holds promise for enhancing anti-tumor immune response. \n",
      "\n",
      " [patsnap](https://vertexaisearch.cloud.google.com/id/1-0) **5. Challenges & Future Directions** \n",
      "\n",
      " *   Challenges remain, including acquired resistance, toxicity, and patient selection. \n",
      "  [nih](https://vertexaisearch.cloud.google.com/id/1-5)*   Identifying patients most likely to benefit is a key priority. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Smarter trial models are needed to track tumor responses over time. \n",
      "  [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)*   Careful dosing strategies are necessary to manage toxicity.\n",
      " [clinicalleader](https://vertexaisearch.cloud.google.com/id/1-4)\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ Azenosertib (ZN-c3) åœ¨ 2024 å¹´å’Œ 2025 å¹´æœ€æ–°ä¸´åºŠè¯•éªŒçš„æ›´æ–°ï¼š\n",
      "\n",
      "**ä¸´åºŠè¯•éªŒçŠ¶æ€**\n",
      "*   FDAè§£é™¤äº†å…ˆå‰å¯¹è¯„ä¼°æ™šæœŸå®ä½“ç˜¤æ‚£è€…WEE1æŠ‘åˆ¶å‰‚Azenosertibç ”ç©¶çš„éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   2024å¹´6æœˆï¼Œç›‘ç®¡æœºæ„å¯¹é’ˆå¯¹æ™šæœŸå®ä½“ç˜¤æ‚£è€…çš„1æœŸZN-c3-001è¯•éªŒ (NCT04158336)ã€é’ˆå¯¹é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€…çš„2æœŸDENALIè¯•éªŒ (NCT05128825) ä»¥åŠé’ˆå¯¹å­å®«æµ†æ¶²æ€§ç™Œæ‚£è€…çš„2æœŸT [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-0) [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ETONè¯•éªŒ (NCT04814108) å‘å¸ƒäº†éƒ¨åˆ†ä¸´åºŠæç½®ã€‚\n",
      "*   è¯¥å†³å®šæºäºDENALIè¯•éªŒä¸­æŠ¥å‘Šçš„ä¸¤ä¾‹å› æ¨å®šè´¥è¡€ç—‡å¯¼è‡´çš„æ­»äº¡ã€‚\n",
      "*   åœ¨å®¡æŸ¥äº†Azenosertibçš„å¼€å‘å•†Zentalis Pharmaceuticalsçš„å®Œæ•´å›å¤æ–¹æ¡ˆåï¼ŒFDAæ‰¹å‡†è¿™äº›ç ”ç©¶æ¢å¤æ‰€æœ‰æ­£åœ¨è¿›è¡Œçš„è¯¥è¯ç‰©ç ”ç©¶çš„æ‚£è€…æ‹›å‹Ÿï¼Œä¸”ä¸´åºŠå¼€å‘è®¡åˆ’æ²¡æœ‰ä»»ä½•å˜æ›´.\n",
      "\n",
      "**æ­£åœ¨è¿›è¡Œå’Œè®¡åˆ’ä¸­çš„è¯•éªŒ**\n",
      "*   **ZN-c3-001ï¼š** ä¸€é¡¹1æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒã€å‰‚é‡é€’å¢å’Œæ‰©å±•ç ”ç©¶ï¼Œæ—¨åœ¨ç ”ç©¶Azenosertibä½œä¸ºå•è¯ç–—æ³•æ²»ç–—æ™šæœŸå®ä½“ç˜¤æ‚£è€…ã€‚è¯¥ç ”ç©¶å·²å®Œå…¨æ‹›å‹Ÿ [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) (n=274)ã€‚\n",
      "*   **DENALIï¼š** ä¸€é¡¹2æœŸå¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œçº³å…¥è‡³å°‘18å²ä¸”æ‚£æœ‰é“‚è€è¯æ€§é«˜çº§åˆ«æµ†æ¶²æ€§åµå·¢ç™Œã€è¾“åµç®¡ç™Œæˆ–åŸå‘æ€§è…¹è†œç™Œçš„æ‚£è€…ã€‚DENALI [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-2) 2æœŸè¯•éªŒé¢„è®¡å°†äº2025å¹´ä¸ŠåŠå¹´å¼€å§‹æ‹›å‹Ÿã€‚ç¬¬äºŒéƒ¨åˆ†å°†åˆ†ä¸¤ä¸ªéƒ¨åˆ†è¿›è¡Œã€‚Part 2a å°†è¯„ä¼°å¹¶ç¡®è®¤æœ€ä½³ç»™è¯ç­–ç•¥ï¼Œæ¯”è¾ƒä¸»è¦çš„ 400 æ¯«å…‹é—´æ­‡ç»™è¯æ–¹æ¡ˆï¼ˆç”¨è¯ 5 å¤©ï¼Œåœè¯ 2 å¤©ï¼‰ä¸ç›¸åŒæ–¹æ¡ˆçš„ 300 æ¯«å…‹å‰‚é‡ã€‚æ¯ä¸ªé˜Ÿåˆ—å°†æ‹›å‹Ÿçº¦ 30 åæ‚£è€…ã€‚\n",
      "*   **TETONï¼š** ä¸€é¡¹å¼€æ”¾æ ‡ç­¾ã€å¤šä¸­å¿ƒç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibåœ¨ç»„ç»‡å­¦è¯å®ä¸ºå¤å‘æ€§æˆ–æŒç»­æ€§å­å®«æµ†æ¶²æ€§ç™Œä¸”æ— æœ‰æ•ˆç–—æ³•æˆ–æ— æ³•è€å—å¯ç”¨æ ‡å‡†æ²»ç–—çš„è‡³å°‘18å²æ‚£è€…ä¸­çš„åº”ç”¨ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ã€‚\n",
      "*   **ZN-c3-016ï¼š** ä¸è¾‰ç‘åˆä½œè¿›è¡Œçš„ä¸€é¡¹1/2æœŸç ”ç©¶ï¼Œæ—¨åœ¨è¯„ä¼°Azenosertibè”åˆEncorafenibå’Œè¥¿å¦¥æ˜”å•æŠ—åœ¨è½¬ç§»æ€§BRAF V600Eçªå˜å‹ç»“ç›´è‚ ç™Œæ‚£è€…ä¸­çš„åº”ç”¨ã€‚ZN-c3-016ç ”ç©¶çš„å‰‚é‡æ¢ç´¢é˜¶æ®µå·²å®Œå…¨æ‹›å‹Ÿ (n=44)ã€‚\n",
      "\n",
      "**ä¸´åºŠæ•°æ®**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼ŒZN-c3-001çš„ç»“æœæ˜¾ç¤ºï¼Œåœ¨é—´æ­‡ç»™è¯æ–¹æ¡ˆä¸‹ï¼Œæ€»æ—¥å‰‚é‡æ°´å¹³â‰¥30 [onclive](https://vertexaisearch.cloud.google.com/id/2-1)0mgçš„Cyclin E1+ PROCæ‚£è€…ä¸­ï¼Œå®¢è§‚ç¼“è§£ç‡ (ORR)  [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)å’Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (mDOR) ä»¤äººé¼“èˆ (n=23)ã€‚åœ¨è¿™äº›æ‚£è€…ä¸­ï¼Œè§‚å¯Ÿåˆ°ORRä¸º34.8% (8/23ï¼›95% CIï¼š16.4-57.3)ï¼ŒmDORä¸º5.2ä¸ªæœˆ (95% CIï¼š2.8, 6.9)ã€‚\n",
      "*   åœ¨DENALIè¯•éªŒçš„1béƒ¨åˆ†ä¸­ï¼Œå•è¯Azenosertibåœ¨43åå¯è¯„ä¼°ååº”çš„ã€ç»è¿‡å¤§é‡é¢„å¤„ç†çš„Cyclin E1é˜³æ€§é“‚è€è¯æ€§åµå·¢ç™Œæ‚£è€… [onclive](https://vertexaisearch.cloud.google.com/id/2-1)ä¸­äº§ç”Ÿäº†34.9%çš„å®¢è§‚ç¼“è§£ç‡ (ORR) (95% CI, 21.0%-50.9%)ã€‚\n",
      "*   æˆªè‡³2024å¹´12æœˆ2 [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5)æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨æ¥å—è‡³å°‘ä¸€å‰‚Azenosertibçš„Cyclin E1+ PROCæ„å‘æ²»ç–—æ‚£è€…ä¸­ï¼ŒORRä¸º31.3% (15/48ï¼›95% CIï¼š18.7 - 46.3)ã€‚æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œæ„å‘æ²»ç–—äººç¾¤çš„mDORä»åœ¨æˆç†Ÿï¼Œçº¦ä¸º5.5ä¸ªæœˆ (95% CIï¼š2.7 â€“ ä¸å¯ä¼°è®¡)ã€‚\n",
      "*   Zentalis PharmaceuticalsæŠ¥å‘Šäº†Azenosertibæ­£åœ¨è¿›è¡Œçš„DENALI Part 1bä¸´åºŠè¯•éªŒçš„æœ€æ–°ä¸´åºŠæ•°æ®ï¼Œåœ¨å¯è¯„ä¼°ååº”çš„æ‚£è€…ä¸­ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)ä¸º6.3ä¸ªæœˆï¼Œå®¢è§‚ç¼“è§£ç‡çº¦ä¸º35%ã€‚\n",
      "\n",
      "**å®‰å…¨æ€§ä¸è€å—æ€§**\n",
      "*   æˆªè‡³2024å¹´12æœˆ2æ—¥çš„æ•°æ®æˆªæ­¢ï¼Œåœ¨ZN-c3-001ç ”ç©¶ä¸­ï¼ŒAzenosertibåœ¨æ‰€æœ‰è‚¿ç˜¤ç±»å‹ä¸”ä¸è€ƒè™‘ç”Ÿç‰©æ ‡å¿—ç‰©çŠ¶æ€çš„æƒ…å†µä¸‹ï¼Œåœ¨æ€»æ—¥å‰‚é‡æ°´å¹³â‰¥300mg (n=193) æ—¶å‡æ˜¾ç¤ºå‡ºè‰¯å¥½çš„è€å—æ€§ï¼Œæœªè§‚å¯Ÿåˆ°3çº§ä»¥ä¸Šèƒƒè‚ é“æ²»ç–—ç›¸å…³ä¸è‰¯äº‹ä»¶ (TRAE)ï¼Œä¸”3çº§ä»¥ä¸Šè¡€æ¶²å­¦æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½ï¼Œå¤§å¤šæ•°è¡€æ¶²å­¦æ¯’æ€§äº‹ä»¶ä¸º3çº§ã€‚\n",
      "*   å¯¼è‡´åœè¯çš„TRAEå‘ç”Ÿç‡è¾ƒä½ (n=10, 5.2%)ã€‚ [onclive](https://vertexaisearch.cloud.google.com/id/2-1)è¯¥ç ”ç©¶ä¸­å…ˆå‰æŠ¥å‘Šäº†ä¸€èµ·æ²»ç–—ç›¸å…³çš„5çº§äº‹ä»¶ (n=1, 0.5%)ã€‚\n",
      "*   DENALI 1béƒ¨åˆ†å…ˆå‰å·²æŠ¥å‘Šäº†ä¸¤èµ·æ²»ç–—ç›¸å…³çš„5çº§ä¸è‰¯äº‹ä»¶ (AE)ã€‚\n",
      "\n",
      "**å…¶ä»–å‘å±•**\n",
      "*   Zentalisé¢„è®¡å°†åœ¨2024å¹´ç¬¬å››å­£åº¦æä¾›Azenosertibçš„æ›´å¤šæ•°æ®ã€‚\n",
      "*   Zentalisè®¡åˆ’åœ¨2025å¹´ä¸ŠåŠå¹´å¯åŠ¨DENALIä¸´åºŠè¯•éªŒçš„ç¬¬äºŒéƒ¨åˆ†ã€‚\n",
      "*   é¢„è®¡åˆ°2026å¹´åº•å°†è·å¾—å…· [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)æœ‰æ³¨å†Œæ„å‘çš„é¡¶çº¿æ•°æ®ï¼Œè¿™ä½¿Zentalisæœ‰å¯èƒ½è·å¾—FDAçš„åŠ é€Ÿæ‰¹å‡†ã€‚\n",
      "*   ä¸´åºŠå‰æ•°æ®æ˜¾ç¤ºï¼ŒAzenosertibä¸åŸº [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)äºå¾®ç®¡æŠ‘åˆ¶å‰‚çš„æŠ—ä½“è¯ç‰©å¶è”ç‰©è”åˆä½¿ç”¨æ—¶ï¼Œæ˜¾ç¤ºå‡ºååŒæŠ—è‚¿ç˜¤ä½œç”¨ï¼Œè¿™è¡¨æ˜Azenosertibåœ¨æ²»ç–—å„ç§æ™šæœŸå®ä½“ç˜¤æ–¹é¢å…·æœ‰æ›´å¹¿æ³›çš„æ²»ç–—æ½œåŠ›ã€‚\n",
      "*   Zentalisæ­£åœ¨å‰Šå‡40%çš„å‘˜å·¥ï¼Œä»¥å°†ç°é‡‘å»¶é•¿åˆ°Azenosertibæ½œåœ¨æ³¨å†Œç ”ç©¶çš„é¢„æœŸæ•°æ®è¯»å–ä¹‹åã€‚\n",
      "*   Zentaliså·²ä¸FDAå°±éå¯¹ç…§æ³¨å†Œè¯•éªŒDenali part 2açš„ä¸€éƒ¨åˆ†â€œè¾¾æˆä¸€è‡´â€ï¼Œè¯¥å…¬å¸å¸Œæœ›è¿™å°†æ˜¯å…¶åŠ é€Ÿæ‰¹å‡†Azenosertibçš„ç¬¬ä¸€æ­¥ã€‚\n",
      " [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [oncologypipeline](https://vertexaisearch.cloud.google.com/id/2-7) [nasdaq](https://vert [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6)exaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [target [targetedonc](https://vertexaisearch.cloud.google.com/id/2-4)edonc](https://vertexaisearch.cloud.google.com/id/2-4) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3) [larvol](https://vertexaisearch.cloud.google.com/id/2-6) [nasdaq](https://vertexaisearch.cloud.google.com/id/2-5) [zentalis](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "---\n",
      "\n",
      "Im Jahr 2024 und 2025 laufen klinische Studien mit den WEE1-Inhibitoren Debio0123 und ACR-2316.\n",
      "\n",
      "**Debio0123:**\n",
      "\n",
      "*   Debio0123 ist ein selektiver WEE1-Kinase-Inhibitor, der die Blut-Hirn-Schranke Ã¼berwinden kann. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0) Er wird als Monotherapie und in Kombination mit anderen Krebsbehandlungen bei verschiedenen soliden Tumoren untersucht. [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)\n",
      "*   Debiopharm fÃ¼hrt mehrere klinische Studien mit Debio0123 durch, um die Wirkung von DNA-schÃ¤digenden Substanzen zu verstÃ¤rken. Eine Studie untersucht die Kombination von Debio0123 mit einer Standard-Chemotherapie bei kleinzelligem Lungenkrebs und Glioblastom.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debio0123 zeigt in vivo eine starke Synergie und Antitumorwirksamkeit in Kombination mit Chemotherapie und Strahlentherapie.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Debiopharm untersucht Debio0123 auch in Kombination mit Lunresertib (einem PKMYT1-Inhibitor von Repare) bei Patienten mit fortgeschrittenen soliden Tumoren.\n",
      "*  [drugdiscoverytrends](https://vertexaisearch.cloud.google.com/id/3-1)  Eine Phase-1-Studie mit Debio0123 als Monotherapie wird in den USA, Spanien und der Schweiz durchgefÃ¼hrt, um die Sicherheit, VertrÃ¤glichkeit und vorlÃ¤ufige AntitumoraktivitÃ¤t bei Patienten mit rezidivierenden oder progressiven soliden Tumoren zu untersuchen. Zwei d [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)er drei Erweiterungsarme dieser Studie verwenden Biomarker, um Patienten mit verschiedenen soliden Tumoren vorab auszuwÃ¤hlen, wÃ¤hrend der dritte Arm Patienten mit rezidivierendem serÃ¶sem Endometriumkarzinom behandelt.\n",
      "\n",
      "**ACR-23 [debiopharm](https://vertexaisearch.cloud.google.com/id/3-0)16:**\n",
      "\n",
      "*   ACR-2316 ist ein neuartiger, selektiver dualer WEE1/PKMYT1-Inhibitor, der fÃ¼r eine Ã¼berlegene EinzelwirkstoffaktivitÃ¤t entwickelt wurde.\n",
      "*   Acrivon  [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)Therapeutics plant, bis zum vierten Quartal 2024 einen IND-Antrag (Investigational New Drug) fÃ¼r ACR-2316 einzureichen.\n",
      "*   Eine lauf [acrivon](https://vertexaisearch.cloud.google.com/id/3-2) [acrivon](https://vertexaisearch.cloud.google.com/id/3-4)ende Phase-1-Monotherapie-Studie untersucht die Sicherheit und VertrÃ¤glichkeit von ACR-2316. Die Dosierung  [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)der Patienten in dieser Studie hat bereits begonnen.\n",
      "*   ACR-2316 z [acrivon](https://vertexaisearch.cloud.google.com/id/3-3)eigte in prÃ¤klinischen Studien eine Ã¼berlegene AktivitÃ¤t im Vergleich zu klinischen Benchmark-Inhibitoren (Azenosertib, Debio-0123 und Lunresertib).\n",
      "*   Auf dem Gebie [acrivon](https://vertexaisearch.cloud.google.com/id/3-3) [acrivon](https://vertexaisearch.cloud.google.com/id/3-2)t des Endometriumkarzinoms wurde eine bestÃ¤tigte partielle Remission beobachtet, was auf das breite Potenzial dieses Wirkstoffs hinweist.\n",
      "*   Acrivon Therap [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5)eutics plant, in der zweiten HÃ¤lfte des Jahres 2025 erste klinische Daten aus der Phase-1-Studie mit ACR-2316 vorzulegen.\n",
      "*   Die ersten drei [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6) Dosis-Eskalationskohorten der Phase-1-Studie mit ACR-2316 sind abgeschlossen. Es wurden eine unge [quiverquant](https://vertexaisearch.cloud.google.com/id/3-5) [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)fÃ¤hre DosisproportionalitÃ¤t, ein Target-Engagement und eine erste klinische AktivitÃ¤t mit signifikanter Tumorschrumpfung bereits bei Dosislevel drei beobachtet.\n",
      " [globenewswire](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "ä»¥ä¸‹æ˜¯å…³äº WEE1 æŠ‘åˆ¶å‰‚ AZD1775 (Adavosertib) åœ¨ 2024 å¹´å’Œ 2025 å¹´è¿›è¡Œçš„ä¸´åºŠè¯•éªŒçš„ä¿¡æ¯ï¼š\n",
      "\n",
      "*   **å•è¯ Adavosertib ç–—æ³•:**\n",
      "    *   ä¸€é¡¹é’ˆå¯¹ SETD2 çªå˜çš„æ™šæœŸå®ä½“è‚¿ç˜¤æ‚£è€…çš„ II æœŸç ”ç©¶è¡¨æ˜ï¼Œå°½ç®¡æœ‰ä¸´åºŠå‰æ•°æ®è¡¨æ˜å…¶å…·æœ‰åˆæˆè‡´æ­»æ•ˆåº”ï¼Œä½† Adavosertib å•è¯æ²»ç–—çš„ä¸´åºŠæ´»æ€§æœ‰é™ã€‚\n",
      "    *   å°½ç®¡æ²¡æœ‰è§‚å¯Ÿåˆ°å®¢è§‚ååº”ï¼Œä½†åœ¨éƒ¨åˆ†æ‚£è€…ä¸­è§‚å¯Ÿåˆ°è½»å¾®çš„è‚¿ç˜¤æ¶ˆé€€å’Œå»¶é•¿çš„ç–¾ç—…ç¨³å®šã€‚\n",
      "\n",
      "*   **Adavosertib è”åˆç–—æ³•:**\n",
      "    *   **è‚ºé³çŠ¶ç»†èƒç™Œ:** ä¸€é¡¹é’ˆå¯¹è‚ºé³çŠ¶ç»†èƒç™Œçš„ II æœŸå•è‡‚ç ”ç©¶å°† Adavosertib ä¸å¡é“‚å’Œç´«æ‰é†‡è”åˆä½¿ç”¨ï¼Œä¸­ä½ PFS ä¸º 4.8 ä¸ªæœˆã€‚ ç–¾ç—…æ§ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)åˆ¶ç‡ (DCR) ä¸º 60.9%ï¼Œä¸­ä½ç¼“è§£æŒç»­æ—¶é—´ (DoR) ä¸º 4.44 ä¸ªæœˆã€‚\n",
      "    *   **å„¿ç«¥æ¶æ€§è‚¿ç˜¤:** åœ¨ AcSÃ©-ESMART è¯•éªŒçš„ C ç»„ä¸­ï¼ŒAdavosertib ä¸å¡é“‚è”åˆç”¨äºæ²»ç–—æ‚£æœ‰åˆ†å­å¯Œé›†å¤å‘/éš¾æ²»æ€§æ¶æ€§è‚¿ç˜¤ [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1)çš„å„¿ç«¥å’Œé’å°‘å¹´ï¼Œä½†ç”±äºè¡€æ¶²å­¦æ¯’æ€§ï¼Œæœªç¡®å®š II æœŸæ¨èå‰‚é‡ã€‚\n",
      "    *   **å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤:** ä¸€é¡¹é’ˆå¯¹å¤å‘æ€§ç¥ç»æ¯ç»†èƒç˜¤ã€é«“æ¯ç»†èƒç˜¤å’Œæ¨ªçº¹è‚Œè‚‰ç˜¤çš„å„¿ç§‘ II æœŸè¯•éªŒå°† Adavosertib ä¸ä¼Šç«‹æ›¿åº·è”åˆä½¿ç”¨ã€‚ ç¥ç»æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸‰ä¸ªå®¢è§‚ååº”ï¼Œæ¾æœä½“æ¯ç»†èƒç˜¤æ‚£è€…æœ‰ä¸€ä¸ªéƒ¨åˆ†ååº”ã€‚\n",
      "\n",
      "æ€»çš„æ¥è¯´ï¼Œç°æœ‰çš„ç ”ç©¶è¡¨æ˜ï¼ŒAdavosertib å•è¯æ²»ç–—åœ¨å®ä½“è‚¿ç˜¤ä¸­å¯èƒ½ç–—æ•ˆ [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)æœ‰é™ï¼Œä½†ä¸å…¶ä»–åŒ–ç–—è¯ç‰©è”åˆä½¿ç”¨å¯èƒ½å¯¹æŸäº›ç™Œç—‡æœ‰æ•ˆã€‚ [umn](https://vertexaisearch.cloud.google.com/id/4-5) [umn [ascopubs](https://vertexaisearch.cloud.google.com/id/4-2)](https://vertexaisearch.cloud.google.com/id/4-5) [nih](https://vertexaisearch.cloud.google.com/id/4-3) [aacrjournals](https://vertexaisearch.cloud.google.com/id/4-4)\n",
      "---\n",
      "\n",
      "Azenosertib is a WEE1 inhibitor being developed by Zentalis Pharmaceuticals for various cancers, including ovarian cancer [onclive](https://vertexaisearch.cloud.google.com/id/1-0) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-1) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2) [zentalis](https://vertexaisearch.cloud.google.com/id/1-3). It is currently being evaluated in clinical trials as both a monotherapy and in combination with other treatments [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [zentalis](https://vertexaisearch.cloud.google.com/id/1-3) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **DENALI Trial (Platinum-Resistant Ovarian Cancer):**\n",
      "    *   The DENALI trial is a Phase 2 study evaluating azenosertib in patients with platinum-resistant ovarian cancer [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-1) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5) [onclive](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "    *   Updated data from Part 1b of the DENALI trial showed an objective response rate (ORR) of 34.9% in Cyclin E1+ patients (a biomarker-defined subgroup representing approximately 50% of PROC cases) [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "    *   In the intent-to-treat patients with Cyclin E1+ PROC, the ORR was 31.3%, and the median duration of response (mDOR) was 6.3 months [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   Zentalis is on track to initiate enrollment of DENALI Part 2 in the first half of 2025 and expects to disclose topline data from DENALI Part 2 by year end 2026 [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "    *   DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Combination Therapies:**\n",
      "    *   Early data suggests azenosertib in combination with encorafenib and cetuximab shows a manageable safety profile and potential in metastatic BRAF V600E mutant colorectal cancer [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "    *   Preclinical data suggests azenosertib combined with microtubule inhibitor-based antibody-drug conjugates (ADCs) exhibits synergistic antitumor activity in vitro and in vivo [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Manageable Safety Profile:** The trial evaluating safety and dose escalation demonstrated a manageable safety profile, with no unexpected adverse events reported as of April 4, 2025 [ainvest](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "*   **Common Adverse Events:** Gastrointestinal toxicities and fatigue were found to be the most common treatment-related adverse events [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Clinical Hold:** In June 2024, the FDA placed a clinical hold on three azenosertib monotherapy studies after two deaths occurred in the Phase II DENALI trial in platinum-resistant ovarian cancer; the deaths were presumed to be due to sepsis [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "\n",
      "**Overall:**\n",
      "\n",
      "Azenosertib is a promising WEE1 inhibitor that has shown encouraging early results in clinical trials for ovarian cancer and other solid tumors [ainvest](https://vertexaisearch.cloud.google.com/id/1-6) [onclive](https://vertexaisearch.cloud.google.com/id/1-7) [nasdaq](https://vertexaisearch.cloud.google.com/id/1-2). The FDA had placed a partial clinical hold on monotherapy studies of azenosertib after two deaths occurred in one of them [patsnap](https://vertexaisearch.cloud.google.com/id/1-4) [biocentury](https://vertexaisearch.cloud.google.com/id/1-5). Zentalis is working with the FDA to resolve the partial clinical hold [patsnap](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "\n",
      "---\n",
      "\n",
      "Debio-0123 is an investigational, orally bioavailable, highly selective, and brain-penetrant ATP-competitive inhibitor of the WEE1 tyrosine kinase [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1). It is currently in phase 1 clinical trials [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0). WEE1 is a key regulator of cell cycle progression that influences entry into mitosis by modulating activity of cyclin-dependent kinase 1 (CDK1) through phosphorylation [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "Here's what the search results indicate regarding clinical trials and results of Debio-0123 in ovarian cancer for 2024 and 2025:\n",
      "\n",
      "**2024 Results:**\n",
      "\n",
      "*   **Phase 1 Dose-Finding Study:** A phase 1 dose-escalation study of Debio 0123 as a monotherapy in adult patients with advanced solid tumors (including ovarian cancer) was conducted to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   As of October 24, 2023, 27 patients were treated, with ovarian cancer being the most common primary tumor (33%) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   The MTD was determined to be 260 mg [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   Two ovarian cancer patients achieved a 17% and 20% reduction in target lesions, despite needing dose reductions during the first cycle. One of these patients also had a CA-125 response [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "*   **Debio-0123-102 Trial:** This phase 1 dose-escalation study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Debio 0123 in patients with advanced solid tumors [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   The most frequent treatment-related adverse events (TRAEs) were increased blood creatinine (37%), QTcF prolongation (37%), nausea (33%), vomiting (26%), dysgeusia (22%), and fatigue (22%) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "    *   Of the 25 patients with post-baseline tumor assessment, 8 (32%) had stable disease as their best response for â‰¥5 weeks.\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-3)\n",
      "**2025 Results:**\n",
      "\n",
      "*   **AACR Annual Meeting 2025:**\n",
      "    *   Debio 0123 is currently in phase 1 clinical trials.\n",
      " [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0)    *   Preclinical data demonstrates that the WEE1 inhibitor, Debio 0123, is synergistic with the PKMYT1 inhibitor, lunresertib, and consistently leads to deep and sustained regressions in vivo in models of ovarian and breast cancer.\n",
      " [researchgate](https://vertexaisearch.cloud.google.com/id/2-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5)    *   The combination of Debio 0123 and lunresertib resulted in complete and sustained regression of all tumors in in vivo models of ovarian or breast cancer.\n",
      " [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5) [researchgate](https://vertexaisearch.cloud.google.com/id/2-4)*   **ASCO Annual Meeting 2025:**\n",
      "    *   Debiopharm presented data on Debio 0123 at the ASCO Annual Meeting.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)    *   A Trial in Progress (TiP) poster outlined the framework and objectives of the ongoing dose expansion phase of the Debio 0123-102 monotherapy study.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)    *   An abstract publication and three poster presentations highlighted Debio 0123's potential across solid tumors.\n",
      " [ritzau](https://vertexaisearch.cloud.google.com/id/2-6)*   **Phase 1 Study in Gynecologic Cancers:** A phase 1 study is assessing Debio 0123 in gynecologic cancers, including ovarian, uterine serous carcinoma, primary peritoneal, and fallopian tube cancers.\n",
      " [mskcc](https://vertexaisearch.cloud.google.com/id/2-7)    *   The study includes an expansion phase with patients who have recurrent uterine serous carcinoma or high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with high cyclin E1.\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8) [mskcc](https://vertexaisearch.cloud.google.com/id/2-7)    *   The primary endpoints are safety, tolerability, and overall response rate (ORR).  [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8)Secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS).\n",
      " [ascopubs](https://vertexaisearch.cloud.google.com/id/2-8)*   **Debio 0123 in Combination with Lunresertib:**\n",
      "    *   Preclinical models of ovarian and breast cancer show that Debio 0123 is synergistic with lunresertib.\n",
      " [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-5) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1) [researchgate](https://vertexaisearch.cloud.google.com/id/2-4) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0)    *   The combination of Debio 0123 and lunresertib induces strong phosphorylation of CDK1, potentially leading to premature mitotic entry, chromosome pulverization, and cancer cell death.\n",
      " [debiopharm](https://vertexaisearch.cloud.google.com/id/2-0) [debiopharm](https://vertexaisearch.cloud.google.com/id/2-1)\n",
      "---\n",
      "\n",
      "The latest data on the APR-1051 WEE1 inhibitor in clinical trials for ovarian cancer comes from 2024 and 2025.\n",
      "\n",
      "**2024:**\n",
      "\n",
      "*   The FDA cleared Aprea Therapeutics' Investigational New Drug (IND) application for APR-1051 in March 2024 [aprea](https://vertexaisearch.cloud.google.com/id/3-0) [aprea](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "*   A Phase 1 dose-escalation trial (ACESOT-1051) was initiated to evaluate the safety, tolerability, and preliminary efficacy of APR-1051 in patients with advanced solid tumors [biospace](https://vertexaisearch.cloud.google.com/id/3-2) [aprea](https://vertexaisearch.cloud.google.com/id/3-0). The trial is ongoing at sites in the U.S [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   Preliminary data from the Phase 1 trial presented in October 2024 showed that APR-1051 was safe and well-tolerated, with mostly Grade 1 or 2 adverse events [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2) [aprea](https://vertexaisearch.cloud.google.com/id/3-4). No hematologic toxicity was observed [onclive](https://vertexaisearch.cloud.google.com/id/3-3) [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   The trial enrolled patients in cohorts receiving doses from 10 mg to 150 mg once daily [biospace](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "**2025:**\n",
      "\n",
      "*   Aprea Therapeutics presented updated data from the ACESOT-1051 trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2025 [aprea](https://vertexaisearch.cloud.google.com/id/3-5) [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [aprea](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   Results from Dose Level 6 (100 mg once daily) showed that 3 out of 4 patients achieved stable disease (per RECIST v1.1) in heavily pretreated gastrointestinal and gynecologic malignancies [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [aprea](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   Disease stabilization was observed in patients with FBXW7, CCNE1, and KRASG12V + TP53 alterations, molecular profiles known to drive replication stress and WEE1 dependency [aprea](https://vertexaisearch.cloud.google.com/id/3-6) [aprea](https://vertexaisearch.cloud.google.com/id/3-4).\n",
      "*   Dose escalation is continuing, with patients now enrolling in the 150 mg cohort [aprea](https://vertexaisearch.cloud.google.com/id/3-6) [aprea](https://vertexaisearch.cloud.google.com/id/3-5).\n",
      "*   APR-1051 was generally well-tolerated, with mostly Grade 1 or 2 adverse events, mainly gastrointestinal events and fatigue [aprea](https://vertexaisearch.cloud.google.com/id/3-4).\n",
      "*   Maxim Group issued a Buy Rating on Aprea (Nasdaq: APRE) with a $10 price target over the next 12 months [financialcontent](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   Aprea has cash runway into the fourth quarter of 2026 [aprea](https://vertexaisearch.cloud.google.com/id/3-4) [financialcontent](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are being explored as a cancer therapy target due to their role in cell cycle control and potential impact on cancer cell survival [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). By inhibiting WEE1, cancer cells are forced into mitosis with damaged DNA, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/4-1) [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). This strategy is promising against difficult-to-treat cancers [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0). Many cancers, especially those with TP53 mutations, upregulate WEE1 to counteract replication stress and DNA damage, making WEE1 a key therapeutic target [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "\n",
      "**WEE1 Inhibitors in Clinical Trials:**\n",
      "\n",
      "Several WEE1 inhibitors are currently in clinical trials, including:\n",
      "\n",
      "*   **Azenosertib (ZN-c3):** A potent oral WEE1 inhibitor [patsnap](https://vertexaisearch.cloud.google.com/id/4-1) [frontiersin](https://vertexaisearch.cloud.google.com/id/4-3). Zentalis Pharmaceuticals is developing azenosertib and expects to launch a phase 3 trial in the first quarter of 2024 [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4). Clinical data has shown anti-tumor activity in difficult-to-treat tumor types when combined with standard chemotherapy regimens [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   **Adavosertib (AZD1775):** Has shown strong preclinical and clinical activity in ovarian, breast, gastrointestinal, and head and neck cancers [nih](https://vertexaisearch.cloud.google.com/id/4-2). However, it has a narrow therapeutic window and associated toxicities [onclive](https://vertexaisearch.cloud.google.com/id/4-5).\n",
      "*   **Debio 0123:** A next-generation, brain-penetrant WEE1 inhibitor with an enhanced safety profile and improved cancer treatment outcomes is currently being researched [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/4-6).\n",
      "*   **APR-1051, SC0191, and ACR-2316** [patsnap](https://vertexaisearch.cloud.google.com/id/4-1)\n",
      "\n",
      "**Efficacy and Safety in Ovarian Cancer Clinical Trials:**\n",
      "\n",
      "*   **Azenosertib:** In a Phase 1b trial of azenosertib combined with chemotherapy in patients with platinum-resistant ovarian cancer, the highest overall response rate (ORR) was 50% with azenosertib plus paclitaxel chemotherapy [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/4-6). Azenosertib is emerging as a promising clinical candidate, with demonstrated anti-tumor activity in difficult-to-treat tumor types when used in combination with standard chemotherapy regimens [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4). The addition of azenosertib increased ORRs and mPFS over those observed historically with chemotherapy alone, or compared to adavosertib in combination with chemotherapy [fiercebiotech](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   **Adavosertib:** A phase II clinical trial (NCT01164995) confirmed the safety and effectiveness of Adavosertib and carboplatin in patients with TP53-mutant epithelial OC resistant to paclitaxel and carboplatin (TC) within three months [nih](https://vertexaisearch.cloud.google.com/id/4-7). The remission rate was 43%, with one patient achieving long-term complete remission [nih](https://vertexaisearch.cloud.google.com/id/4-7). The median progression-free survival (PFS) and OS were 5.3 and 12.6 months, respectively [nih](https://vertexaisearch.cloud.google.com/id/4-7). The most common grade â‰¥ 3 adverse events (AEs) were thrombocytopenia (48%) and neutropenia (37%).  [nih](https://vertexaisearch.cloud.google.com/id/4-7)A multicenter randomized phase II clinical study (NCT01357161) evaluated the effect of Adavosertib combined with TC vs TC alone in platinum-sensitive TP53-mutant OC patients.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-7)\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   **Toxicity:** First-generation WEE1 inhibitors showed limitations due to their lack of selectivity and resulting toxicity.  [debiopharm](https://vertexaisearch.cloud.google.com/id/4-0)AZD1775 has high toxicity at effective dosages, manifesting as adverse side-effects.\n",
      " [frontiersin](https://vertexaisearch.cloud.google.com/id/4-3)*   **Resistance:** Acquired resistance remains an obstacle to clinical implementation.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-2)*   **Patient Selection:** Patient selection remains a challenge to clinical implementation.  [nih](https://vertexaisearch.cloud.google.com/id/4-2)Biomarkers such as TP53 mutations are increasingly used to guide treatment selection.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)*   **Combinations:** WEE1 inhibitors can be combined with other anticancer treatments, including DNA-damaging agents like chemotherapy and radiation, and immune checkpoint inhibitors.\n",
      " [nih](https://vertexaisearch.cloud.google.com/id/4-2) [patsnap](https://vertexaisearch.cloud.google.com/id/4-1)*   **Personalized Medicine:** The increasing focus on personalized medicine is enhancing the utility of WEE1 inhibitors.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)*   **Market Growth:** The WEE1 Inhibitor Therapeutics market is expected to grow at a remarkable CAGR of 21.8% from 2025 to 2033, with forecasts indicating the market will reach approximately USD 2.36 billion by 2033.\n",
      " [growthmarketreports](https://vertexaisearch.cloud.google.com/id/4-8)\n",
      "---\n",
      "\n",
      "ACR-2316 is a novel, selective dual inhibitor of WEE1 and PKMYT1 designed for cancer treatment [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5). Acrivon Therapeutics is currently evaluating ACR-2316 in a Phase 1 monotherapy clinical trial in patients with advanced solid tumors [researcher](https://vertexaisearch.cloud.google.com/id/1-6). Initial clinical data from this trial is expected in the second half of 2025 [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [researcher](https://vertexaisearch.cloud.google.com/id/1-6).\n",
      "\n",
      "Here's a breakdown of ACR-2316's mechanism of action, efficacy, and safety:\n",
      "\n",
      "**Mechanism of Action:**\n",
      "\n",
      "*   **Dual Inhibition:** ACR-2316 inhibits both WEE1 and PKMYT1 kinases [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4). This dual inhibition is designed to overcome resistance mechanisms that can arise with single-target WEE1 inhibitors [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **CDK Activation:** By inhibiting WEE1 and PKMYT1, ACR-2316 promotes strong activation of CDK1, CDK2, and PLK1 [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11). These kinases are crucial for cell cycle progression and mitotic regulation [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Disruption of Cell Cycle Checkpoints:** ACR-2316 disrupts cell cycle checkpoints, leading to S/G2-M cell cycle arrest, premature mitosis, DNA damage, and ultimately, pro-apoptotic cell death [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11).\n",
      "*   **AP3 Platform Design:** ACR-2316 was designed using Acrivon's Predictive Precision Proteomics (AP3) platform [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-11) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8). This platform allows for the rational design of drug candidates with optimal target selectivity and potency [acrivon](https://vertexaisearch.cloud.google.com/id/1-4). AP3 helps in understanding drug-induced resistance mechanisms and optimizing the target selectivity profile [acrivon](https://vertexaisearch.cloud.google.com/id/1-4) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Superior Preclinical Activity:** In preclinical studies, ACR-2316 has demonstrated superior single-agent anti-cancer activity compared to clinical benchmark WEE1 or PKMYT1 inhibitors [globenewswire](https://vertexaisearch.cloud.google.com/id/1-10) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-9) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [conventus](https://vertexaisearch.cloud.google.com/id/1-1) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Tumor Regression:** ACR-2316 induces tumor regression in CDX and PDX tumor mouse models [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [researchgate](https://vertexaisearch.cloud.google.com/id/1-2) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8). It has also shown activity in tumors progressing on azenosertib, a WEE1 inhibitor [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Broad Spectrum Activity:** ACR-2316 demonstrates anti-cancer activity across a broad spectrum of in vitro cancer line models, including those insensitive to WEE1 or PKMYT1 inhibitors [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Dose-Dependent Efficacy:** ACR-2316 demonstrates dose-dependent efficacy and near-complete regressions in a human ovarian tumor xenograft model [acrivon](https://vertexaisearch.cloud.google.com/id/1-3). It also shows comparable efficacy across a range of intermittent dosing schedules [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Mechanism-Based and Reversible Adverse Events:** Preclinical IND-enabling GLP safety-toxicity studies suggest that adverse events are mechanism-based but transient and fully reversible [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Well Tolerated:** ACR-2316 is well-tolerated in rodent models, with only mechanism-based, transient, and reversible myelosuppression observed across a range of intermittent dosing regimens [acrivon](https://vertexaisearch.cloud.google.com/id/1-8) [acrivon](https://vertexaisearch.cloud.google.com/id/1-5).\n",
      "*   **Phase 1 Trial Focus:** The ongoing Phase 1 clinical trial is designed to assess the safety and tolerability of ACR-2316 [acrivon](https://vertexaisearch.cloud.google.com/id/1-3) [gcs-web](https://vertexaisearch.cloud.google.com/id/1-7) [acrivon](https://vertexaisearch.cloud.google.com/id/1-8).\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are being explored as a cancer therapy, with the lead candidate being adavosertib (AZD1775) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [onclive](https://vertexaisearch.cloud.google.com/id/2-1) [nih](https://vertexaisearch.cloud.google.com/id/2-2). These inhibitors target the WEE1 kinase, a key regulator of the cell cycle, particularly the G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-2). By inhibiting WEE1, cancer cells with damaged DNA are forced into mitosis, leading to mitotic catastrophe and cell death [nih](https://vertexaisearch.cloud.google.com/id/2-2) [patsnap](https://vertexaisearch.cloud.google.com/id/2-3). This approach is particularly promising in tumors with TP53 mutations, as these cells rely more heavily on the G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "Here's a breakdown of the efficacy, safety, limitations, and resistance mechanisms associated with WEE1 inhibitors in single-target clinical trials:\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Monotherapy:** Adavosertib has demonstrated promising activity as a monotherapy in some cases [onclive](https://vertexaisearch.cloud.google.com/id/2-1). For example, a phase II single-arm clinical trial of adavosertib showed a median progression-free survival (PFS) of 6.1 months in patients with recurrent or persistent Uterine Serous Carcinoma (USC) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Combination Therapy:** WEE1 inhibition can enhance the effectiveness of chemotherapies, including platinum-based agents, antimetabolites, and PARP inhibitors [nih](https://vertexaisearch.cloud.google.com/id/2-2). It also synergizes with radiotherapy and immune checkpoint inhibitors [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "*   **Specific Cancers:** Clinical trials have shown strong preclinical and clinical activity of adavosertib in ovarian, breast, gastrointestinal, and head and neck cancers [nih](https://vertexaisearch.cloud.google.com/id/2-2).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Tolerability:** Adavosertib has been shown to be safe and tolerable as a single agent and in combination with chemotherapy [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4) [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5).\n",
      "*   **Toxicities:** The most common toxicities associated with adavosertib include myelosuppression (anemia, neutropenia, and thrombocytopenia), nausea, vomiting, diarrhea, and fatigue [ascopubs](https://vertexaisearch.cloud.google.com/id/2-5) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "*   **Dose-Limiting Toxicities (DLTs):** DLTs reported in clinical trials include supraventricular tachyarrhythmia and myelosuppression [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "\n",
      "**Limitations:**\n",
      "\n",
      "*   **Toxicity:** Effective dosages of adavosertib can cause high toxicity, manifesting as adverse side effects [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Specificity:** Adavosertib may have lower than ideal specificity, targeting PLK1 alongside WEE1 in therapeutic trials [frontiersin](https://vertexaisearch.cloud.google.com/id/2-4).\n",
      "*   **Biomarkers:** There is a need for comprehensive biomarker panels to predict response and potential toxicity [patsnap](https://vertexaisearch.cloud.google.com/id/2-3). TP53 status has been proposed as a predictive biomarker, but its utility remains inconsistent [patsnap](https://vertexaisearch.cloud.google.com/id/2-3) [nih](https://vertexaisearch.cloud.google.com/id/2-6).\n",
      "*   **Clinical Development:** Despite promising safety and efficacy, adavosertib has yet to proceed to a phase 3 trial [onclive](https://vertexaisearch.cloud.google.com/id/2-1).\n",
      "\n",
      "**Resistance Mechanisms:**\n",
      "\n",
      "*   **Upregulation of PKMYT1:** A mechanism of acquired resistance to adavosertib is the upregulation of PKMYT1, a kinase functionally related to WEE1 [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/2-7).\n",
      "*   **Reversal of Expression Profiles:** Reversal of expression profiles of genes that are the base for WEE1 inhibitor vulnerability can lead to resistance. For example, while cyclin E overexpression sensitizes cancer cells to AZD1775, reducing cyclin E levels has the opposite effect [frontiersin](https://vertexaisearch.cloud.google.com/id/2-0).\n",
      "*   **Activation of Alternative Cell Cycle Checkpoints:** Tumor cells can adapt to the stress induced by WEE1 inhibition by activating alternative cell cycle checkpoints [patsnap](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "*   **Upregulation of DNA Repair Pathways:** Resistance mechanisms may involve the upregulation of DNA repair pathways [patsnap](https://vertexaisearch.cloud.google.com/id/2-3).\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "Dual WEE1 and PKMYT1 inhibitors are being explored as a strategy to improve cancer therapy compared to single WEE1 inhibitors, with a focus on efficacy, safety, and overcoming resistance [citedrive](https://vertexaisearch.cloud.google.com/id/3-0) [researchgate](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "\n",
      "**Efficacy:**\n",
      "\n",
      "*   **Synergistic effects:** Combining WEE1 and PKMYT1 inhibition has demonstrated synergistic effects in eradicating cancer cells, including ovarian cancer and breast cancer cells with acquired CDK4/6 inhibitor resistance [citedrive](https://vertexaisearch.cloud.google.com/id/3-0) [researchgate](https://vertexaisearch.cloud.google.com/id/3-1) [nih](https://vertexaisearch.cloud.google.com/id/3-2). This combination promotes CDK activation, exacerbates DNA replication stress and catastrophe, and increases genomic instability [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   **Improved anti-tumor activity:** Preclinical studies show that dual inhibitors can have stronger antitumor activity than either WEE1 or PKMYT1 inhibitors alone [bioworld](https://vertexaisearch.cloud.google.com/id/3-3). For example, SGR-3515, a dual inhibitor, resulted in marked reductions of tumor volumes and superior antitumor activity compared to single inhibitors in xenograft tumor models [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "*   **Overcoming resistance:** Dual inhibition of WEE1 and PKMYT1 can be more effective than single-agent treatments in eliminating CDK4/6 inhibitor-resistant organoids [citedrive](https://vertexaisearch.cloud.google.com/id/3-0). This approach can overcome resistance to WEE1-targeted monotherapies [citedrive](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "*   **Efficacy in specific cancers:** Studies have shown high efficacy of PKMYT1 inhibitors in late-stage, post-treatment non-small cell lung cancer models [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5).\n",
      "\n",
      "**Safety:**\n",
      "\n",
      "*   **Low-dose approach:** A multiple low-dose approach utilizing joint WEE1 and PKMYT1 inhibition may allow exploitation of synthetic lethality while minimizing adverse effects [nih](https://vertexaisearch.cloud.google.com/id/3-2) [nih](https://vertexaisearch.cloud.google.com/id/3-6).\n",
      "*   **Tolerability:** In a mouse model, the combination of a PKMYT1 inhibitor (RP-6306) and a WEE1 inhibitor (Debio-0123) was well-tolerated and demonstrated tumor regressions at sub-therapeutic monotherapy doses [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   **Intermittent dosing:** Dual inhibitors like SGR-3515 can support intermittent dosing schedules to permit recovery from myelosuppression [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "*   **Phase 1 clinical trials:** SGR-3515 is currently in phase 1 clinical trials to evaluate its safety and tolerability in patients with advanced solid tumors [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8).\n",
      "\n",
      "**Resistance:**\n",
      "\n",
      "*   **Reduced resistance development:** Multiple low-dose therapy reduces cancer selective pressure against a single target, which may result in less treatment resistance [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   **Myt1 co-inhibition:** Myt1 co-inhibition enhances activity and leverages synthetic lethality, with the potential to reduce tumor resistance [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8).\n",
      "*   **Upregulation of PKMYT1:** Upregulation of PKMYT1 has been shown to promote resistance of cancer cells to WEE1 inhibition [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      "**Other relevant points:**\n",
      "\n",
      "*   WEE1 and PKMYT1 are key regulators of cell cycle progression and DNA damage response [schrodinger](https://vertexaisearch.cloud.google.com/id/3-8) [researchgate](https://vertexaisearch.cloud.google.com/id/3-9) [nih](https://vertexaisearch.cloud.google.com/id/3-10).\n",
      "*   WEE1 inhibitors, like adavosertib (AZD1775), have shown preclinical and clinical activity in various cancers [nih](https://vertexaisearch.cloud.google.com/id/3-10) [frontiersin](https://vertexaisearch.cloud.google.com/id/3-11).\n",
      "*   PKMYT1 inhibitors, such as RP-6306 and EVT-0003023, are being developed and have shown promise in preclinical studies [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5) [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [nih](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "*   Dual inhibition can lead to increased DNA damage, premature mitosis, and cell death in cancer cells [nih](https://vertexaisearch.cloud.google.com/id/3-10) [nih](https://vertexaisearch.cloud.google.com/id/3-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   CCNE1 amplification is a biomarker for sensitivity to PKMYT1 inhibition [onclive](https://vertexaisearch.cloud.google.com/id/3-12) [researchgate](https://vertexaisearch.cloud.google.com/id/3-4) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-5) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-13) [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-7).\n",
      "*   Schrodinger Inc. has presented preclinical characterization of SGR-3515, a dual inhibitor of WEE1 and PKMYT1, which is in early clinical development for advanced solid tumors [bioworld](https://vertexaisearch.cloud.google.com/id/3-3).\n",
      "\n",
      "---\n",
      "\n",
      "WEE1 inhibitors are emerging as a promising strategy in cancer therapy, particularly in combination with other anticancer agents like chemotherapy, immunotherapy, and targeted therapies [nih](https://vertexaisearch.cloud.google.com/id/1-0) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [kcl](https://vertexaisearch.cloud.google.com/id/1-2) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3). These inhibitors target the WEE1 kinase, a central regulator of the cell cycle, which prevents premature mitosis and maintains genomic integrity [nih](https://vertexaisearch.cloud.google.com/id/1-0) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1). By blocking WEE1 activity, cancer cells with damaged DNA are forced into mitosis, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "\n",
      "**Clinical Trials and Results:**\n",
      "\n",
      "*   **Combination Therapies:** Clinical trials are exploring the potential of combining WEE1 inhibitors with various other therapies [kcl](https://vertexaisearch.cloud.google.com/id/1-2) [patsnap](https://vertexaisearch.cloud.google.com/id/1-1). These include:\n",
      "    *   Chemotherapy: WEE1 inhibitors can sensitize cancer cells to DNA-damaging agents like chemotherapy, enhancing the antitumor response [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-0). For example, ZN-c3 (Azenosertib) with gemcitabine in pancreatic cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Immunotherapy: Combining WEE1 inhibitors with immune checkpoint inhibitors holds promise for directly killing tumor cells and rendering the tumor microenvironment more immunogenic [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-0). The \"ZAP-IT\" trial is testing ZN-c3 with carboplatin and pembrolizumab in metastatic triple-negative breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Targeted therapies: Clinical trials are investigating WEE1 inhibitors with targeted agents like trastuzumab deruxtecan in HER2-expressing solid tumors [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "*   **Specific WEE1 Inhibitors in Trials:** Several WEE1 inhibitors are in active clinical development [patsnap](https://vertexaisearch.cloud.google.com/id/1-1):\n",
      "    *   Azenosertib (ZN-c3): Being investigated in combination with gemcitabine for pancreatic cancer and with carboplatin and pembrolizumab for triple-negative breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   Debio0123: Being evaluated in combination with sacituzumab govitecan in triple-negative or HR+/HER2-negative advanced/metastatic breast cancer [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   APR-1051: Is in phase 1 trial for advanced solid tumors [patsnap](https://vertexaisearch.cloud.google.com/id/1-1).\n",
      "    *   AZD1775 (Adavosertib): In combination with carboplatin has demonstrated clinical benefit in patients with TP53-mutant, platinum-resistant ovarian cancer [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-4).\n",
      "*   **Machine Learning to predict synergistic combinations:** Machine learning models are being used to predict synergistic drug combinations with WEE1 inhibitors, identifying potential new cancer types where these combinations may be effective [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-3).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   **Resistance and Toxicity:** Overcoming acquired resistance, managing toxicity, and improving patient selection remain challenges in clinical implementation [nih](https://vertexaisearch.cloud.google.com/id/1-0).\n",
      "*   **Biomarkers:** Identifying biomarkers to predict patient response to WEE1 inhibitors is crucial for patient stratification and optimizing treatment strategies [nih](https://vertexaisearch.cloud.google.com/id/1-0) [aacrjournals](https://vertexaisearch.cloud.google.com/id/1-4). TP53 mutation has not been shown to be the most reliable predictive biomarker [kcl](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "*   **Novel Combinations:** Exploring novel combinations of WEE1 inhibitors with other agents, such as ATR/CHK1 inhibitors or PARP inhibitors, is a promising direction [patsnap](https://vertexaisearch.cloud.google.com/id/1-1) [kcl](https://vertexaisearch.cloud.google.com/id/1-2).\n",
      "\n",
      "---\n",
      "\n",
      "Here's an update on the regulatory developments and FDA approval status of WEE1 inhibitors in 2024 and 2025: \n",
      "\n",
      " **What are WEE1 Inhibitors?** \n",
      "\n",
      " WEE1 inhibitors work by blocking the WEE1 kinase, a key regulator of the cell cycle. By inhibiting WEE1, cancer cells with damaged DNA are forced into mitosis prematurely, leading to cell death [patsnap](https://vertexaisearch.cloud.google.com/id/2-0) [frontiersin](https://vertexaisearch.cloud.google.com/id/2-1). This approach is particularly promising in tumors with defective p53, which rely heavily on the WEE1-regulated G2/M checkpoint [patsnap](https://vertexaisearch.cloud.google.com/id/2-0). Combining WEE1 inhibitors with DNA-damaging drugs can also overwhelm the cancer cells' repair mechanisms, triggering apoptosis [patsnap](https://vertexaisearch.cloud.google.com/id/2-0). \n",
      "\n",
      " **Developments in 2024:** \n",
      "\n",
      " *   **Partial Clinical Hold on Azenosertib:** In June 2024, the FDA placed a partial clinical hold on three studies investigating Zentalis Pharmaceuticals' azenosertib after two trial participants died from presumed blood-related infections [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). The trials affected were investigating azenosertib in solid tumors (Phase I) and in ovarian and uterine cancer (Phase II) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). Monotherapy trials were paused, but dosing continued for participants in combination studies [patsnap](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      " *   **Clinical Hold Lifted:**  The FDA lifted the partial clinical hold on azenosertib in September 2024, allowing Zentalis to resume enrollment in all ongoing clinical studies without changes to the development plan [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3) [precisionmedicineonline](https://vertexaisearch.cloud.google.com/id/2-4). Following this decision, Zentalis' stock value increased significantly [patsnap](https://vertexaisearch.cloud.google.com/id/2-2) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3). \n",
      " *   **Planned Data Presentation:** Zentalis planned to present azenosertib monotherapy data and provide updates on clinical development timelines at a corporate event later in 2024 [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/2-3) [patsnap](https://vertexaisearch.cloud.google.com/id/2-2). \n",
      "\n",
      " **Developments in 2025:** \n",
      "\n",
      " *   **Azenosertib Fast Track Designation:** In January 2025, the FDA granted fast track designation to azenosertib for treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who are positive for cyclin E1 [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/2-5) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/2-6). \n",
      " *   **MRANK-106 IND Clearance:** The FDA cleared the investigational new drug (IND) application for MRANK-106, a dual WEE1/YES1 kinase inhibitor for advanced solid tumors, on March 7, 2025 [targetedonc](https://vertexaisearch.cloud.google.com/id/2-7). \n",
      " *   **Acrivon Therapeutics' ACR-2316:** Acrivon Therapeutics is dosing patients in a Phase 1 monotherapy dose-escalation trial of ACR-2316 (a WEE1/PKMYT1 inhibitor) for certain solid tumor types with high unmet need [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). Initial clinical activity, including tumor shrinkage and a confirmed partial response, has been observed across several solid tumor types [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). Acrivon presented data at the AACR-NCI-EORTC conference demonstrating that ACR-2316 was designed to achieve superior activity through potent WEE1 inhibition with concomitant suppression of WEE1 inhibitor-induced PKMYT1 resistance mechanisms, while triggering robust activation of CDK1, CDK2, and PLK1 to induce potent tumor cell death [taiwannews](https://vertexaisearch.cloud.google.com/id/2-8). \n",
      "\n",
      " **Ongoing Clinical Trials:** \n",
      "\n",
      " *   Azenosertib is currently in a Phase III trial (DENALI) for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). Topline data is expected by the end of 2026, with potential for an FDA accelerated approval application [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). \n",
      "\n",
      " **Potential Future Developments:** \n",
      "\n",
      " *   **Azenosertib Accelerated Approval (Potential):** Zentalis is aiming for potential accelerated approval of azenosertib in late 2026, but faces competition and regulatory hurdles [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). Success depends on the FDA's acceptance of the DENALI trial data [ainvest](https://vertexaisearch.cloud.google.com/id/2-9). \n",
      "\n",
      " Keep in mind that clinical trials are ongoing, and the information above reflects data available up to November 21, 2025.\n",
      "\n",
      "---\n",
      "\n",
      "### æœ¬åœ°ä¸´åºŠè¯•éªŒæ•°æ®ï¼ˆæ¥è‡ªå·¥å…· get_clinical_resultsï¼‰\n",
      "\n",
      "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
      "| --- | --- | --- | --- | --- |\n",
      "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06612203 | Zedoresertibã€æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ ã€æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-516322-60-00 | Zedoresertib ã€ æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ ã€ HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ ã€ éå°ç»†èƒè‚ºç™Œ ã€ æ™šæœŸç™Œç—‡ ã€ åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— ã€ Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06363552 | SC-0191 ã€ äºšå¶é…¸é’™ ã€ è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT06351332 | å¡é“‚ ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ ã€ è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| CTIS2024-511227-33-00 | LB-100 ã€ Azenosertib | è‚¿ç˜¤ ã€ ç»“ç›´è‚ ç™Œ ã€ è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06109883 | LB-100 ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT06055348 | SC-0191 ã€ ç´«æ‰é†‡ ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ ã€ å¤å‘æ€§åµå·¢ç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ ã€ Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ ã€ æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05815160 | Zedoresertib ã€ ä¾æ‰˜æ³Šè‹· ã€ å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05765812 | Zedoresertib ã€ æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ ã€ å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— ã€ æ©è€ƒèŠ¬å°¼ ã€ Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT05682170 | Asaretoclax ã€ Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05431582 | è´ä¼ç å•æŠ— ã€ å¸•åšåˆ©ç å•æŠ— ã€ Azenosertib | è‚ºç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤ ã€ ä¹³è…ºç™Œ ã€ èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
      "| CTR20221135 | äºšå¶é…¸é’™ ã€ è´ä¼ç å•æŠ— ã€ Azenosertib ã€ æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢ç™Œ ã€ è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
      "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT05212025 | Adavosertib ã€ ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
      "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© ã€ Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ ã€ é“‚è€è¯æ€§åµå·¢ç™Œ ã€ è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
      "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ ã€ åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ ã€ è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
      "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
      "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| CTR20211986 | Azenosertib | åµå·¢ç™Œ ã€ è…¹è†œç™Œ ã€ è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
      "| NCT04959266 | ä¼Šæ›²åº·å”‘ã€å¥¥ç¾æ‹‰å”‘ ã€Adavosertib ã€ åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ ã€ æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
      "\n",
      "\n",
      "æ¥æºï¼š[PharmaOne](http://pharma1.pharmadl.test/)\n",
      "---\n",
      "\n",
      "Here's a summary of recent clinical trial results involving Adavosertib (AZD1775) in combination therapies, with a focus on 2024 and 2025: \n",
      "\n",
      " **Adavosertib (AZD1775) as a single agent:** \n",
      "\n",
      " *   A Phase II trial (NCT03284385) evaluated adavosertib in solid tumor malignancies with a SETD2 mutation [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).  No objective responses were observed [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). Minor tumor regressions were seen in 4/18 patients, and stable disease was the best response in 10/18 patients [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). The most common adverse events were nausea, anemia, diarrhea, and neutropenia [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0). The study concluded that adavosertib monotherapy had limited clinical activity in patients with SETD2-altered solid tumors [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "\n",
      " *   Another study noted limited clinical activity with single-agent adavosertib in genomically unselected patient populations, which is consistent with prior results of this agent and other single-agent WEE1 inhibitors [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-0).\n",
      "\n",
      " *   However, adavosertib monotherapy has demonstrated a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification, especially in epithelial ovarian cancer [ascopubs](https://vertexaisearch.cloud.google.com/id/3-1).\n",
      "\n",
      " **Adavosertib in Combination Therapy:** \n",
      "\n",
      " *   **Squamous Cell Lung Cancer (SqCLC):** A phase II trial combined adavosertib with carboplatin and paclitaxel in patients with advanced/metastatic SqCLC [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The median progression-free survival (PFS) was 4.8 months, and the median overall survival (OS) was 7.3 months [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The disease control rate (DCR) was 60.9% [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The most common adverse events were fatigue, diarrhea, and nausea [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2). The study met its primary endpoint with the combination of adavosertib with carboplatin and paclitaxel [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2).\n",
      "\n",
      " *   **Pediatric Cancers:** A Phase I/II study (AcSÃ©-ESMART Arm C) investigated adavosertib in combination with carboplatin in children and young adults with recurrent/refractory malignancies. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) The combination exhibited significant hematologic toxicity. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) The overall response rate was 11%, with partial responses in 2 patients with neuroblastoma. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4) Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA-damaging therapy in molecularly enriched pediatric cancers. [aacrjournals](https://vertexaisearch.cloud.google.com/id/3-3) [nih](https://vertexaisearch.cloud.google.com/id/3-4)\n",
      "\n",
      " *   **Gynecological Cancers:** A phase I study evaluated adavosertib with chemoradiation in cervical, upper vaginal, and uterine cancers. [nih](https://vertexaisearch.cloud.google.com/id/3-5) The recommended phase II dose could not be determined due to clinical toxicity. [nih](https://vertexaisearch.cloud.google.com/id/3-5) The overall response rate at 4 months was 71.4%, including four complete responses. [nih](https://vertexaisearch.cloud.google.com/id/3-5)\n",
      "\n",
      " *   **Advanced Solid Tumors:** An open-label, multicenter, phase I study is assessing the safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. [ascopubs](https://vertexaisearch.cloud.google.com/id/3-2)\n",
      "\n",
      " **Ongoing Research:** \n",
      "\n",
      " *   A Phase 2 study is investigating adavosertib in women with recurrent or persistent uterine serous carcinoma or uterine carcinosarcoma. [dana-farber](https://vertexaisearch.cloud.google.com/id/3-6)\n",
      "\n",
      "---\n",
      "\n",
      "Several clinical trials are exploring the combination of WEE1, ATR, and PARP inhibitors in cancer therapy [mdpi](https://vertexaisearch.cloud.google.com/id/4-0) [nih](https://vertexaisearch.cloud.google.com/id/4-1). These combinations aim to overcome PARP inhibitor resistance, particularly in ovarian cancer and other solid tumors with DNA damage repair (DDR) alterations [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "\n",
      "**WEE1 Inhibitors:**\n",
      "\n",
      "*   WEE1 kinase is crucial for cell cycle checkpoint arrest in the S and G2 phases [nih](https://vertexaisearch.cloud.google.com/id/4-2) [researchgate](https://vertexaisearch.cloud.google.com/id/4-5). Inhibiting WEE1 can inactivate the G2/M checkpoint, leading to irreparable DNA damage and apoptosis, especially in tumor cells with G1/S phase checkpoint inactivation [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   Adavosertib, a WEE1 inhibitor, has shown clinical efficacy in combination with olaparib in PARPi-resistant ovarian cancer [nih](https://vertexaisearch.cloud.google.com/id/4-2). It is also used with gemcitabine for platinum-resistant or -refractory recurrent ovarian cancer [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   However, WEE1 inhibitors like adavosertib can have safety issues due to low selectivity and off-target effects [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "\n",
      "**ATR Inhibitors:**\n",
      "\n",
      "*   ATR kinase regulates cellular processes, including cell cycle arrest and replication fork initiation [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3) [nih](https://vertexaisearch.cloud.google.com/id/4-2).\n",
      "*   Combining PARP inhibitors with ATR inhibitors can prevent recovery from PARP inhibitor-induced DNA damage, leading to cell death [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4). This combination has shown promise in delaying and overcoming acquired PARP inhibitor resistance in preclinical studies [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   Clinical trials are assessing the efficacy of ATR inhibitors in combination with PARP inhibitors [nih](https://vertexaisearch.cloud.google.com/id/4-1). The combination of PARPi-ATRi enhances anti-cancer effects in ATM-deficient cancer cells by promoting genome instability and cell death [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "\n",
      "**Clinical Trials and Studies:**\n",
      "\n",
      "*   Early-phase trials have tested the safety and efficacy of PARP inhibition plus ATR inhibition in patients with relapsed or refractory solid tumors with DDR alterations [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   The TRESR trial tested camonsertib (ATR inhibitor) plus talazoparib (PARP inhibitor), and the ATTACC trial tested camonsertib plus niraparib or olaparib [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4). These combinations appeared safe with manageable hematologic adverse effects and showed responses across multiple tumor types [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   The ATARI trial (ENGOT/GYN1/NCRI) is a phase 2 study assessing ceralasertib (ATR inhibitor) alone and in combination with olaparib in patients with gynecologic tumors [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "*   A Phase 2 umbrella trial (NCT04298021) is investigating the combination of AZD6738 (ATR inhibitor) with Durvalumab or Olaparib in patients with advanced biliary tract cancer [nih](https://vertexaisearch.cloud.google.com/id/4-1).\n",
      "*   Combinations of ATR, Chk1, and Wee1 inhibitors with olaparib have shown synergistic effects in both PARP-sensitive and resistant cell lines, regardless of HR status [mdpi](https://vertexaisearch.cloud.google.com/id/4-0).\n",
      "\n",
      "**Challenges and Future Directions:**\n",
      "\n",
      "*   Further studies are needed to determine the potential off-target effects and efficacy of WEE1 inhibitors in clinical practice [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   Maintaining the efficacy of inhibitors while controlling the balance between WEE1 kinase inhibitors and other drugs to deliver maximum benefits to patients remains a challenge [nih](https://vertexaisearch.cloud.google.com/id/4-2) [cancerbiomed](https://vertexaisearch.cloud.google.com/id/4-3).\n",
      "*   Identifying predictive biomarkers and selecting appropriate patient populations for these combination therapies is crucial [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "*   Further investigation is warranted in biomarker-selected populations, especially in platinum-resistant ovarian cancer [oncologynewscentral](https://vertexaisearch.cloud.google.com/id/4-4).\n",
      "\n",
      "2025-11-21 14:42:59 [INFO] agent.graph - ğŸš€==============================END=================================ğŸš€\n"
     ]
    }
   ],
   "source": [
    "from agent.graph import graph\n",
    "\n",
    "state = graph.invoke({\"messages\": [{\"role\": \"user\", \"content\": \"\"\"WEE1é¶ç‚¹ç®¡çº¿è°ƒç ”\"\"\"}], \"max_research_loops\": 3, \"initial_search_query_count\": 3})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'messages': [HumanMessage(content='Who won the euro 2024', additional_kwargs={}, response_metadata={}, id='4b0ccc12-2e74-4a55-a85e-c512e7867c26'),\n",
       "  AIMessage(content=\"Spain won the UEFA Euro 2024 tournament [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL).\\n\\nIn the final match held in Berlin, Germany, Spain defeated England 2-1 [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL). Nico Williams scored the opening goal for Spain, and Mikel Oyarzabal scored the winning goal [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz). Cole Palmer scored England's only goal [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz).\\n\\nThis victory marked Spain's record fourth European Championship title [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL). Spain achieved this by winning all seven of their matches throughout the tournament [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgwKo5lPes5M_GObnkYEzn3QYn1kpTQpx42ANaNqvNMgRsB1Xp2TIXI82SYTSYuLd9ysgKfmlJJy3lcLxrmNBg1R_Z37PCO9vbqIBIbw6DKqMif7pHdtDTS7FUq69c29hkYb_b5w==) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL) [newsbytesapp](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s=).\\n\\nKey individual awards for the tournament went to Spain's players: Rodri was named the Best Player, and Lamine Yamal was named the Best Young Player [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==0) [bet9ja](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q==) [beinsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA==) [thehindu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw==).\", additional_kwargs={}, response_metadata={}, id='4c4aa673-391d-48b2-954a-9fcb7053c634')],\n",
       " 'search_query': ['Euro 2024 winner',\n",
       "  \"What were Spain's key team performance statistics throughout Euro 2024?\",\n",
       "  'What specific stats or performances led to Rodri being named Euro 2024 Best Player?',\n",
       "  'What specific stats or performances led to Lamine Yamal being named Euro 2024 Best Young Player?'],\n",
       " 'web_research_result': [\"Spain won the UEFA Euro 2024, securing their record fourth title [youtube](https://vertexaisearch.cloud.google.com/id/0-0) [aljazeera](https://vertexaisearch.cloud.google.com/id/0-1) [foxsports](https://vertexaisearch.cloud.google.com/id/0-2) [wikipedia](https://vertexaisearch.cloud.google.com/id/0-3) [youtube](https://vertexaisearch.cloud.google.com/id/0-4) [uefa](https://vertexaisearch.cloud.google.com/id/0-5). The final match was held in Berlin, Germany, where Spain defeated England 2-1 [olympics](https://vertexaisearch.cloud.google.com/id/0-6) [aljazeera](https://vertexaisearch.cloud.google.com/id/0-1) [foxsports](https://vertexaisearch.cloud.google.com/id/0-2). Spain's Nico Williams scored the opening goal, and Mikel Oyarzabal scored the winning goal [youtube](https://vertexaisearch.cloud.google.com/id/0-0) [aljazeera](https://vertexaisearch.cloud.google.com/id/0-1) [foxsports](https://vertexaisearch.cloud.google.com/id/0-2). England's Cole Palmer scored their lone goal [olympics](https://vertexaisearch.cloud.google.com/id/0-6) [aljazeera](https://vertexaisearch.cloud.google.com/id/0-1) [foxsports](https://vertexaisearch.cloud.google.com/id/0-2).\\n\\nSpain won all seven of their matches in the tournament [youtube](https://vertexaisearch.cloud.google.com/id/0-7) [wikipedia](https://vertexaisearch.cloud.google.com/id/0-3) [youtube](https://vertexaisearch.cloud.google.com/id/0-4) [uefa](https://vertexaisearch.cloud.google.com/id/0-5). In the quarter-finals, Spain defeated Germany 2-1 after extra time [olympics](https://vertexaisearch.cloud.google.com/id/0-6) [wikipedia](https://vertexaisearch.cloud.google.com/id/0-3). In the semi-finals, Spain beat France 2-1 [olympics](https://vertexaisearch.cloud.google.com/id/0-6) [aljazeera](https://vertexaisearch.cloud.google.com/id/0-8) [wikipedia](https://vertexaisearch.cloud.google.com/id/0-3). Lamine Yamal became the youngest player to score in a UEFA European Championship [ndtv](https://vertexaisearch.cloud.google.com/id/0-9) [uefa](https://vertexaisearch.cloud.google.com/id/0-5).\\n\\nThe top scorers of the tournament were Harry Kane, Georges Mikautadze, Jamal Musiala, Cody Gakpo, Ivan Schranz and Dani Olmo, each with 3 goals [wikipedia](https://vertexaisearch.cloud.google.com/id/0-10). Rodri was named best player and Lamine Yamal best young player of the tournament [wikipedia](https://vertexaisearch.cloud.google.com/id/0-10). Luis de la Fuente was the coach who led Spain to victory [transfermarkt](https://vertexaisearch.cloud.google.com/id/0-11).\\n\",\n",
       "  \"Spain won Euro 2024, defeating England 2-1 in the final to secure their record fourth European Championship [aljazeera](https://vertexaisearch.cloud.google.com/id/1-0) [coachesvoice](https://vertexaisearch.cloud.google.com/id/1-1) [aljazeera](https://vertexaisearch.cloud.google.com/id/1-2) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-3). They won all seven of their matches in the competition [wikipedia](https://vertexaisearch.cloud.google.com/id/1-3).\\n\\nHere's a summary of Spain's key team performance statistics throughout Euro 2024:\\n\\n**General Stats:**\\n\\n*   **Goals Scored:** Spain scored 15 goals throughout the tournament, setting a new record for most goals in a single European Championship [wikipedia](https://vertexaisearch.cloud.google.com/id/1-3). They scored 13 goals before the final [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5).\\n*   **Goals Conceded:** Spain conceded only three goals in the tournament [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5).\\n*   **Wins:** Spain had a 100% win record in Euro 2024 [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5). They won all six of their matches leading up to the final [aljazeera](https://vertexaisearch.cloud.google.com/id/1-2) [sportsmole](https://vertexaisearch.cloud.google.com/id/1-6).\\n*   **Clean Sheets:** Spain had three clean sheets in Euro 2024 [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [thehindu](https://vertexaisearch.cloud.google.com/id/1-7).\\n*   **Possession:** Spain averaged 57.3% possession during the tournament [thehindu](https://vertexaisearch.cloud.google.com/id/1-4). They often maintained possession for over 65% of their matches [spanishprofootball](https://vertexaisearch.cloud.google.com/id/1-8).\\n*   **Passing Accuracy:** Spain had a passing accuracy of 90% [thehindu](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Ball Recoveries:** Spain led the tournament in ball recoveries with 255 [thehindu](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Shots:** Spain had 80 shots (excluding blocks), with 38 on target [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5). They had the most attempts in Euro 2024, with 108, 37 of which were on target [thehindu](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Chances Created:** Spain created 85 chances [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5).\\n*   **Tackles:** Spain made 92 tackles [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5).\\n\\n**Team Composition and Tactics:**\\n\\n*   The squad featured a blend of experienced players and young talents [totalfootballanalysis](https://vertexaisearch.cloud.google.com/id/1-9).\\n*   Luis de la Fuente employed multifaceted tactics, adapting to different opponents [totalfootballanalysis](https://vertexaisearch.cloud.google.com/id/1-10).\\n*   Spain dominated possession and controlled the tempo of matches [spanishprofootball](https://vertexaisearch.cloud.google.com/id/1-8).\\n*   They utilized a high pressing strategy and quick recovery [spanishprofootball](https://vertexaisearch.cloud.google.com/id/1-8).\\n*   Fluid midfield dynamics were powered by players like Pedri, Rodri, and Gavi [spanishprofootball](https://vertexaisearch.cloud.google.com/id/1-8).\\n\\n**Individual Player Stats:**\\n\\n*   **Dani Olmo:** Joint leading goal scorer with three goals [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5). He also provided two assists [newsbytesapp](https://vertexaisearch.cloud.google.com/id/1-5).\\n*   **Lamine Yamal:** Joint assist leader with three assists [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [thehindu](https://vertexaisearch.cloud.google.com/id/1-7). He also became the youngest-ever Euros scorer [sportsmole](https://vertexaisearch.cloud.google.com/id/1-6) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-3).\\n*   **Rodri:** Completed the most passes for Spain [thehindu](https://vertexaisearch.cloud.google.com/id/1-4) [thehindu](https://vertexaisearch.cloud.google.com/id/1-7).\\n*   **Aymeric Laporte:** Recovered the ball the most number of times for Spain defensively [thehindu](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Unai Simon:** Conceded three goals and made 12 saves in five matches [thehindu](https://vertexaisearch.cloud.google.com/id/1-4).\\n*   **Nico Williams:** Named Man of the Match in the final [wikipedia](https://vertexaisearch.cloud.google.com/id/1-3).\\n\\nSpain's coach, Luis de la Fuente, emphasized versatility, pace on the wings, control in the middle, and a solid defense as key to their balance [coachesvoice](https://vertexaisearch.cloud.google.com/id/1-1).\\n\",\n",
       "  'Rodri was named Euro 2024 Best Player due to his consistent and brilliant performances throughout the tournament [bet9ja](https://vertexaisearch.cloud.google.com/id/2-0). He was the centerpiece of Spain\\'s midfield, playing a crucial role in nearly every game [europeanchampionship2024](https://vertexaisearch.cloud.google.com/id/2-1). Here\\'s a breakdown of the specific stats and performances that led to the award:\\n\\n*   **Key Role in Spain\\'s Victories:** Rodri played a crucial role in Spain\\'s victories over Germany and France [bet9ja](https://vertexaisearch.cloud.google.com/id/2-0).\\n*   **Midfield Dominance:** Rodri\\'s consistent presence in midfield was pivotal for Spain [europeanchampionship2024](https://vertexaisearch.cloud.google.com/id/2-1).\\n*   **Only Goal:** He scored a goal in Spain\\'s 4-1 win over Georgia in the Last 16 [indiatimes](https://vertexaisearch.cloud.google.com/id/2-2) [bet9ja](https://vertexaisearch.cloud.google.com/id/2-0).\\n*   **Passing Accuracy:** Rodri had a remarkable passing accuracy of 92.84% [uefa](https://vertexaisearch.cloud.google.com/id/2-3) [mancity](https://vertexaisearch.cloud.google.com/id/2-4) [uefa](https://vertexaisearch.cloud.google.com/id/2-5). Only Aymeric Laporte completed more passes for Spain with 411 passes [mancity](https://vertexaisearch.cloud.google.com/id/2-4).\\n*   **Ball Recoveries:** Rodri was also pivotal when out of possession, with just one other midfielder registering more ball recoveries than the Spaniard\\'s 33 [mancity](https://vertexaisearch.cloud.google.com/id/2-4).\\n*   **Leadership:** He led his team with distinction [europeanchampionship2024](https://vertexaisearch.cloud.google.com/id/2-1). Rodri\\'s leadership on the field helped integrate young talents [bet9ja](https://vertexaisearch.cloud.google.com/id/2-0).\\n*   **Strategic Rest:** He started in six of Spain\\'s seven matches, only sitting out the final group stage game against Slovakia, which Spain won 1-0. This strategic rest allowed Rodri to stay fresh for the knockout stages [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Calmness Under Pressure:** Rodri\\'s calmness under pressure was a recurring theme throughout the tournament [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Dictating Tempo:** His ability to dictate the tempo of the game, coupled with his defensive prowess, made Rodri indispensable [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Orchestration:** Rodri\\'s orchestration was crucial in maintaining possession and preventing Germany from gaining momentum in the quarter-final [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Midfield Control:** His performance against France in the semi-finals was another masterclass in midfield control [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Composure and Strategic Thinking:** Rodri\\'s composure and strategic thinking brought a sense of reliability to Spain\\'s gameplay [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n*   **Impact in the Final:** Despite his early exit due to a hamstring injury in the final against England, Rodri\\'s presence in the first half helped Spain establish control and set the tone for the rest of the match [upthrust](https://vertexaisearch.cloud.google.com/id/2-6).\\n\\nLuis de la Fuente, the coach of the Spanish team, described Rodri as a \"perfect computer\" due to his precise passing and exceptional understanding of the game [indiatimes](https://vertexaisearch.cloud.google.com/id/2-2) [bet9ja](https://vertexaisearch.cloud.google.com/id/2-0). UEFA\\'s team of technical observers at EURO 2024 also recognized Rodri\\'s influence in central midfield [uefa](https://vertexaisearch.cloud.google.com/id/2-7).\\n',\n",
       "  \"Lamine Yamal was named Euro 2024 Young Player of the Tournament due to several outstanding achievements [uefa](https://vertexaisearch.cloud.google.com/id/3-0) [beinsports](https://vertexaisearch.cloud.google.com/id/3-1) [thehindu](https://vertexaisearch.cloud.google.com/id/3-2). He played in all seven of Spain's Euro 2024 matches, starting in six of them [uefa](https://vertexaisearch.cloud.google.com/id/3-0). He became the youngest player ever to play in the tournament when he started against Croatia at 16 years, 338 days old [uefa](https://vertexaisearch.cloud.google.com/id/3-0) [uefa](https://vertexaisearch.cloud.google.com/id/3-3). In the semi-final against France, he scored a remarkable goal, making him the youngest goalscorer in Euros history at 16 years, 362 days [wikipedia](https://vertexaisearch.cloud.google.com/id/3-4) [uefa](https://vertexaisearch.cloud.google.com/id/3-0) [uefa](https://vertexaisearch.cloud.google.com/id/3-3) [beinsports](https://vertexaisearch.cloud.google.com/id/3-1) [thehindu](https://vertexaisearch.cloud.google.com/id/3-2). Furthermore, he provided four assists during the tournament [wikipedia](https://vertexaisearch.cloud.google.com/id/3-4) [thehindu](https://vertexaisearch.cloud.google.com/id/3-5) [beinsports](https://vertexaisearch.cloud.google.com/id/3-1). In the final, he set up the opening goal against England [uefa](https://vertexaisearch.cloud.google.com/id/3-0).\\n\\nKey statistics from the tournament include [uefa](https://vertexaisearch.cloud.google.com/id/3-6) [uefa](https://vertexaisearch.cloud.google.com/id/3-7):\\n*   7 Matches played\\n*   507 Minutes played\\n*   1 Goal\\n*   4 Assists\\n\\nThese performances led to Yamal receiving the Euro 2024 Young Player of the Tournament award [uefa](https://vertexaisearch.cloud.google.com/id/3-0) [beinsports](https://vertexaisearch.cloud.google.com/id/3-1) [thehindu](https://vertexaisearch.cloud.google.com/id/3-2).\\n\"],\n",
       " 'sources_gathered': [{'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q=='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig=='},\n",
       "  {'label': 'foxsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP'},\n",
       "  {'label': 'olympics',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe'},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig=='},\n",
       "  {'label': 'foxsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q=='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig=='},\n",
       "  {'label': 'foxsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz'},\n",
       "  {'label': 'olympics',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe'},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig=='},\n",
       "  {'label': 'foxsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgwKo5lPes5M_GObnkYEzn3QYn1kpTQpx42ANaNqvNMgRsB1Xp2TIXI82SYTSYuLd9ysgKfmlJJy3lcLxrmNBg1R_Z37PCO9vbqIBIbw6DKqMif7pHdtDTS7FUq69c29hkYb_b5w=='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP'},\n",
       "  {'label': 'olympics',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o='},\n",
       "  {'label': 'olympics',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe'},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFdu_dxqteuc9vM3oGH5WgEnFuOA6vlmbqof-iVRg2OviD2jzkp1jlCRsWkLfb64cK8TJ_g5jKKfZgmaMCk4LA-E2zjYGBfmsWiHdwfSg5Zv3VDMngM3HxT-VLjWYdBdpvpcBTj9VNRkqSCAjGVL9ar0VAOF0uRF6Z96LFz7G9KCSL50llqG7XLpbXmQTFIV4FUsffI8aQG9KKmIaZ1eGqeWQl2xaaRu6-Pwzqxizg8'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o='},\n",
       "  {'label': 'ndtv',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFRRH83ij2MgKWwrGFVWMaFDAT0_GKCFdwVIjaYn7DOoBlxXCGR-Y2RTw9AdKH8dYuhXxSxUTaZNXOBac2nknNZpdmwJiGIj51H6lRWREPUPOiKQkfVPJ0f4ubRSJBLm7_QcAkz4BwzJr3OM06jh-41TbNFZ9t6D7WrbzxmSs7x1O5DCnrPM2OeI6Nc0OhVT0AbeC6f_dTaBR9APlQFDrzIsvDIAn-W5eWuEohDs8w6np0eW65RuhQWrofdY8vFz-bsHgK0J3ew'},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGbyTk6AGj4XMhW66noNoKqe8eCt9-HZUMs6FXsKVyXcMuoG1WLLhBHa9dITcU3zQFJqCzcxPmnu6rj3ZHmJp-n2xdffBtWYFl2pqxmLrEiZONNYLwleA-T8cnaL7gXWfFlJ2jnvB0='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGbyTk6AGj4XMhW66noNoKqe8eCt9-HZUMs6FXsKVyXcMuoG1WLLhBHa9dITcU3zQFJqCzcxPmnu6rj3ZHmJp-n2xdffBtWYFl2pqxmLrEiZONNYLwleA-T8cnaL7gXWfFlJ2jnvB0='},\n",
       "  {'label': 'transfermarkt',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-11',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFMeGs_GRmx0zI6E_xQZfylxykYcTT9MnZlM3ICoa41Pogn4H-1tLirtdPBOrumyI8s_C9i9cBukjUKHxlPfPP49aqTep7xFPgfe2uQFyG37Acsn9RtVv5VenCS5kfPLDQB7sGR-Tyj6wGyiptaTP1uhRnGgYg0u92BW5OH-MY='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co='},\n",
       "  {'label': 'coachesvoice',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv'},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU='},\n",
       "  {'label': 'sportsmole',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEVHkRwlOhx_8CZHVDe9XPE_nCs4XYVbx6aIl19aXGNLZxDpcsK5-hcYvMX_et8vasZtMNzmJNTtVd3Vne666vIkkRFUNJxVSBH9bMoGEFcPMcPoxFMUY5LV1YGZjm3n6xbDrkskawWb9MBS-zIIXiXZk7n6TluCji9k3ur3i5-ZhJcgPtAYU-KyfWRTdN0JY4bJt4tAl87Ba9ZInk9YuRlLlAFJ6flaKI-a4cZSXYDQeERhB742z_heWOhDchdvlPfoJaAuYSKKaABrbZQeZw='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG7_kutwvl9NHZQl-k0Vpvj_1I7o8MCX8jNlw6rYXEOGSC9QcRvzaH9ycR3JQUjJLvUhUSeaR7hmJ-qPTgMSfw9US7uXQzTF3CJ-tXnIVI1UC8VRyJoW6fH2r-MRFd5EI-PS494grt4Xey1x7WsaZ_Q7tRcQgVX_EM0JxQK12s8yYAY3TIUpa1L5fZOmsi6ZKq-jrXYOmIV5OTu2AaleBeQE_Z-B10oU2qin2Q3T8w6LP2ispUlVEh54d5fWLcHlEtskrRHC8psjrarTgqn'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'spanishprofootball',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFG8gCwweIne3MmZpbUnDq24EeYu1w6OpSNeS2U5DtRYUbqRVtIjCnFAOjlXy8XjD8MvbmoNIsRD9rdadJ7tWoyG3T5fj2QvlMdWjCXwpMs7W3D_49AT_d1vWRuu8i_-nAK0WHpo6Wo5abiRpwUyjtFX1rYGXujmwsodi5hUV9Q4Qd1ltJe2cuLhq2cPRU='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'totalfootballanalysis',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGQ6VynwIGq-L7FKFu-L5vh_TzCWZHXL9rXmzI0uuR1Qexwi1jRKOzvfthF3hl-KGOQhdsEC67FoNIH5ojbVkEVCxdDkX73E9DZUv8Vz_GRld1NHm0gm0i7n-KaZ5w72dfptRLWKyKnfY6UZawwFX3OtwTfYQzHd32wv1s4sk0PIUNOj-FdhnWxaYO-PJSC_aZcwpuVrmEgOqXy0Xk='},\n",
       "  {'label': 'totalfootballanalysis',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHYrmUdaz_yH2TIUYp54IQ9PxJYBikelavTVFZ5gy2Up1Kaavkf0zeM14L7mTiuPxGEHjaQjn8mLt3I1HdZH34VrBJn6sZ07KzPCX9Bo7gkM44oroevlhaXZtFG65maD7igABOGLBJjZE0Hg17i3EIGTMVfE-OEn0NN53EhY1pLQObHKWJogrtjbLil0XJOV9Ym5_La7JuWQpKo7IiuPlH-w7N_vJHgTDZOxJMY'},\n",
       "  {'label': 'spanishprofootball',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFG8gCwweIne3MmZpbUnDq24EeYu1w6OpSNeS2U5DtRYUbqRVtIjCnFAOjlXy8XjD8MvbmoNIsRD9rdadJ7tWoyG3T5fj2QvlMdWjCXwpMs7W3D_49AT_d1vWRuu8i_-nAK0WHpo6Wo5abiRpwUyjtFX1rYGXujmwsodi5hUV9Q4Qd1ltJe2cuLhq2cPRU='},\n",
       "  {'label': 'spanishprofootball',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFG8gCwweIne3MmZpbUnDq24EeYu1w6OpSNeS2U5DtRYUbqRVtIjCnFAOjlXy8XjD8MvbmoNIsRD9rdadJ7tWoyG3T5fj2QvlMdWjCXwpMs7W3D_49AT_d1vWRuu8i_-nAK0WHpo6Wo5abiRpwUyjtFX1rYGXujmwsodi5hUV9Q4Qd1ltJe2cuLhq2cPRU='},\n",
       "  {'label': 'spanishprofootball',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFG8gCwweIne3MmZpbUnDq24EeYu1w6OpSNeS2U5DtRYUbqRVtIjCnFAOjlXy8XjD8MvbmoNIsRD9rdadJ7tWoyG3T5fj2QvlMdWjCXwpMs7W3D_49AT_d1vWRuu8i_-nAK0WHpo6Wo5abiRpwUyjtFX1rYGXujmwsodi5hUV9Q4Qd1ltJe2cuLhq2cPRU='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG7_kutwvl9NHZQl-k0Vpvj_1I7o8MCX8jNlw6rYXEOGSC9QcRvzaH9ycR3JQUjJLvUhUSeaR7hmJ-qPTgMSfw9US7uXQzTF3CJ-tXnIVI1UC8VRyJoW6fH2r-MRFd5EI-PS494grt4Xey1x7WsaZ_Q7tRcQgVX_EM0JxQK12s8yYAY3TIUpa1L5fZOmsi6ZKq-jrXYOmIV5OTu2AaleBeQE_Z-B10oU2qin2Q3T8w6LP2ispUlVEh54d5fWLcHlEtskrRHC8psjrarTgqn'},\n",
       "  {'label': 'sportsmole',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEVHkRwlOhx_8CZHVDe9XPE_nCs4XYVbx6aIl19aXGNLZxDpcsK5-hcYvMX_et8vasZtMNzmJNTtVd3Vne666vIkkRFUNJxVSBH9bMoGEFcPMcPoxFMUY5LV1YGZjm3n6xbDrkskawWb9MBS-zIIXiXZk7n6TluCji9k3ur3i5-ZhJcgPtAYU-KyfWRTdN0JY4bJt4tAl87Ba9ZInk9YuRlLlAFJ6flaKI-a4cZSXYDQeERhB742z_heWOhDchdvlPfoJaAuYSKKaABrbZQeZw='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG7_kutwvl9NHZQl-k0Vpvj_1I7o8MCX8jNlw6rYXEOGSC9QcRvzaH9ycR3JQUjJLvUhUSeaR7hmJ-qPTgMSfw9US7uXQzTF3CJ-tXnIVI1UC8VRyJoW6fH2r-MRFd5EI-PS494grt4Xey1x7WsaZ_Q7tRcQgVX_EM0JxQK12s8yYAY3TIUpa1L5fZOmsi6ZKq-jrXYOmIV5OTu2AaleBeQE_Z-B10oU2qin2Q3T8w6LP2ispUlVEh54d5fWLcHlEtskrRHC8psjrarTgqn'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHtzvfIxJ0Lv3W7kqwlmY7CzFQxcbvXZqh4rRp3xBgV1vY01z4BRWA-GFu4INE8yFv9DE-eCib4cYnC-iv_PVgR8yPkBv8uRhI93Yf29MdbDoi_LGu46heOoxRLdMV58jlLI5nr-1sxKdfPutXE_rjuKehCswPGD-9RlbPI8NjyUQ69XAAOjDDhAN-MBxcIt_r3raV86AQfoo1UtYpUoUjhTGVcYBisvHRxv8-XjDjkr65nPm9vdaO7j28yCcokCCeGWv074_AGWeewDQWwczQM'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'coachesvoice',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv'},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'europeanchampionship2024',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGLP8ZiV1gSErFyEW_mBaeUabOdyppbZMUHyMPTq_nC68lIlF28o4vXtvlsLYq7C-ANzy6iwTpWA4ri2fUKevBCGLRotUVZjLX6Au_hnO-mbPGp_Z7nyomkjYhu2iLoPXbmTS8KmWJr8ZAul7j0XQA-S621HaOSBDk0-XBGiKgISgeQb7Tuc-OGj_NMlPQkzK2y4qrs_TBcPgfh5w=='},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'europeanchampionship2024',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGLP8ZiV1gSErFyEW_mBaeUabOdyppbZMUHyMPTq_nC68lIlF28o4vXtvlsLYq7C-ANzy6iwTpWA4ri2fUKevBCGLRotUVZjLX6Au_hnO-mbPGp_Z7nyomkjYhu2iLoPXbmTS8KmWJr8ZAul7j0XQA-S621HaOSBDk0-XBGiKgISgeQb7Tuc-OGj_NMlPQkzK2y4qrs_TBcPgfh5w=='},\n",
       "  {'label': 'indiatimes',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXESZAkHCLh4VxzVLM3prMQrm-sk5x27L8Z70Q4PKkte0vxhTZVZGCY1s5VfC7u5gECHBavdf1DHRCmh77mAaONSIJ78dcaGelojd2Cd5NuJcyQD8juxOERO1zD147S62xcwKy0GZ9Pb64Yj9cPLEx3fDJvTEm4sn013e_e13dTXUQd4m2yHuO72CfsZSbEq-wVsP47O20GMQXLlZov73MCd1uS1eMq9I5cj1QjiIOjiTC484inoCaShm3LTkXA-Jk5L8GvL'},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFG1hC1YkRcN1pqrLp05aZRwvU2gEv7qauPowe-Co8wgi3HfVrNby2N2i7C3--nu8eYku9ak1DQeH8zJX6XRVKe8psOQ02y3nY5TYcHp-Uk3aZay-sGe4bQZJxVKeF5NS2vtG-h09y3TD_5Aox3V9Yh0z1MYKTBE3Q='},\n",
       "  {'label': 'mancity',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFs-OAM9wd4bVstgUzRYVeAqGBbUckmq77-BWTs9IkGYZc-WwzHbZ1khSV8T91YQpZkd8c6vZTke-Wgkf4O1SdhMLwYXVj3SsWViVDOT-eeZPBI5v1BuE1Wb0wg9XGzxOl66-faN_8zKvvdm-KEzx5OfL7ytu0i-cG9AzKpZPgi5HNCuLw8PwcbPPxXB_QE5VSuCC5uYGMJ'},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHlzgFESCAkLrjGTw5ZRNnr68tC-GrAg3iL61UJu3ZT8SJX4HYaFE6qOIR8iNpXpJDUMDnTwIpG6IFrT6NPqAbQCSoj_GIPC-eBrrVrUqA8IdzvncYpRAubOVFFkNVBZGbY64I2FiF6wA-biL0bKFD02adziHempLuyjM5YvnOFDR1r0A=='},\n",
       "  {'label': 'mancity',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFs-OAM9wd4bVstgUzRYVeAqGBbUckmq77-BWTs9IkGYZc-WwzHbZ1khSV8T91YQpZkd8c6vZTke-Wgkf4O1SdhMLwYXVj3SsWViVDOT-eeZPBI5v1BuE1Wb0wg9XGzxOl66-faN_8zKvvdm-KEzx5OfL7ytu0i-cG9AzKpZPgi5HNCuLw8PwcbPPxXB_QE5VSuCC5uYGMJ'},\n",
       "  {'label': 'mancity',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFs-OAM9wd4bVstgUzRYVeAqGBbUckmq77-BWTs9IkGYZc-WwzHbZ1khSV8T91YQpZkd8c6vZTke-Wgkf4O1SdhMLwYXVj3SsWViVDOT-eeZPBI5v1BuE1Wb0wg9XGzxOl66-faN_8zKvvdm-KEzx5OfL7ytu0i-cG9AzKpZPgi5HNCuLw8PwcbPPxXB_QE5VSuCC5uYGMJ'},\n",
       "  {'label': 'europeanchampionship2024',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGLP8ZiV1gSErFyEW_mBaeUabOdyppbZMUHyMPTq_nC68lIlF28o4vXtvlsLYq7C-ANzy6iwTpWA4ri2fUKevBCGLRotUVZjLX6Au_hnO-mbPGp_Z7nyomkjYhu2iLoPXbmTS8KmWJr8ZAul7j0XQA-S621HaOSBDk0-XBGiKgISgeQb7Tuc-OGj_NMlPQkzK2y4qrs_TBcPgfh5w=='},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'upthrust',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGAjXBUZABbe0t7dJcEjK-t1A0Gqoyhqd7tS8SrIRQNiNGFC_prv2xazEc-9Xd7vH1V9PgjWB5k8TBWcxtRc8Z2ZHRS3i6cwhdKxLswfDAFFuamfuITm699F648K4tmBYZABT6neMReI4c4sINJAEKqrn6hNzZZjtTt44X78i2dTIOQe74qvl9ofmwm6Q=='},\n",
       "  {'label': 'indiatimes',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXESZAkHCLh4VxzVLM3prMQrm-sk5x27L8Z70Q4PKkte0vxhTZVZGCY1s5VfC7u5gECHBavdf1DHRCmh77mAaONSIJ78dcaGelojd2Cd5NuJcyQD8juxOERO1zD147S62xcwKy0GZ9Pb64Yj9cPLEx3fDJvTEm4sn013e_e13dTXUQd4m2yHuO72CfsZSbEq-wVsP47O20GMQXLlZov73MCd1uS1eMq9I5cj1QjiIOjiTC484inoCaShm3LTkXA-Jk5L8GvL'},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHcZMzOblU6pNw1gc0QlnRNhCK5VfMY4bW1wPz51w6-AyhvvZnyXcfFxJd4JPdnEfEPD0GB5vHPql6jFppUeKKRysRvwpwaTwaDyFAkvRGab-UAPOOUuK72HsYGrlGVEUHLO6mkzthFd_p8HUaj_JJqlhIaQOuosrZ2y7vf9ouEvd10Uh-rBOqmPRclpkcg3o3WpHhgBY5xNUPEw22V45KhXrqiQhUn5ZSKw3TcsGjla-vA'},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'beinsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA=='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGIh15GjQTH5sloOsTsyL7xu4UxiL1iUhCOmOYuQn2I3oTzOmC8I6vpqG7puUq20dPwFWNyGzUT1m4eiDf3XTrvfO-BRbRz80it26jo1H0Wq6Dr8jI2xYQbW8suUGcHTE6aT6FUa57v2oHiBP2yTBe4FyTP3w-us4RhdAgxy32VvGJhczpHTp36FWBtxK-ESh5KTcPHflNroQkKP0rE17DLYrMfoQVNGf41jeTM2YCvoSeymtFHc-wvySulmtIFlQ=='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGEIQE8ljNdOpLHYgNFDjPekNZfDVP_W7aAbZgzTSgSraVNbalzctN2llZ3do9v9r7sRqxOXioKpebZrVCBnux58qbMLK8wpc4MmOKDRG3bAD8hwE7xMl_InBIfHuIMbuZ_twEC'},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGIh15GjQTH5sloOsTsyL7xu4UxiL1iUhCOmOYuQn2I3oTzOmC8I6vpqG7puUq20dPwFWNyGzUT1m4eiDf3XTrvfO-BRbRz80it26jo1H0Wq6Dr8jI2xYQbW8suUGcHTE6aT6FUa57v2oHiBP2yTBe4FyTP3w-us4RhdAgxy32VvGJhczpHTp36FWBtxK-ESh5KTcPHflNroQkKP0rE17DLYrMfoQVNGf41jeTM2YCvoSeymtFHc-wvySulmtIFlQ=='},\n",
       "  {'label': 'beinsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA=='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw=='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGEIQE8ljNdOpLHYgNFDjPekNZfDVP_W7aAbZgzTSgSraVNbalzctN2llZ3do9v9r7sRqxOXioKpebZrVCBnux58qbMLK8wpc4MmOKDRG3bAD8hwE7xMl_InBIfHuIMbuZ_twEC'},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEMtKj653gIrpD8CpAaGVkViYwCyEhmCj8w_zAO27Y874XFgkkvvuoVtNU8EXpJiVPDKnShMChgFWK7PnBV3QvbRcOYN268OM1yuPY9DK17q4-9-oGuqw_TYIaEECQxe5JpzVXGBtNidMqlMxM902_iqlm5wQnzMjMO8Vuqj5V3MdMdYj9O_rde6dkewGJFWGMZvPHAySCCMoZPoERD5ErPcaRjpyFQp7VjKoUWvG-mBQkBEn7NP93nxb49ZKVqpt_JhQPlk2HTq-yVyXxh_loL1JE6'},\n",
       "  {'label': 'beinsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXH4pOTdyyQxNadaQjyKh8oQuOvZAoJv3h8lUaUpf_DBGcg11x3NZ3be0osuI4NKZmKmtGvI4IXelQLdf0gHIZB2h6x13iHVuz5kCoohIkFmaL2HaKjkQlzZw3KDIAr8j3KoVbWNXnx34wDW2qtFTmECR6UBkLFiy0VEjcYwowJ_8ex10JM14KzcvA=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXE1pV-r8eRyTFjoRu12FcAetb5Lb1qPrl-GdPkb649C5b4zo99jtjYGI4y5B2EiF6SE413Ct9omXh3NwD0-r8rGqOMROSYEsfwUaFafM10vFtJGs_eWVcMMLVqgqNELj9BrG4JeBEHbYjDRSlCmVMQcWbIHC28goFDBa-dqi3Q='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'beinsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA=='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw=='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q=='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig=='},\n",
       "  {'label': 'foxsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz'},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o='},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP'},\n",
       "  {'label': 'olympics',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe'},\n",
       "  {'label': 'youtube',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgwKo5lPes5M_GObnkYEzn3QYn1kpTQpx42ANaNqvNMgRsB1Xp2TIXI82SYTSYuLd9ysgKfmlJJy3lcLxrmNBg1R_Z37PCO9vbqIBIbw6DKqMif7pHdtDTS7FUq69c29hkYb_b5w=='},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co='},\n",
       "  {'label': 'coachesvoice',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv'},\n",
       "  {'label': 'aljazeera',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU='},\n",
       "  {'label': 'wikipedia',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL'},\n",
       "  {'label': 'newsbytesapp',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s='},\n",
       "  {'label': 'bet9ja',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/2-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA=='},\n",
       "  {'label': 'uefa',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-0',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q=='},\n",
       "  {'label': 'beinsports',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-1',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA=='},\n",
       "  {'label': 'thehindu',\n",
       "   'short_url': 'https://vertexaisearch.cloud.google.com/id/3-2',\n",
       "   'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw=='}],\n",
       " 'initial_search_query_count': 3,\n",
       " 'max_research_loops': 3,\n",
       " 'research_loop_count': 2}"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "state"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Spain won the UEFA Euro 2024 tournament [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL).\n",
       "\n",
       "In the final match held in Berlin, Germany, Spain defeated England 2-1 [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL). Nico Williams scored the opening goal for Spain, and Mikel Oyarzabal scored the winning goal [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz). Cole Palmer scored England's only goal [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFARil0pwjYQuFrDObawlDzu-eVtUPC4_nINjcXT-mlTL3MDgVPI83UB8gWS1rzGZkaMEmAUIeAzo2ihpMXUsWibzVzeAdQ7nUyqAOq0En87kpfuISduBuWI3__7yJw-vmdApD56-_G2ZhhZC4d_ll2iyNBaZHxxdNqXbb76mUiq99xV0hdoPEkp9RLk7T-uYYfTYXa8oYCXy2ysa9SZDa9hffEHrVe) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz).\n",
       "\n",
       "This victory marked Spain's record fourth European Championship title [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGFcidniPKtBR-_QjSR1P1Oathq_0T9FTwfpCAWZxbXsroItHQU8zRcyOPDgMcvsWoD2fEnwYFKwanV18ep2_cyS5BlHF6-OFNsijWb-peAgsgLAVRiubekRnzMugsYtiWrhZyO3Q==) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHh_4hBL0Giyuw_cyfT8m7tUSnMqBqH4Lis1CtJICPJNGGLhT6PADTIoUtrj3Rl5qcKNE9T6rzOmedAER_gxJOBDrCF8pnr9lUvhYvmDJxYCJzELkE5rTap4dx6FzOIKZKm1QBp5aHXzd_LCkSTV9ag7Q1A6_t8Vjdbskch6ZG3BoIfjYDQSPgRKDNFAAwt5J07cVFV5pDQzggmM7pxwsUz4drz) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFY5CRvcfjdkBz3h8Md_PscguyZ7LtYrxeHHP3eagcmIOnjaMyZbOHFqUAsa2cgkwvb26FZTvGiRgLKNLfiAsH1oP-5kGwnL6Ejhm4ZXhWGg0R3yE_8zkIKde4RgjIXlBvQW4kZ-LI5yhag-ESoh771z6hob8AigAVXT7WeWABMlQNfcbyG_UZIkqAs18U5e6to44ruNbSyDIyd5gobsVpEmdU256oVxa9d7co=) [coachesvoice](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHxgpkZWF64tZ8-iypkI2fiFi2cpsj4AFjZXkcYUzf5hSOWYb5etIbCoZd_L6zDJi6mWWisxAO6T5V4T8H7XiRow6dmVqXpSEIKhPSdG0HAQbQK74lwxeV_uXx9fSPllIKPOs2tFNRqTuHdJBNcwpcJp6MJbVLEskyhYnWlyOd9ouQv) [aljazeera](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEV-g6Hxxcan5Xre1yYGM3BtP3fo9uF2zHQ9sVeK_4poD-aBN5CRvhz471beYCC26wdrjhtbiCvDT9dAnPI-ruyqJZhwB3vbKS5HCFb9tPn7Dkj99LpjLXqYyuzbFGsHCbr5SCHoMEhNg--dMU7xB5TiH8HeqKH8B4lk_h00dqhEVQFb05w5TuLtbX1UdXN6NDzHlFN_xyXzOU=) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL). Spain achieved this by winning all seven of their matches throughout the tournament [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgwKo5lPes5M_GObnkYEzn3QYn1kpTQpx42ANaNqvNMgRsB1Xp2TIXI82SYTSYuLd9ysgKfmlJJy3lcLxrmNBg1R_Z37PCO9vbqIBIbw6DKqMif7pHdtDTS7FUq69c29hkYb_b5w==) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGd9ZQky3X7RQLbTs6mY1i4Pg7ppcI5H_vtxpvQPiEyD8Qw0f7hjvn3QeoOeAVcCG_pEt5Aeu8ofWCgjwQy4_u6qU-NOOJsYPWOW94XcvtkmKiv46vbNkJF-Mb4OpvBztrDa28BfIdCGHdfF9o=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZc-qDhRx_v3mPelXEfAVmWCpNTa_rzUKundc0pRc7PlTgppymao-_wO7O1oPaAhJYLcZkazIg8T5jA6t9OGgOxUd_Vl88BjouHsot0OK8TlM5hmPf4ECMWGeJthqVwndE3h4wdQ==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG1Lj9FnmuckfU0k1NC_ThQBZVxFCppp4tPl4FCcM3JZGF9aPvn9ZNFUo0fLfqw4Adt63Cdv8thcFSbsBRcf3rj1sz4LALJvrGfh6OayGo0KJ-UEKmKoOz8cxj5nIILCzKjFh2_0ZgTwrf1pkhhYbnWqj2E8hrVN4S5_sxvlCpLXPxjTsE4R0gYKXH_utqqm1NBkpl3p-C9v6kz-zm6V-JJoePAppIXFICF0DMYjOIBA9Mj0z4yO9Y9Tdgx2oaP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFNtaBQTFVnSbEW5Bbo8LUIs0h5cv4Pc4aS6Q8qG7jIMCsJPKy5_o6R8x7Z_xQ7AuDEAFlj2JY_AVV1YpwLqtXZxiAyvpfboH_VuMpo6MVbQAu2ZASSSD2slWaIqsUGkTEaPa2z2809z7UhEWUL) [newsbytesapp](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIl5Xc3f44I1nYw_YrJqkByrRl20SiAopZqjfJIK6U62o27CrxLvxaJ4v1M7L5eOfTMMlBCHHYCUooPoG0aObaeRG3YxrcoFT7Xtd4KIrvCS6AWWRpOZasCW-sGtFA56DEDf-qbJ8lsXEJ4GQ386iGTdRkyK9EtJWw1mRpDu7dfPQ6Qy1hNIqTgTdo-3yq1WNmWEl8Xtnag0s=).\n",
       "\n",
       "Key individual awards for the tournament went to Spain's players: Rodri was named the Best Player, and Lamine Yamal was named the Best Young Player [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEk7ApC7Y41UOrTWJ40wP2rsT0VDxqhqF-WJEI-FNKW7SNpR7LoA22sRQecS8hZNeZ_-62Vh7X75RmcmZUtnAOuQunrLAsETkkSx5l75dt9ESgTRkIURwtu4Pew7hn8yFz_LY_FJXUpmRfoWP7MWrDfPHcKrOpfmKqONj6mJcASNvAfCZ0p6qK3K4PvKWye6NyBMyYxWCuJig==0) [bet9ja](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFgj0MP_IEmC842xTfmMPnbybBGYTUb_wEpwJ58keX5x_qPfUmC7Zz0o6IQeQ8TEqoRpv-Uq6oOqfbazu_aP0fMhP7UrSln6rB4SRvCRC327tM1LNaXpiXN-h6xlg0TN_-AWQORV4PSH7G5u2qD_NaNEWkz_oaEHxj22-qOam52fwRvqISOdoFDNTptlM6t0BbhcA==) [uefa](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGKGygrv0aVjWa7JUdwqtuttcPxVIiVFb2_Mxv32q-4AyOVwd8oMKLXq6sl2kw4A37lHLmUUQYqVfDMkX3DLXr4or1Xpx1lnOpIUanPjOtrr2Hk6tPPc0308hdE0xJ5CClC220Tz30xD6538_DOvrVWqfA7pV7x651519Zz37wgqYhN00Ah3LX4QZnW981_-SM8tjVSLDXutPphZBXXmMehNgUynvNd2IiGB9UtkLyGeWINIqR2F7lejStuXJ8U2Q==) [beinsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXExRli0zGmQZlemPPItRH3qShabB-QVHrgUAECeXIs3GUKgd2oIHd45-ULY--TosnkRkiM-XHqZlPxeQlOV6Ktgxb-L5r9Hhf8M-nQS_T0N7NK0BeynreRZtFivuKzwwOByq6uALzoVtombjsREMmsPG7s07CMlMrQjyJCVX8McNdnGC7-mdlHEjdfXN4sgi-YGxdxCdAxaHUaMQxPL0GUUmqDzMMpzVC_lRnrYfuk17UhXI9QhsEi3TMeuUgHu3kl16g1mHA==) [thehindu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAlCtejIOwzHPUOAXi7oLu469wYzGUJN86oxtrB6YCAHKAocfkxog6XZeXOUjAl9MTY2_jU5igYEOpyy5RZV2jhxGHtahvQGi8Bq0XkJmaFvludGqwpuBn-vFf-MR3As1CXu9GZNh0TW5f3eLPgvDjB6N3IoYaGhGT8BUiqSyZS6k41T-vL9h6fEFMoOFUYhG2S0AfuVZDuyF2nJHJP1WVWZS42csWXEJUDxqhYjyzmx33HaCxKk0Rbe3_Ovc_Kgdagw==)."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from IPython.display import Markdown\n",
    "\n",
    "Markdown(state[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "state = graph.invoke({\"messages\": state[\"messages\"] + [{\"role\": \"user\", \"content\": \"How has the most titles? List the top 5\"}]})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "Based on the number of UEFA European Championship titles won, Spain holds the record [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [yahoo](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEN_wi1zong77ArtYg3CR5q-wmd_1KK_G72jrRoZv8_QlUFZUvjqyDXL5Co8RzGzWRzP9To5pq0kSBorMh3qgNVcOLGuCbF3giTuegc9yb0k9JqiOTFNYINKJQNAAmMo2ZziC5Iu_F1S5cpLJkKgCXLKk3VLkhqY-hSV1h_ryZRIMjENlsw7Q0=) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXF2tzG9OJk8Y6nPflMmiUEr826naRNP0ncayg9rczFwi4d_IOq9k99b_7K4ISJPMpAOTzV_VCw8H33rEC6z2N99GWxlB7evrGw__IwY8ZILaE4kYzojFvnmrvRwEdAQsRU2xkUH2AM_VDc6bXduEQBjjkHRi1XFwuY5OvVbGImLznn0dEidu45aQ0Kq) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGCVmrxZzE4ELt_Nl2fd2hYXp7QBGE7bqB8y4I0CRyiGrIB4dMu7krUBEuukEN1Go8KCJme8GuKl3dNqiW-UD7oR6MNWR47NKy1wqoNBxzrgZ2q1nnmjCAqxSeNejx_KTeAkiRVjUBXOQApJL_gUDI4Lwl3BCGcmlNVZGcuP88YN09iuu_stghqGJ7ulc6rUpHEZy9w0SpxUzexpKo27306oSXBPvvYVX6VnltFWvASMRsDfmD3dc94t715Ig04wFvaSIicHg==) [nbcsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHgdp86b29MgI2_Kvo4j5P0Iz8d3W8YgVkRwx31hZAoC9_dL-zyj_jP1vbDkxBiCA8kYArwSMPRVetYZR9WYYAwm3VwowkVtH7slpfObvQLnlHb2SQ386cBdZeZBZmEhgvVFE07YR4Z83RgohnOi26cW1BsZiRYlm1Adh1pgWtiNeiUl7ZNUMxtMQ5XvBx0GM1FpBd1QPsnhjU-pwNz-7ETG_XhsC7ocHEgWyMozF0cJOsEoR-Uye62Q0M=).\n",
       "\n",
       "Here are the top countries ranked by the number of UEFA European Championship titles:\n",
       "\n",
       "1.  **Spain:** 4 titles (1964, 2008, 2012, 2024) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [yahoo](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEN_wi1zong77ArtYg3CR5q-wmd_1KK_G72jrRoZv8_QlUFZUvjqyDXL5Co8RzGzWRzP9To5pq0kSBorMh3qgNVcOLGuCbF3giTuegc9yb0k9JqiOTFNYINKJQNAAmMo2ZziC5Iu_F1S5cpLJkKgCXLKk3VLkhqY-hSV1h_ryZRIMjENlsw7Q0=) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXF2tzG9OJk8Y6nPflMmiUEr826naRNP0ncayg9rczFwi4d_IOq9k99b_7K4ISJPMpAOTzV_VCw8H33rEC6z2N99GWxlB7evrGw__IwY8ZILaE4kYzojFvnmrvRwEdAQsRU2xkUH2AM_VDc6bXduEQBjjkHRi1XFwuY5OvVbGImLznn0dEidu45aQ0Kq) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGCVmrxZzE4ELt_Nl2fd2hYXp7QBGE7bqB8y4I0CRyiGrIB4dMu7krUBEuukEN1Go8KCJme8GuKl3dNqiW-UD7oR6MNWR47NKy1wqoNBxzrgZ2q1nnmjCAqxSeNejx_KTeAkiRVjUBXOQApJL_gUDI4Lwl3BCGcmlNVZGcuP88YN09iuu_stghqGJ7ulc6rUpHEZy9w0SpxUzexpKo27306oSXBPvvYVX6VnltFWvASMRsDfmD3dc94t715Ig04wFvaSIicHg==) [nbcsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHgdp86b29MgI2_Kvo4j5P0Iz8d3W8YgVkRwx31hZAoC9_dL-zyj_jP1vbDkxBiCA8kYArwSMPRVetYZR9WYYAwm3VwowkVtH7slpfObvQLnlHb2SQ386cBdZeZBZmEhgvVFE07YR4Z83RgohnOi26cW1BsZiRYlm1Adh1pgWtiNeiUl7ZNUMxtMQ5XvBx0GM1FpBd1QPsnhjU-pwNz-7ETG_XhsC7ocHEgWyMozF0cJOsEoR-Uye62Q0M=). Spain is also the only nation to have won consecutive titles (2008 and 2012) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXF2tzG9OJk8Y6nPflMmiUEr826naRNP0ncayg9rczFwi4d_IOq9k99b_7K4ISJPMpAOTzV_VCw8H33rEC6z2N99GWxlB7evrGw__IwY8ZILaE4kYzojFvnmrvRwEdAQsRU2xkUH2AM_VDc6bXduEQBjjkHRi1XFwuY5OvVbGImLznn0dEidu45aQ0Kq) [nbcsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHgdp86b29MgI2_Kvo4j5P0Iz8d3W8YgVkRwx31hZAoC9_dL-zyj_jP1vbDkxBiCA8kYArwSMPRVetYZR9WYYAwm3VwowkVtH7slpfObvQLnlHb2SQ386cBdZeZBZmEhgvVFE07YR4Z83RgohnOi26cW1BsZiRYlm1Adh1pgWtiNeiUl7ZNUMxtMQ5XvBx0GM1FpBd1QPsnhjU-pwNz-7ETG_XhsC7ocHEgWyMozF0cJOsEoR-Uye62Q0M=).\n",
       "2.  **Germany:** 3 titles (1972, 1980, 1996) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [yahoo](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEN_wi1zong77ArtYg3CR5q-wmd_1KK_G72jrRoZv8_QlUFZUvjqyDXL5Co8RzGzWRzP9To5pq0kSBorMh3qgNVcOLGuCbF3giTuegc9yb0k9JqiOTFNYINKJQNAAmMo2ZziC5Iu_F1S5cpLJkKgCXLKk3VLkhqY-hSV1h_ryZRIMjENlsw7Q0=) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXF2tzG9OJk8Y6nPflMmiUEr826naRNP0ncayg9rczFwi4d_IOq9k99b_7K4ISJPMpAOTzV_VCw8H33rEC6z2N99GWxlB7evrGw__IwY8ZILaE4kYzojFvnmrvRwEdAQsRU2xkUH2AM_VDc6bXduEQBjjkHRi1XFwuY5OvVbGImLznn0dEidu45aQ0Kq) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXETMGJq-qIccM3rUu2XPme69mRXj51ItevakpVZcxWa26F74sDgeP3slSuSCccKFyv9Xx5P1r4-3kY4ckWQclfnA3leE1ctTGdnIn-5GBRQrjxIwNSlKADP46pBTqgg_LhybRo2at4=). (Note: The first two titles were won as West Germany) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [byfarthegreatestteam](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHbs0yJwq86sGLUvo-8IgZfAus8ZnQcTe_dDlaZhfp7awMYMvU3mq8EL4VYyYWhahCYeRlACi-5eOq4maub0x3GsfKHvhgLBe8KOJG7f-CaPLRKjmRFPRNS2sig2ZCw6VXQeyLq_JWgmbIof5uLvNFqs_qOwFwqZvSmqWKbEnrw2dXMdEmsLKprFbsvAwd9GdMzFr9HojBPpSSk95SzVt2a849gqAGFyIq89tv-mirQaMRqwVUL).\n",
       "3.  **Italy:** 2 titles (1968, 2021) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [foxsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXF2tzG9OJk8Y6nPflMmiUEr826naRNP0ncayg9rczFwi4d_IOq9k99b_7K4ISJPMpAOTzV_VCw8H33rEC6z2N99GWxlB7evrGw__IwY8ZILaE4kYzojFvnmrvRwEdAQsRU2xkUH2AM_VDc6bXduEQBjjkHRi1XFwuY5OvVbGImLznn0dEidu45aQ0Kq) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=).\n",
       "4.  **France:** 2 titles (1984, 2000) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [youtube](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXETMGJq-qIccM3rUu2XPme69mRXj51ItevakpVZcxWa26F74sDgeP3slSuSCccKFyv9Xx5P1r4-3kY4ckWQclfnA3leE1ctTGdnIn-5GBRQrjxIwNSlKADP46pBTqgg_LhybRo2at4=).\n",
       "5.  **Tied with 1 title each:**\n",
       "    *   Soviet Union (1960) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "    *   Czechoslovakia (1976) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "    *   Netherlands (1988) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "    *   Denmark (1992) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "    *   Greece (2004) [olympics](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHoAXOG7_3DUjYvRr_buN8IAL3xE5yQoPetZCb1KlcaMOgJEE5BeBoqQEVVkDZLDpwgTmFkPYeWS7i_D23Vd5bKzUTfc0HSLI481VbXjMD9ECeZRFZ17g3xAYLg5I0QU34RWLCRcV_zgphUsJZ0L5gXjpYz5gl8syuYAX3VkHCwh0x6Wqau4er_cZ56CoiA-3S_r2I=) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "    *   Portugal (2016) [sportsadda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEYq2a0benYn0vF2WrfvmqEsgwriQ08aVcDdpS1MUjBxlzaV_scV0ldVeUpwqcgVLCfxgX3oVmbUxbkFPzeHbknsAbxLFk4Iyvtxgacx54AZBnL1szGQ9cQQGOOT8f-zGZhzKWEhAIOYTsz89uAr55R546MlC31OFXiU7AGhMgLi0Ekk6wQvPJVTWs_TiaG4MHoHo0obaRhJK1iPYaAxqHKD2Zf5rTr2jmdPBPd9w==) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFvGr1KOv5qWkUO63kL5-QFEKn41IArXdrcLcMuaCc69bmwu_VsGzE7QI4scHdLjQxYxoFD3eg4ZflqzFcnNk7UJKM5cT8IR13LrrWodcNzotVidnczmVCFCd1-w10ixHS2rgykLdSr8UqFNJ88T2hZL-HL6YCLUUAXJjFP) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXG_0rXuWu0vsaIzCzaUG9Rw0L65I3o3RWhCp4gzXiHDZW3GaJXLntEQNi-O88mGf5LlE0tAkMNd_5VBNOkzIxAkbVsdkpPjwtzuY1sjv2gjtHLnvbIa8Y9jFbdS8kE3xqj95_TayzxNWpyr-XkwY9qLW4NI) [wikipedia](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFXDSskdzRBS66rtxun9egUAz7spzUcDjq30yCoOdFr_SzKkrXBLgAPbzZKVQhx-Z28pOO3phMnr-qIhLuS9zJrp0MTCyIohI6EYxlJ3DpFXTNxneDn9OzNs7sZX_LwKKYA2E-7Mjr46dqZuprKzRn9amiPHusHo3dRWKpOzMSfhXpO) [topendsports](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHD7IG-bFCCNoc-2iRxXvo468klJLjiQmPdQCkRubtvT83i-Xbpg5XKxyLQB9Yc7qVwRuLjHIB37ywnZ8fdT3fM2ydpLggvdTGxAUVL1M0havCvEQpxiqcmS9LaBnOqWnMOWyy_ztdfTrVihPRb0chKtGeDHA-2EMQlW9ge) [sportingnews](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFAkEqJsPiiUSSUWhHm2Qtc30qed2JljSZ9Nu4JrcJ--CkX_Rif1AO5L0Kxl09j6yo8n5MS9NWdFsXi7KRIg5EJL0d0jm8YA-E4sllbJojNNQDwII8cb1A3b9b5RP3JoFTp2xEYQu914rrEFmRmjsFb44LU8bgGFJijrBG237B67YqLXiQThCPZjP-Gq3BKv3cTxZKseIXSRjaxosiM4LDpxDxZPAdpeIIpb3aiH7w_IyC8dWXpCyoHZYZfYe6EGNXfkmE=) [sportskeeda](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFIIs54t2O4RL3Y8cvfgbTs_CjcMeedsitpXc8PsaUZXOA7sohYdYTdTiN1-kLAhtXi2UZT4A-iIPZ6ufIpvuD_53Qtr4zqZnqZ6ox74EgyOPyjxs9k1qS_Gq1kR57IdjnMG4JbC7y9nVq2xZRNevSC-PJLSfCoLc36ahu6Xp6Fssl1Yw8LjgX2ranBbG72OvyijpJj1UygG-SVqr7h0y-DECQ=)\n",
       "\n",
       "Therefore, while Spain has the most titles, the top 5 ranking positions are held by Spain (1st), Germany (2nd), Italy and France (tied 3rd), and the six nations tied for 5th place."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Markdown(state[\"messages\"][-1].content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gemini key prefix: AIzaSyCPEQ\n",
      "Sending request...\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31m_InactiveRpcError\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\grpc_helpers.py:75\u001b[39m, in \u001b[36m_wrap_unary_errors.<locals>.error_remapped_callable\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m     74\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m---> \u001b[39m\u001b[32m75\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mcallable_\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     76\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m grpc.RpcError \u001b[38;5;28;01mas\u001b[39;00m exc:\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_interceptor.py:276\u001b[39m, in \u001b[36m_UnaryUnaryMultiCallable.__call__\u001b[39m\u001b[34m(self, request, timeout, metadata, credentials, wait_for_ready, compression)\u001b[39m\n\u001b[32m    267\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m__call__\u001b[39m(\n\u001b[32m    268\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m    269\u001b[39m     request: Any,\n\u001b[32m   (...)\u001b[39m\u001b[32m    274\u001b[39m     compression: Optional[grpc.Compression] = \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[32m    275\u001b[39m ) -> Any:\n\u001b[32m--> \u001b[39m\u001b[32m276\u001b[39m     response, ignored_call = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_with_call\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    277\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    278\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    279\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    280\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcredentials\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcredentials\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    281\u001b[39m \u001b[43m        \u001b[49m\u001b[43mwait_for_ready\u001b[49m\u001b[43m=\u001b[49m\u001b[43mwait_for_ready\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    282\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcompression\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcompression\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    283\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    284\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_interceptor.py:331\u001b[39m, in \u001b[36m_UnaryUnaryMultiCallable._with_call\u001b[39m\u001b[34m(self, request, timeout, metadata, credentials, wait_for_ready, compression)\u001b[39m\n\u001b[32m    328\u001b[39m call = \u001b[38;5;28mself\u001b[39m._interceptor.intercept_unary_unary(\n\u001b[32m    329\u001b[39m     continuation, client_call_details, request\n\u001b[32m    330\u001b[39m )\n\u001b[32m--> \u001b[39m\u001b[32m331\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mcall\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m, call\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_channel.py:438\u001b[39m, in \u001b[36m_InactiveRpcError.result\u001b[39m\u001b[34m(self, timeout)\u001b[39m\n\u001b[32m    437\u001b[39m \u001b[38;5;250m\u001b[39m\u001b[33;03m\"\"\"See grpc.Future.result.\"\"\"\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m438\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_interceptor.py:314\u001b[39m, in \u001b[36m_UnaryUnaryMultiCallable._with_call.<locals>.continuation\u001b[39m\u001b[34m(new_details, request)\u001b[39m\n\u001b[32m    313\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m314\u001b[39m     response, call = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_thunk\u001b[49m\u001b[43m(\u001b[49m\u001b[43mnew_method\u001b[49m\u001b[43m)\u001b[49m\u001b[43m.\u001b[49m\u001b[43mwith_call\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    315\u001b[39m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    316\u001b[39m \u001b[43m        \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mnew_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    317\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mnew_metadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    318\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcredentials\u001b[49m\u001b[43m=\u001b[49m\u001b[43mnew_credentials\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    319\u001b[39m \u001b[43m        \u001b[49m\u001b[43mwait_for_ready\u001b[49m\u001b[43m=\u001b[49m\u001b[43mnew_wait_for_ready\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    320\u001b[39m \u001b[43m        \u001b[49m\u001b[43mcompression\u001b[49m\u001b[43m=\u001b[49m\u001b[43mnew_compression\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    321\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    322\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m _UnaryOutcome(response, call)\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_channel.py:1180\u001b[39m, in \u001b[36m_UnaryUnaryMultiCallable.with_call\u001b[39m\u001b[34m(self, request, timeout, metadata, credentials, wait_for_ready, compression)\u001b[39m\n\u001b[32m   1177\u001b[39m state, call = \u001b[38;5;28mself\u001b[39m._blocking(\n\u001b[32m   1178\u001b[39m     request, timeout, metadata, credentials, wait_for_ready, compression\n\u001b[32m   1179\u001b[39m )\n\u001b[32m-> \u001b[39m\u001b[32m1180\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_end_unary_response_blocking\u001b[49m\u001b[43m(\u001b[49m\u001b[43mstate\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcall\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mTrue\u001b[39;49;00m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\grpc\\_channel.py:996\u001b[39m, in \u001b[36m_end_unary_response_blocking\u001b[39m\u001b[34m(state, call, with_call, deadline)\u001b[39m\n\u001b[32m    995\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m state.response\n\u001b[32m--> \u001b[39m\u001b[32m996\u001b[39m \u001b[38;5;28;01mraise\u001b[39;00m _InactiveRpcError(state)\n",
      "\u001b[31m_InactiveRpcError\u001b[39m: <_InactiveRpcError of RPC that terminated with:\n\tstatus = StatusCode.UNAVAILABLE\n\tdetails = \"failed to connect to all addresses; last error: UNKNOWN: ipv4:142.250.73.74:443: socket is null\"\n\tdebug_error_string = \"UNKNOWN:Error received from peer  {grpc_message:\"failed to connect to all addresses; last error: UNKNOWN: ipv4:142.250.73.74:443: socket is null\", grpc_status:14}\"\n>",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[31mServiceUnavailable\u001b[39m                        Traceback (most recent call last)",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:147\u001b[39m, in \u001b[36mretry_target\u001b[39m\u001b[34m(target, predicate, sleep_generator, timeout, on_error, exception_factory, **kwargs)\u001b[39m\n\u001b[32m    146\u001b[39m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m147\u001b[39m     result = \u001b[43mtarget\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    148\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m inspect.isawaitable(result):\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\timeout.py:130\u001b[39m, in \u001b[36mTimeToDeadlineTimeout.__call__.<locals>.func_with_timeout\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    128\u001b[39m     kwargs[\u001b[33m\"\u001b[39m\u001b[33mtimeout\u001b[39m\u001b[33m\"\u001b[39m] = remaining_timeout\n\u001b[32m--> \u001b[39m\u001b[32m130\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\grpc_helpers.py:77\u001b[39m, in \u001b[36m_wrap_unary_errors.<locals>.error_remapped_callable\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m     76\u001b[39m \u001b[38;5;28;01mexcept\u001b[39;00m grpc.RpcError \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[32m---> \u001b[39m\u001b[32m77\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m exceptions.from_grpc_error(exc) \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34;01mexc\u001b[39;00m\n",
      "\u001b[31mServiceUnavailable\u001b[39m: 503 failed to connect to all addresses; last error: UNKNOWN: ipv4:142.250.73.74:443: socket is null",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m                         Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[9]\u001b[39m\u001b[32m, line 12\u001b[39m\n\u001b[32m      9\u001b[39m llm = ChatGoogleGenerativeAI(model=\u001b[33m\"\u001b[39m\u001b[33mgemini-2.5-flash\u001b[39m\u001b[33m\"\u001b[39m, temperature=\u001b[32m0.7\u001b[39m,api_key=os.getenv(\u001b[33m\"\u001b[39m\u001b[33mGEMINI_API_KEY\u001b[39m\u001b[33m\"\u001b[39m))\n\u001b[32m     11\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mSending request...\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m---> \u001b[39m\u001b[32m12\u001b[39m result = \u001b[43mllm\u001b[49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mList three AI research breakthroughs in 2024.\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[32m     13\u001b[39m \u001b[38;5;28mprint\u001b[39m(\u001b[33m\"\u001b[39m\u001b[33mResponse:\u001b[39m\u001b[33m\"\u001b[39m, result)\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_google_genai\\chat_models.py:1999\u001b[39m, in \u001b[36mChatGoogleGenerativeAI.invoke\u001b[39m\u001b[34m(self, input, config, code_execution, stop, **kwargs)\u001b[39m\n\u001b[32m   1996\u001b[39m         msg = \u001b[33m\"\u001b[39m\u001b[33mTools are already defined.code_execution tool can\u001b[39m\u001b[33m'\u001b[39m\u001b[33mt be defined\u001b[39m\u001b[33m\"\u001b[39m\n\u001b[32m   1997\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(msg)\n\u001b[32m-> \u001b[39m\u001b[32m1999\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43msuper\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\u001b[43m.\u001b[49m\u001b[43minvoke\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_core\\language_models\\chat_models.py:379\u001b[39m, in \u001b[36mBaseChatModel.invoke\u001b[39m\u001b[34m(self, input, config, stop, **kwargs)\u001b[39m\n\u001b[32m    365\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m    366\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34minvoke\u001b[39m(\n\u001b[32m    367\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m    372\u001b[39m     **kwargs: Any,\n\u001b[32m    373\u001b[39m ) -> AIMessage:\n\u001b[32m    374\u001b[39m     config = ensure_config(config)\n\u001b[32m    375\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(\n\u001b[32m    376\u001b[39m         \u001b[33m\"\u001b[39m\u001b[33mAIMessage\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m    377\u001b[39m         cast(\n\u001b[32m    378\u001b[39m             \u001b[33m\"\u001b[39m\u001b[33mChatGeneration\u001b[39m\u001b[33m\"\u001b[39m,\n\u001b[32m--> \u001b[39m\u001b[32m379\u001b[39m             \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mgenerate_prompt\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    380\u001b[39m \u001b[43m                \u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_convert_input\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43minput\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    381\u001b[39m \u001b[43m                \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    382\u001b[39m \u001b[43m                \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mcallbacks\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    383\u001b[39m \u001b[43m                \u001b[49m\u001b[43mtags\u001b[49m\u001b[43m=\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mtags\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    384\u001b[39m \u001b[43m                \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mmetadata\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    385\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_name\u001b[49m\u001b[43m=\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mget\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mrun_name\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    386\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_id\u001b[49m\u001b[43m=\u001b[49m\u001b[43mconfig\u001b[49m\u001b[43m.\u001b[49m\u001b[43mpop\u001b[49m\u001b[43m(\u001b[49m\u001b[33;43m\"\u001b[39;49m\u001b[33;43mrun_id\u001b[39;49m\u001b[33;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    387\u001b[39m \u001b[43m                \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    388\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m.generations[\u001b[32m0\u001b[39m][\u001b[32m0\u001b[39m],\n\u001b[32m    389\u001b[39m         ).message,\n\u001b[32m    390\u001b[39m     )\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_core\\language_models\\chat_models.py:1088\u001b[39m, in \u001b[36mBaseChatModel.generate_prompt\u001b[39m\u001b[34m(self, prompts, stop, callbacks, **kwargs)\u001b[39m\n\u001b[32m   1079\u001b[39m \u001b[38;5;129m@override\u001b[39m\n\u001b[32m   1080\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34mgenerate_prompt\u001b[39m(\n\u001b[32m   1081\u001b[39m     \u001b[38;5;28mself\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m   1085\u001b[39m     **kwargs: Any,\n\u001b[32m   1086\u001b[39m ) -> LLMResult:\n\u001b[32m   1087\u001b[39m     prompt_messages = [p.to_messages() \u001b[38;5;28;01mfor\u001b[39;00m p \u001b[38;5;129;01min\u001b[39;00m prompts]\n\u001b[32m-> \u001b[39m\u001b[32m1088\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mgenerate\u001b[49m\u001b[43m(\u001b[49m\u001b[43mprompt_messages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m=\u001b[49m\u001b[43mcallbacks\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_core\\language_models\\chat_models.py:903\u001b[39m, in \u001b[36mBaseChatModel.generate\u001b[39m\u001b[34m(self, messages, stop, callbacks, tags, metadata, run_name, run_id, **kwargs)\u001b[39m\n\u001b[32m    900\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m i, m \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28menumerate\u001b[39m(input_messages):\n\u001b[32m    901\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m    902\u001b[39m         results.append(\n\u001b[32m--> \u001b[39m\u001b[32m903\u001b[39m             \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_generate_with_cache\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    904\u001b[39m \u001b[43m                \u001b[49m\u001b[43mm\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    905\u001b[39m \u001b[43m                \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    906\u001b[39m \u001b[43m                \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_managers\u001b[49m\u001b[43m[\u001b[49m\u001b[43mi\u001b[49m\u001b[43m]\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mif\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[43mrun_managers\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43;01melse\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[32m    907\u001b[39m \u001b[43m                \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    908\u001b[39m \u001b[43m            \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    909\u001b[39m         )\n\u001b[32m    910\u001b[39m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m e:\n\u001b[32m    911\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m run_managers:\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_core\\language_models\\chat_models.py:1192\u001b[39m, in \u001b[36mBaseChatModel._generate_with_cache\u001b[39m\u001b[34m(self, messages, stop, run_manager, **kwargs)\u001b[39m\n\u001b[32m   1190\u001b[39m     result = generate_from_stream(\u001b[38;5;28miter\u001b[39m(chunks))\n\u001b[32m   1191\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m inspect.signature(\u001b[38;5;28mself\u001b[39m._generate).parameters.get(\u001b[33m\"\u001b[39m\u001b[33mrun_manager\u001b[39m\u001b[33m\"\u001b[39m):\n\u001b[32m-> \u001b[39m\u001b[32m1192\u001b[39m     result = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_generate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   1193\u001b[39m \u001b[43m        \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m=\u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrun_manager\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\n\u001b[32m   1194\u001b[39m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   1195\u001b[39m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[32m   1196\u001b[39m     result = \u001b[38;5;28mself\u001b[39m._generate(messages, stop=stop, **kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_google_genai\\chat_models.py:2113\u001b[39m, in \u001b[36mChatGoogleGenerativeAI._generate\u001b[39m\u001b[34m(self, messages, stop, run_manager, tools, functions, safety_settings, tool_config, generation_config, cached_content, tool_choice, **kwargs)\u001b[39m\n\u001b[32m   2111\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[33m\"\u001b[39m\u001b[33mmax_retries\u001b[39m\u001b[33m\"\u001b[39m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m kwargs:\n\u001b[32m   2112\u001b[39m     kwargs[\u001b[33m\"\u001b[39m\u001b[33mmax_retries\u001b[39m\u001b[33m\"\u001b[39m] = \u001b[38;5;28mself\u001b[39m.max_retries\n\u001b[32m-> \u001b[39m\u001b[32m2113\u001b[39m response: GenerateContentResponse = \u001b[43m_chat_with_retry\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m   2114\u001b[39m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m=\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2115\u001b[39m \u001b[43m    \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2116\u001b[39m \u001b[43m    \u001b[49m\u001b[43mgeneration_method\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mclient\u001b[49m\u001b[43m.\u001b[49m\u001b[43mgenerate_content\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2117\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43mdefault_metadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m   2118\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m   2119\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m _response_to_result(response)\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_google_genai\\chat_models.py:247\u001b[39m, in \u001b[36m_chat_with_retry\u001b[39m\u001b[34m(generation_method, **kwargs)\u001b[39m\n\u001b[32m    238\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m\n\u001b[32m    240\u001b[39m params = (\n\u001b[32m    241\u001b[39m     {k: v \u001b[38;5;28;01mfor\u001b[39;00m k, v \u001b[38;5;129;01min\u001b[39;00m kwargs.items() \u001b[38;5;28;01mif\u001b[39;00m k \u001b[38;5;129;01min\u001b[39;00m _allowed_params_prediction_service}\n\u001b[32m    242\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m (request := kwargs.get(\u001b[33m\"\u001b[39m\u001b[33mrequest\u001b[39m\u001b[33m\"\u001b[39m))\n\u001b[32m   (...)\u001b[39m\u001b[32m    245\u001b[39m     \u001b[38;5;28;01melse\u001b[39;00m kwargs\n\u001b[32m    246\u001b[39m )\n\u001b[32m--> \u001b[39m\u001b[32m247\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43m_chat_with_retry\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mparams\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\tenacity\\__init__.py:338\u001b[39m, in \u001b[36mBaseRetrying.wraps.<locals>.wrapped_f\u001b[39m\u001b[34m(*args, **kw)\u001b[39m\n\u001b[32m    336\u001b[39m copy = \u001b[38;5;28mself\u001b[39m.copy()\n\u001b[32m    337\u001b[39m wrapped_f.statistics = copy.statistics  \u001b[38;5;66;03m# type: ignore[attr-defined]\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m338\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mcopy\u001b[49m\u001b[43m(\u001b[49m\u001b[43mf\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkw\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\tenacity\\__init__.py:477\u001b[39m, in \u001b[36mRetrying.__call__\u001b[39m\u001b[34m(self, fn, *args, **kwargs)\u001b[39m\n\u001b[32m    475\u001b[39m retry_state = RetryCallState(retry_object=\u001b[38;5;28mself\u001b[39m, fn=fn, args=args, kwargs=kwargs)\n\u001b[32m    476\u001b[39m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m477\u001b[39m     do = \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43miter\u001b[49m\u001b[43m(\u001b[49m\u001b[43mretry_state\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretry_state\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    478\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(do, DoAttempt):\n\u001b[32m    479\u001b[39m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\tenacity\\__init__.py:378\u001b[39m, in \u001b[36mBaseRetrying.iter\u001b[39m\u001b[34m(self, retry_state)\u001b[39m\n\u001b[32m    376\u001b[39m result = \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[32m    377\u001b[39m \u001b[38;5;28;01mfor\u001b[39;00m action \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m.iter_state.actions:\n\u001b[32m--> \u001b[39m\u001b[32m378\u001b[39m     result = \u001b[43maction\u001b[49m\u001b[43m(\u001b[49m\u001b[43mretry_state\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    379\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m result\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\tenacity\\__init__.py:400\u001b[39m, in \u001b[36mBaseRetrying._post_retry_check_actions.<locals>.<lambda>\u001b[39m\u001b[34m(rs)\u001b[39m\n\u001b[32m    398\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_post_retry_check_actions\u001b[39m(\u001b[38;5;28mself\u001b[39m, retry_state: \u001b[33m\"\u001b[39m\u001b[33mRetryCallState\u001b[39m\u001b[33m\"\u001b[39m) -> \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    399\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m (\u001b[38;5;28mself\u001b[39m.iter_state.is_explicit_retry \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;28mself\u001b[39m.iter_state.retry_run_result):\n\u001b[32m--> \u001b[39m\u001b[32m400\u001b[39m         \u001b[38;5;28mself\u001b[39m._add_action_func(\u001b[38;5;28;01mlambda\u001b[39;00m rs: \u001b[43mrs\u001b[49m\u001b[43m.\u001b[49m\u001b[43moutcome\u001b[49m\u001b[43m.\u001b[49m\u001b[43mresult\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m)\n\u001b[32m    401\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m\n\u001b[32m    403\u001b[39m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.after \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mD:\\Users\\wujie\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\concurrent\\futures\\_base.py:449\u001b[39m, in \u001b[36mFuture.result\u001b[39m\u001b[34m(self, timeout)\u001b[39m\n\u001b[32m    447\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m CancelledError()\n\u001b[32m    448\u001b[39m \u001b[38;5;28;01melif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._state == FINISHED:\n\u001b[32m--> \u001b[39m\u001b[32m449\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m__get_result\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    451\u001b[39m \u001b[38;5;28mself\u001b[39m._condition.wait(timeout)\n\u001b[32m    453\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._state \u001b[38;5;129;01min\u001b[39;00m [CANCELLED, CANCELLED_AND_NOTIFIED]:\n",
      "\u001b[36mFile \u001b[39m\u001b[32mD:\\Users\\wujie\\AppData\\Local\\Programs\\Python\\Python312\\Lib\\concurrent\\futures\\_base.py:401\u001b[39m, in \u001b[36mFuture.__get_result\u001b[39m\u001b[34m(self)\u001b[39m\n\u001b[32m    399\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception:\n\u001b[32m    400\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m401\u001b[39m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;28mself\u001b[39m._exception\n\u001b[32m    402\u001b[39m     \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[32m    403\u001b[39m         \u001b[38;5;66;03m# Break a reference cycle with the exception in self._exception\u001b[39;00m\n\u001b[32m    404\u001b[39m         \u001b[38;5;28mself\u001b[39m = \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\tenacity\\__init__.py:480\u001b[39m, in \u001b[36mRetrying.__call__\u001b[39m\u001b[34m(self, fn, *args, **kwargs)\u001b[39m\n\u001b[32m    478\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(do, DoAttempt):\n\u001b[32m    479\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m480\u001b[39m         result = \u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    481\u001b[39m     \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mBaseException\u001b[39;00m:  \u001b[38;5;66;03m# noqa: B902\u001b[39;00m\n\u001b[32m    482\u001b[39m         retry_state.set_exception(sys.exc_info())  \u001b[38;5;66;03m# type: ignore[arg-type]\u001b[39;00m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\langchain_google_genai\\chat_models.py:217\u001b[39m, in \u001b[36m_chat_with_retry.<locals>._chat_with_retry\u001b[39m\u001b[34m(**kwargs)\u001b[39m\n\u001b[32m    214\u001b[39m \u001b[38;5;129m@retry_decorator\u001b[39m\n\u001b[32m    215\u001b[39m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[34m_chat_with_retry\u001b[39m(**kwargs: Any) -> Any:\n\u001b[32m    216\u001b[39m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[32m--> \u001b[39m\u001b[32m217\u001b[39m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mgeneration_method\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    218\u001b[39m     \u001b[38;5;28;01mexcept\u001b[39;00m FailedPrecondition \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[32m    219\u001b[39m         \u001b[38;5;28;01mif\u001b[39;00m \u001b[33m\"\u001b[39m\u001b[33mlocation is not supported\u001b[39m\u001b[33m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m exc.message:\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\ai\\generativelanguage_v1beta\\services\\generative_service\\client.py:869\u001b[39m, in \u001b[36mGenerativeServiceClient.generate_content\u001b[39m\u001b[34m(self, request, model, contents, retry, timeout, metadata)\u001b[39m\n\u001b[32m    866\u001b[39m \u001b[38;5;28mself\u001b[39m._validate_universe_domain()\n\u001b[32m    868\u001b[39m \u001b[38;5;66;03m# Send the request.\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m869\u001b[39m response = \u001b[43mrpc\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    870\u001b[39m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    871\u001b[39m \u001b[43m    \u001b[49m\u001b[43mretry\u001b[49m\u001b[43m=\u001b[49m\u001b[43mretry\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    872\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    873\u001b[39m \u001b[43m    \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m=\u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    874\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    876\u001b[39m \u001b[38;5;66;03m# Done; return the response.\u001b[39;00m\n\u001b[32m    877\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\gapic_v1\\method.py:131\u001b[39m, in \u001b[36m_GapicCallable.__call__\u001b[39m\u001b[34m(self, timeout, retry, compression, *args, **kwargs)\u001b[39m\n\u001b[32m    128\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m._compression \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[32m    129\u001b[39m     kwargs[\u001b[33m\"\u001b[39m\u001b[33mcompression\u001b[39m\u001b[33m\"\u001b[39m] = compression\n\u001b[32m--> \u001b[39m\u001b[32m131\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mwrapped_func\u001b[49m\u001b[43m(\u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:294\u001b[39m, in \u001b[36mRetry.__call__.<locals>.retry_wrapped_func\u001b[39m\u001b[34m(*args, **kwargs)\u001b[39m\n\u001b[32m    290\u001b[39m target = functools.partial(func, *args, **kwargs)\n\u001b[32m    291\u001b[39m sleep_generator = exponential_sleep_generator(\n\u001b[32m    292\u001b[39m     \u001b[38;5;28mself\u001b[39m._initial, \u001b[38;5;28mself\u001b[39m._maximum, multiplier=\u001b[38;5;28mself\u001b[39m._multiplier\n\u001b[32m    293\u001b[39m )\n\u001b[32m--> \u001b[39m\u001b[32m294\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mretry_target\u001b[49m\u001b[43m(\u001b[49m\n\u001b[32m    295\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtarget\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    296\u001b[39m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_predicate\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    297\u001b[39m \u001b[43m    \u001b[49m\u001b[43msleep_generator\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    298\u001b[39m \u001b[43m    \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[43m=\u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_timeout\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    299\u001b[39m \u001b[43m    \u001b[49m\u001b[43mon_error\u001b[49m\u001b[43m=\u001b[49m\u001b[43mon_error\u001b[49m\u001b[43m,\u001b[49m\n\u001b[32m    300\u001b[39m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32md:\\code\\gemini-fullstack-langgraph-quickstart\\.venv\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:167\u001b[39m, in \u001b[36mretry_target\u001b[39m\u001b[34m(target, predicate, sleep_generator, timeout, on_error, exception_factory, **kwargs)\u001b[39m\n\u001b[32m    156\u001b[39m next_sleep = _retry_error_helper(\n\u001b[32m    157\u001b[39m     exc,\n\u001b[32m    158\u001b[39m     deadline,\n\u001b[32m   (...)\u001b[39m\u001b[32m    164\u001b[39m     timeout,\n\u001b[32m    165\u001b[39m )\n\u001b[32m    166\u001b[39m \u001b[38;5;66;03m# if exception not raised, sleep before next attempt\u001b[39;00m\n\u001b[32m--> \u001b[39m\u001b[32m167\u001b[39m \u001b[43mtime\u001b[49m\u001b[43m.\u001b[49m\u001b[43msleep\u001b[49m\u001b[43m(\u001b[49m\u001b[43mnext_sleep\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[31mKeyboardInterrupt\u001b[39m: "
     ]
    }
   ],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "print(\"Gemini key prefix:\", (os.getenv(\"GEMINI_API_KEY\") or \"\")[:10])\n",
    "\n",
    "llm = ChatGoogleGenerativeAI(model=\"gemini-2.5-flash\", temperature=0.7,api_key=os.getenv(\"GEMINI_API_KEY\"))\n",
    "\n",
    "print(\"Sending request...\")\n",
    "result = llm.invoke(\"List three AI research breakthroughs in 2024.\")\n",
    "print(\"Response:\", result)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gemini key prefix: AIzaSyCPEQ\n",
      "Sending request...\n",
      "Response: As of mid-2024, here are three significant AI research breakthroughs:\n",
      "\n",
      "1.  **OpenAI's Sora (Text-to-Video Model):** Announced in February 2024, Sora represents a major leap in generative AI's ability to create realistic and coherent videos from text prompts. Unlike previous video generation models, Sora can produce longer, more complex scenes with multiple characters, specific motion, and accurate rendering of object physics within the generated world, significantly advancing the realism and control in video synthesis.\n",
      "\n",
      "2.  **Google DeepMind's AlphaFold 3 (Universal Biomolecular Prediction):** Unveiled in May 2024, AlphaFold 3 extends the groundbreaking work of its predecessors by predicting the structure and interactions of *all* biomolecules, not just proteins. This includes DNA, RNA, proteins, and ligands, as well as modifications to these molecules. This holistic view of the \"molecules of life\" is a monumental scientific breakthrough, promising to revolutionize drug discovery, disease understanding, and fundamental biological research.\n",
      "\n",
      "3.  **OpenAI's GPT-4o (Omni) Multimodal Model:** Announced in May 2024, GPT-4o (o for \"omni\") sets a new standard for real-time, multimodal interaction. It can seamlessly process and generate text, audio, and images. Its most striking feature is its ability to engage in natural, real-time voice conversations, including detecting and expressing emotion, interpreting visual input through a camera, and responding with human-like latency. This marks a significant step towards more intuitive and human-like AI interaction.\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from dotenv import load_dotenv\n",
    "from google import genai\n",
    "\n",
    "# è½½å…¥ .env æ–‡ä»¶ä¸­çš„ GEMINI_API_KEY\n",
    "load_dotenv()\n",
    "\n",
    "api_key = os.getenv(\"GEMINI_API_KEY\")\n",
    "print(\"Gemini key prefix:\", (api_key or \"\")[:10])\n",
    "\n",
    "# åˆ›å»º Gemini å®¢æˆ·ç«¯\n",
    "client = genai.Client(api_key=api_key)\n",
    "\n",
    "print(\"Sending request...\")\n",
    "\n",
    "# ç”Ÿæˆæ¨¡å‹è°ƒç”¨ï¼ˆå»ºè®®ä½¿ç”¨ gemini-2.0-flash æˆ– gemini-2.5-flashï¼‰\n",
    "response = client.models.generate_content(\n",
    "    model=\"gemini-2.5-flash\",\n",
    "    contents=\"List three AI research breakthroughs in 2024.\"\n",
    ")\n",
    "\n",
    "print(\"Response:\", response.text)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "| ç™»è®°å· | è¯•éªŒè¯ | é€‚åº”ç—‡ | è¯•éªŒçŠ¶æ€ | è¯•éªŒåˆ†æœŸ |\n",
    "| --- | --- | --- | --- | --- |\n",
    "| NCT06667141 | PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics) | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06612203 | Zedoresertib\\|æˆˆæ²™å¦¥ç»„å•æŠ— | ä¸‰é˜´æ€§ä¹³è…ºç™Œ \\| HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ \\| æ™šæœŸä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| CTIS2024-516322-60-00 | Zedoresertib \\| æˆˆæ²™å¦¥ç»„å•æŠ— | è‚¿ç˜¤ \\| HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT06476808 | BMS-986463 | å­å®«æµ†æ¶²æ€§ç™Œ \\| éå°ç»†èƒè‚ºç™Œ \\| æ™šæœŸç™Œç—‡ \\| åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06463340 | SGR-3515 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06369155 | Azenosertib | å­å®«æµ†æ¶²æ€§ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
    "| NCT06364410 | å¾·æ›²å¦¥ç å•æŠ— \\| Azenosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ \\| è½¬ç§»æ€§å®ä½“ç˜¤ \\| HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06363552 | SC-0191 \\| äºšå¶é…¸é’™ \\| è´ä¼ç  | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ2æœŸ |\n",
    "| NCT06351332 | å¡é“‚ \\| å¸•åšåˆ©ç å•æŠ— \\| Azenosertib | ä¸‰é˜´æ€§ä¹³è…ºç™Œ \\| è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| CTIS2024-511227-33-00 | LB-100 \\| Azenosertib | è‚¿ç˜¤ \\| ç»“ç›´è‚ ç™Œ \\| è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06260514 | APR-105 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06109883 | LB-100 \\| Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Not yet recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT06055348 | SC-0191 \\| ç´«æ‰é†‡ \\| ç›é…¸å‰è¥¿ä»–æ»¨ | åµå·¢ç™Œ \\| å¤å‘æ€§åµå·¢ç™Œ \\| é“‚è€è¯æ€§åµå·¢ç™Œ | Not yet recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT06015659 | ç›é…¸å‰è¥¿ä»–æ»¨ \\| Azenosertib | èƒ°è…ºå¯¼ç®¡è…ºç™Œ \\| æ™šæœŸèƒ°è…ºè…ºç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
    "| NCT05815160 | Zedoresertib \\| ä¾æ‰˜æ³Šè‹· \\| å¡é“‚ | å¤å‘æ€§å°ç»†èƒè‚ºç™Œ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT05765812 | Zedoresertib \\| æ›¿è«å”‘èƒº | èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ \\| å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ | Recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT05743036 | è¥¿å¦¥æ˜”å•æŠ— \\| æ©è€ƒèŠ¬å°¼ \\| Azenosertib | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
    "| NCT05682170 | Asaretoclax \\| Azenosertib | æ€¥æ€§é«“æ€§ç™½è¡€ç—… | Terminated | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT05431582 | è´ä¼ç å•æŠ— \\| å¸•åšåˆ©ç å•æŠ— \\| Azenosertib | è‚ºç™Œ \\| åµå·¢ç™Œ \\| è½¬ç§»æ€§å®ä½“ç˜¤ \\| ä¹³è…ºç™Œ \\| èƒ°è…ºç™Œ | Withdrawn | ä¸´åºŠ1æœŸ |\n",
    "| CTR20221135 | äºšå¶é…¸é’™ \\| è´ä¼ç å•æŠ— \\| Azenosertib \\| æ°Ÿå°¿å˜§å•¶ | ç»“ç›´è‚ ç™Œ | Terminated | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT05368506 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ \\| åµå·¢ç™Œ \\| è½¬ç§»æ€§å®ä½“ç˜¤  | Withdrawn | æ—©æœŸä¸´åºŠ1æœŸ |\n",
    "| NCT05291182 | SY-4835 | æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
    "| NCT05212025 | Adavosertib \\| ç›é…¸å‰è¥¿ä»–æ»¨ | æ™šæœŸèƒ°è…ºè…ºç™Œ | Withdrawn | ä¸´åºŠ2æœŸ |\n",
    "| NCT05198804 | ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© \\| Azenosertib | åŸå‘æ€§è…¹è†œç™Œ \\| å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ \\| é“‚è€è¯æ€§åµå·¢ç™Œ \\| è¾“åµç®¡ç™Œ | Active, not recruiting | ä¸´åºŠ1/2æœŸ |\n",
    "| NCT05128825 | Azenosertib | åŸå‘æ€§è…¹è†œç™Œ \\| åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ \\| è¾“åµç®¡ç™Œ | Recruiting | ä¸´åºŠ2æœŸ |\n",
    "| NCT05109975 | Zedoresertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ \\| æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Recruiting | ä¸´åºŠ1æœŸ |\n",
    "| NCT05008913 | Adavosertib | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ \\| æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |\n",
    "| CTR20211986 | Azenosertib | åµå·¢ç™Œ \\| è…¹è†œç™Œ \\| è¾“åµç®¡ç™Œ | Terminated | ä¸´åºŠ1æœŸ |\n",
    "| NCT04972422 | Azenosertib | å®ä½“ç˜¤ | Unknown status | ä¸´åºŠ1æœŸ |\n",
    "| NCT04959266 | ä¼Šæ›²åº·å”‘ \\| å¥¥ç¾æ‹‰å”‘ \\| Adavosertib \\| åˆ©ç¦å¹³ | å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ \\| æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | Terminated | ä¸´åºŠ1æœŸ |"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "<table> <tr><th>ç™»è®°å·</th><th>è¯•éªŒè¯</th><th>é€‚åº”ç—‡</th><th>è¯•éªŒçŠ¶æ€</th><th>è¯•éªŒåˆ†æœŸ</th></tr> <tr><td>NCT06667141</td><td>PKMYT1 æŠ‘åˆ¶å‰‚(Acrivon Therapeutics)</td><td>æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06612203</td><td>Zedoresertib|æˆˆæ²™å¦¥ç»„å•æŠ—</td><td>ä¸‰é˜´æ€§ä¹³è…ºç™Œ | HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ | æ™šæœŸä¹³è…ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>CTIS2024-516322-60-00</td><td>Zedoresertib | æˆˆæ²™å¦¥ç»„å•æŠ—</td><td>è‚¿ç˜¤ | HRé˜³æ€§/HER2é˜´æ€§ä¹³è…ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT06476808</td><td>BMS-986463</td><td>å­å®«æµ†æ¶²æ€§ç™Œ | éå°ç»†èƒè‚ºç™Œ | æ™šæœŸç™Œç—‡ | åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§è…ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06463340</td><td>SGR-3515</td><td>æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06369155</td><td>Azenosertib</td><td>å­å®«æµ†æ¶²æ€§ç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ2æœŸ</td><tr><td>NCT06364410</td><td>å¾·æ›²å¦¥ç å•æŠ— | Azenosertib</td><td>å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | è½¬ç§»æ€§å®ä½“ç˜¤ | HER2é˜³æ€§èƒƒé£Ÿç®¡äº¤ç•Œå¤„ç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06363552</td><td>SC-0191 | äºšå¶é…¸é’™ | è´ä¼ç </td><td>è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ</td><td>Not yet recruiting</td><td>ä¸´åºŠ2æœŸ</td><tr><td>NCT06351332</td><td>å¡é“‚ | å¸•åšåˆ©ç å•æŠ— | Azenosertib</td><td>ä¸‰é˜´æ€§ä¹³è…ºç™Œ | è½¬ç§»æ€§ä¸‰é˜´æ€§ä¹³è…ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>CTIS2024-511227-33-00</td><td>LB-100 | Azenosertib</td><td>è‚¿ç˜¤ | ç»“ç›´è‚ ç™Œ | è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ</td><td>Not yet recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06260514</td><td>APR-105</td><td>æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06109883</td><td>LB-100 | Azenosertib</td><td>è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ</td><td>Not yet recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT06055348</td><td>SC-0191 | ç´«æ‰é†‡ | ç›é…¸å‰è¥¿ä»–æ»¨</td><td>åµå·¢ç™Œ | å¤å‘æ€§åµå·¢ç™Œ | é“‚è€è¯æ€§åµå·¢ç™Œ</td><td>Not yet recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT06015659</td><td>ç›é…¸å‰è¥¿ä»–æ»¨ | Azenosertib</td><td>èƒ°è…ºå¯¼ç®¡è…ºç™Œ | æ™šæœŸèƒ°è…ºè…ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ2æœŸ</td><tr><td>NCT05815160</td><td>Zedoresertib | ä¾æ‰˜æ³Šè‹· | å¡é“‚</td><td>å¤å‘æ€§å°ç»†èƒè‚ºç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT05765812</td><td>Zedoresertib | æ›¿è«å”‘èƒº</td><td>èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ŒIDHé‡ç”Ÿå‹ | å¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤</td><td>Recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT05743036</td><td>è¥¿å¦¥æ˜”å•æŠ— | æ©è€ƒèŠ¬å°¼ | Azenosertib</td><td>è½¬ç§»æ€§ç»“ç›´è‚ ç™Œ</td><td>Terminated</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT05682170</td><td>Asaretoclax | Azenosertib</td><td>æ€¥æ€§é«“æ€§ç™½è¡€ç—…</td><td>Terminated</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT05431582</td><td>è´ä¼ç å•æŠ— | å¸•åšåˆ©ç å•æŠ— | Azenosertib</td><td>è‚ºç™Œ | åµå·¢ç™Œ | è½¬ç§»æ€§å®ä½“ç˜¤ | ä¹³è…ºç™Œ | èƒ°è…ºç™Œ</td><td>Withdrawn</td><td>ä¸´åºŠ1æœŸ</td><tr><td>CTR20221135</td><td>äºšå¶é…¸é’™ | è´ä¼ç å•æŠ— | Azenosertib | æ°Ÿå°¿å˜§å•¶</td><td>ç»“ç›´è‚ ç™Œ</td><td>Terminated</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT05368506</td><td>Azenosertib</td><td>åŸå‘æ€§è…¹è†œç™Œ | åµå·¢ç™Œ | è½¬ç§»æ€§å®ä½“ç˜¤ </td><td>Withdrawn</td><td>æ—©æœŸä¸´åºŠ1æœŸ</td><tr><td>NCT05291182</td><td>SY-4835</td><td>æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Unknown status</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT05212025</td><td>Adavosertib | ç›é…¸å‰è¥¿ä»–æ»¨</td><td>æ™šæœŸèƒ°è…ºè…ºç™Œ</td><td>Withdrawn</td><td>ä¸´åºŠ2æœŸ</td><tr><td>NCT05198804</td><td>ç”²è‹¯ç£ºé…¸å°¼æ‹‰å¸•åˆ© | Azenosertib</td><td>åŸå‘æ€§è…¹è†œç™Œ | å¤å‘æ€§é«˜çº§åˆ«è¾“åµç®¡æµ†æ¶²æ€§è…ºç™Œ | é“‚è€è¯æ€§åµå·¢ç™Œ | è¾“åµç®¡ç™Œ</td><td>Active, not recruiting</td><td>ä¸´åºŠ1/2æœŸ</td><tr><td>NCT05128825</td><td>Azenosertib</td><td>åŸå‘æ€§è…¹è†œç™Œ | åµå·¢æµ†æ¶²æ€§è‚¿ç˜¤ | è¾“åµç®¡ç™Œ</td><td>Recruiting</td><td>ä¸´åºŠ2æœŸ</td><tr><td>NCT05109975</td><td>Zedoresertib</td><td>å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Recruiting</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT05008913</td><td>Adavosertib</td><td>å±€éƒ¨æ™šæœŸæ¶æ€§å®ä½“ç˜¤ | æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Terminated</td><td>ä¸´åºŠ1æœŸ</td><tr><td>CTR20211986</td><td>Azenosertib</td><td>åµå·¢ç™Œ | è…¹è†œç™Œ | è¾“åµç®¡ç™Œ</td><td>Terminated</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT04972422</td><td>Azenosertib</td><td>å®ä½“ç˜¤</td><td>Unknown status</td><td>ä¸´åºŠ1æœŸ</td><tr><td>NCT04959266</td><td>ä¼Šæ›²åº·å”‘ | å¥¥ç¾æ‹‰å”‘ | Adavosertib | åˆ©ç¦å¹³</td><td>å±€éƒ¨æ™š-æœŸæ¶æ€§å®ä½“ç˜¤ | æ™šæœŸæ¶æ€§å®ä½“ç˜¤</td><td>Terminated</td><td>ä¸´åºŠ1æœŸ</td></tr> </table>"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
